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 Rheumatoid arthritis (RA) is a chronic inflammatory disease of the joints affecting 
over 1.3 million Americans with annual societal costs estimated at $39.2 billion, rising faster 
than medical inflation. Therapy with tumor necrosis factor inhibitors (TNFi) has greatly 
improved the management of patients with rheumatoid RA; however, substantial numbers of 
patients do not experience an adequate response to these drugs, necessitating a change in 
treatment regimen. There are two basic approaches for TNFi failure: cycling (switching to a 
second TNFi) or swapping (to a drug with another mechanism of action) but the choice is 
controversial due to questions of comparative efficacy and pervasive resource constraints.  
 
The initial goal of this study was to follow the Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) statement and systematically review the 
methodology of decision analyses aimed at determining the most cost-effective sequence of 
treatment for refractory RA in order to gauge best modeling practices and sources of 
disagreement in terms of techniques and parameters. The second goal was to analyze the 
Truven Health Analytics MarketScan® Databases to obtain real-world estimates for cost and 
drug survival parameters for all ten targeted drugs. Ultimately, the aim was to apply the 
  
lessons learned from the systematic review and the estimates calculated from claims data in 
order to develop an original decision analysis model that will assist physicians and patients in 
determining the most cost-effective course of care. 
 
Seven publication met the criteria for inclusion into the systematic review. They had a 
largely homogenous model structure and their efficacy estimates were from the same set of 
randomized clinical trials. Reporting quality was fair and the median ICE for the swapping 
strategy was $70,332/QALY. 
 
The claims analysis demonstrated that 63% of patients cycle to a second TNFi but 
those who swap to a non-TNFi drug are more likely to persist on treatment, even after 
controlling for covariates. There were no differences in time to discontinuation for 
subsequent lines of drugs. While non-TNFi drugs seem to be more effective, they are more 
costly. Adalimumab and abatacept are the most common second-line TNFi and non-TNFi 
respectively. 
 
Lastly, we built a Markov microsimulation model based on the Truven cohort and 
conclude that swapping to a non-TNFi is likely to be cost-effective at a $100,000/QALY 
threshold across a variety of scenarios. Probabilistic sensitivity analysis estimates that the 
basecase has an 80% probability of being cost-effective at $100,000/QALY. Our results 
calibrate well with those seen in the systematic review and have the advantage of being based 
on long-term follow up of a large real-world cohort. 
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BACKGROUND  
Literature Review  
The overall goal of RA therapy is to “treat to target” i.e. to remission or low disease 
activity. The most current treatment guidelines, as published by the ACR (1), recommend 
beginning with methotrexate (MTX) monotherapy, moving to combination conventional 
synthetic disease modifying antirheumatic drug (csDMARDs) therapy or a targeted drug 
(preferably together with MTX) and then adding low-dose corticosteroids. While there is no 
recommendation to use a TNFi versus a biological with another mechanism of action or 
tofacitinib (a targeted synthetic DMARD (tsDMARD)), most clinicians begin with a TNFi.  
 
For patients who fail their initial TNFi and are not on concurrent csDMARDs, the 
ACR strongly recommends adding combination therapy with one or two conventional 
synthetic DMARDs. No double-blind randomized controlled study has directly addressed 
whether to use another TNFi versus a non-TNFi biologic for persons failing their first TNFi 
while on combination therapy. The results from observational studies are mixed and seem to 
indicate greater clinical improvement for non-TNFi drugs but possibly more serious 
infections. No study has compared TNFi to non-TNFi to tofacitinib. Thus, based on 
panelists’ expertise, the ACR conditionally recommend swapping to a non-TNFi biological 
(1). 
 
The EULAR recommendations are similarly equivocal, making no distinction 
between a second TNFi and different classes of biologic agents (2). 
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If a patient has failed to more than one TNFi, indirect observational studies appear to 
show greater effectiveness for non-TNFi’s (with or without MTX) in terms of achieving the 
EULAR “good response” criteria but no difference in the DAS28 nor has a difference been 
shown in terms of serious infections. 
 
Effectiveness 
Switching between TNFi can be effective as, despite belonging to the same class, 
they have differences in formulation, molecular structure, pharmacokinetics and the 
induction of antibodies thereby inhibiting the inflammatory effects of tumor necrosis factor 
alpha in different ways. Targeted drugs with other mechanisms of action block the 
inflammatory effects of cytokines such as interleukin-1 (anakinra (ANA)), interleukin-6 
(tocilizumab (TCZ)). They inhibit T-cells (abatacept (ABA)) or deplete B-cells (rituximab 
(RTX)). The drugs also differ in their methods of administration (injected, infused or 
ingested) and dosing schedules (from daily to six-monthly) which may contribute to 
differences in effectiveness, adherence, persistence, switching and dose escalation. That said, 
when restricting their analysis to patients starting their second targeted treatment after 2005, 
Ramiro et al (3) found no difference between the eight (their study excluded tofacitinib and 
anakinra) survival curves (p=0.239). 
 
Randomized controlled trials (RCTs) show that both TNFi (OPPOSITE – infliximab 
(IFX) (4) GO-AFTER – golimumab (GOL) (5), CERT-001 – certolizumab (CTZ) (6)) and 
non-TNFi (ATTAIN – abatacept (7), REFLEX – rituximab (8), RADIATE – tocilizumab (9) 
and tofacitinib (TOF) (10)) are superior to placebo for patients who have failed their first 
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TNFi, with non-TNFi drugs appearing to be more effective than a second TNFi. Safety 
profiles are similar. Salliot et al (11) performed an indirect comparison of four of these RCTs 
(REFLEX, ATTAIN, RADIATE, GO-AFTER) as well as DANCER (rituximab) and report 
no significant difference between rituximab, tocilizumab, abatacept and golimumab. Schoels 
et al (12) arrived at a similar conclusion after performing an indirect pairwise meta-analysis 
of REFLEX, ATTAIN, RADIATE and GO-AFTER. 
 
Cycling strategies 
Most studies comparing the different TNFi’s have found no difference between them 
(13, 14), indeed, one Veterans Administration study even found no added benefit to cycling 
to a new TNFi compared to restarting the initial drug after a gap of three months or longer 
(15). However there does appear to be a slight advantage to etanercept (ETN) according to 
the ARTIS study, based on the Swedish national registry (16) as well as a study based on the 
LOHREN registry in northern Italy (17). Similarly, in the US, Ramiro et al (3) found a 
significant difference, when comparing the survival curves of the three earliest TNFi 
(p=0.044) with infliximab and etanercept having an advantage over adalimumab (ADA). 
 
 
Swapping strategies 
The ROC trial (18), was a pragmatic, open-label, randomized controlled trial (RCT) 
comparing cycling to swapping in 300 participants. It included a sub-analysis evaluating the 
difference in disease response among abatacept, rituximab and tocilizumab and found no 
significant difference between them. Similarly, the discontinued SWITCH trial found similar 
improvement in outcomes for patients receiving rituximab and abatacept (19). However, a 
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network meta-analysis of randomized clinical  trials in RA patients who had inadequate 
response to TNFi found that tocilizumab 8mg performed best in terms of ACR20 response 
rate and safety, followed by rituximab, abatacept and tofacitinib (20). This result has not 
been reflected in reports from the few observational studies that have compared outcomes 
between non-TNFi drugs as second-line targeted therapy (rituximab versus abatacept (21), 
rituximab versus tocilizumab (22) and abatacept versus tocilizumab(23)) which have not 
shown clear differences between them. 
 
 
Cycling versus Swapping 
The ROC trial (18), mentioned above, the only completed RCT found that directly 
compares cycling (to infliximab etanercept, adalimumab) versus swapping (to abatacept, 
rituximab or tocilizumab) and it found that significantly more patients receiving a non-TNFi 
drug achieved a good or moderate response at 24 weeks. There appears to be a trend towards 
more adverse events in the swapping group but other than for serious adverse events (p=0.1) 
the statistical significance was not reported. The British SWITCH open-label RCT was 
discontinued due to slow enrolment. Based on the 122 randomized patients, they could not 
conclusively determine a clinical difference between rituximab and a second TNFi (19).  
Lastly, an analysis of 32 RCTs using meta-regression determined that cycling results in better 
clinical response (24). Ramiro et al (3) report a somewhat lower discontinuation rate for 
TNFi as second line versus non-TNFi but this was not significant when restricted to patients 
beginning treatment after 2005. 
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Most comparative observational studies comparing rituximab to TNFi’s in patients 
who have failed their first tumor necrosis factor inhibitor conclude that rituximab is more 
effective (22, 25-33). Gomez-Reino et al (31) believe that at least part of their result can be 
attributed to the poorer response they observed in patients cycling to adalimumab or 
infliximab compared to etanercept or rituximab. The SWITCH-RA study (29) did however 
go on to note that patients receiving rituximab had, on average, higher disease activity and 
had discontinued their previous TNFI due to inefficacy rather than adverse events. Finckh et 
al (26, 32) found significantly better improvement in disease activity among those rituximab 
patients who switched due to inadequate response, and no difference between RTX and TNFi 
if the switch was for any other reason. Rubbert-Roth et al (27) performed a prospective 
observational study of 728 patients and found significant improvement over six months for 
seropositive patients (anti-CCP+ n=559) swapping to rituximab versus cycling to a second 
TNFi. No difference was found for seronegative patients (anti-CCP- n=169).  
 
 
Favalli et al (14) found that, regardless of the reason for the switch, those swapping to 
abatacept, rituximab or tocilizumab had better retention rates, with no significant difference 
between the three agents, a Dutch cohort study similarly reports higher effectiveness when 
swapping to non-TNFi’s (34) whereas Ramiro et al (35) report no significant difference in 
discontinuation rates between cyclers and swappers. Strehblow et al (36) report a trend of 
longer survival on anakinra compared to TNFi but this did not reach statistical significance 
and Yoshida et al (37) report no significant difference between tocilizumab and TNFi’s as 
second line treatment. The latter two studies were limited by small sample size (49 – 85 
patients). Rotar and Tomsic (22, 33) found that tocilizumab is superior to TNFi’s. Lastly, 
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Meissner (38) found that abatacept as second-line treatment had lower rates of switching than 
ADA, ETN and IFX as did Rosenblatt et al (39), who calculated that patients swapping from 
first-line TNFi to abatacept had a third of the odds of failing compared to those cycling to 
another TNFi. Schabert et al  (40) report a more favorable efficacy profile for abatacept 
compared to adalimumab, etanercept and infliximab. In the same vein, both Du Pan et al and 
Elkin et al show favorable results for swapping versus cycling (41, 42). However, Harrold et 
al (43) found no difference between a second TNFi and abatacept. Only Studenic et al (44) 
report a higher retention rate for TNFi’s compared to non-TNFi drugs for the second through 
fourth line of treatment. Virkki et al (45) distinguished between reasons for initial failure and 
found that switching to a second TNFi would be most beneficial to those experiencing 
secondary failure. Wakabayashi et al (46) report no significant difference in efficacy between 
tocilizumab and etanercept in 38 Japanese patients who had failed to respond to infliximab. 
 
The most comprehensive studies compared survival times across eight or nine 
second-line drugs using Thomson Reuters MarketScan® Research Databases: the earlier 
study (47) (n=3049) calculated that etanercept and rituximab had the lowest switch rates and 
infliximab had the highest while the updated study (48) (n=6841) found highest persistence 
for rituximab and  lowest for adalimumab with no significant differences between the other 
agents. The latter was the only study to include certolizumab pegol and no study has been 
found comparing tofacitinib as a second line targeted therapy. 
 
In their systematic review of four studies and 41 abstracts looking at rituximab, 
abatacept, adalimumab, etanercept and infliximab as second line biologics, Moots et al (49) 
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conclude that significant benefit can be derived from all of them, qualifying their remarks by 
stating a need to possibly stratify patients according to biomarkers (such as seropositivity) in 
order to optimize therapy for specific subgroups. 
  
Particularly when looking at observational studies, one needs to asses results in terms 
of regression to the mean: because the change to a new medication is triggered by an increase 
in disease activity, regardless of treatment, or lack thereof, any subsequent measure of 
disease activity is likely to reflect the patient’s average disease activity which can be 
incorrectly attributed to drug efficacy. 
 
That said, the evidence appears skewed in favor of the swapping strategy but, despite 
this, US patients tend to cycle to another TNFi rather than swap (3, 30, 50, 51) to a drug with 
another mechanism of action although this trend does appear to be changing (3, 52). 
 
Table 1:  Comparative effectiveness of second-line biologic drugs 
 
Comparators Reference Data source More efficacious 
TNFi versus TNFi 
IFX vs. ETN vs. 
ADA 
Ramiro (3) US prospective cohort IFX, ETN 
 
Chatzidionysiou (16) Swedish Registry ETN 
Caporali (17) Northern Italy registry ETN 
Favalli (14) Italian retrospective cohort No difference 
8 
 
Comparators Reference Data source More efficacious 
IFX vs. ETN vs. 
ADA vs. GOL vs. 
CTZ 
Greenberg (13)  US Registry No difference 
non-TNFi vs. non-TNFi 
ADA vs. RTX vs. 
ABA 
Gottenberg (18) Pragmatic RCT No difference 
RTX vs. ABA Barnabe (21) Canadian retrospective cohort No difference 
RTX vs. TCZ Rotar (22) Slovenian registry RTX (NS) 
TCZ vs. ABA Kume (53, 54) Japanese RCT TCZ 
TCZ vs. ABA Leffers (23) Dutch registry No difference 
TCZ vs. RTX vs. 
ABA vs. TOF 
Lee (20) Meta-analysis TCZ 
RTX vs ABA Brown (19) British RCT RTX 
TNFi vs non-TNFi 
Cycle vs. swap Favalli (14) Italian retrospective cohort Swap 
Rotar (33) Slovenian registry Swap 
Brickmann (34) Dutch retrospective cohort Swap 
Du Pan (41) Swiss registry Swap 
Elkin (42) US retrospective cohort Swap 
Studenic (44) Austrian retrospective cohort Cycle 
Gottenberg (18) French RCT No difference 
Ramiro (3) US prospective cohort No difference 
Cycle vs. RTX Soliman (25) British registry RTX 
Rotar (22) Slovenian registry RTX 
Finck (26, 32) Prospective cohort within Swiss registry RTX 
Rubbert-Roth (27) Global prospective cohort RTX 
Chatzidionysiou (28) Stockholm registry RTX 
Emery (29) Global prospective cohort RTX 
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Comparators Reference Data source More efficacious 
Harrold (30) US registry RTX 
Gomez-Reino (31) Spanish prospective cohort RTX 
 Brown (19) British RCT No difference 
Cycle vs. anakinra Strehblow (36) Prospective cohort Anakinra - NS 
Cycle vs. TCZ Rotar (22) Slovenian registry TCZ 
Yoshida (37) Japanese registry No difference 
Cycle vs. ABA Rosenblatt (39) US claims data ABA 
Harrold (43) Retrospective cohort No difference 
Meissner (38) US claims data ABA 
TCZ vs. ETN Wakabayashi (46) Japanese retrospective cohort No difference 
All vs. all Ramiro (3) US prospective cohort TNFi – pre 2005 
Johnston (67) US claims data ETN, RTX best 
IFX worst 
Johnston (68) US claims data RTX best, ADA 
worst 
 
Cost 
Very few studies were found comparing costs of second line biological drugs for RA. 
Among the first three tumor necrosis factor inhibitors (ETN, IFX, ADA), etanercept appears 
to be consistently associated with the lowest drug cost per treated patient as well as the 
lowest all-cause healthcare costs. Infliximab is the most expensive (40, 55-57). This result 
must be treated with caution as only one study specifically looked at second line treatment, 
the others differentiated between new and continuing patients with no information on the 
treatment history of the continuing patients. Johnston et al (58) specifically compared first 
and second line treatment of sub-cutaneous (SC) targeted drugs and observed the lowest 
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costs for abatacept. Another paper by the same authors compared changes from baseline and 
concluded that while patients receiving abatacept as second line treatment were sicker than 
those receiving etanercept or adalimumab, their relative increase in healthcare costs was the 
lowest (59). When comparing among second line infused drugs, tocilizumab had 
significantly lower per person, per month (PPPM) and all-cause healthcare costs than 
abatacept and infliximab (60). 
 
Overall, cycling appears to be a cheaper strategy than swapping. Patients who swap to 
non-TNFi drugs tend to be older, with more comorbidities and higher steroid use, but even 
after controlling for baseline characteristics, swapping results in approximately 35% higher 
annual all-cause medical costs (61) with 49-63% of the difference being attributed to the cost 
of the drug (51). This latter is attributed to the intravenous (IV) route of administration 
associated with many non-TNFi requiring office visits, facility fees and administration costs 
(51, 61, 62) . No significant difference was found in emergency department or inpatient visits  
(51). 
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Table 1: Comparative cost of second-line targeted drugs 
 
Comparators Paper Source Least costly 
IFX vs. ETN vs. ADA Schabert (40, 56, 57) US claims data ETN 
 Harrison (55) US claims data ETN 
SC drugs (ADA vs. ETN 
vs. ABA) 
Johnston (58, 59) US claims data ABA 
IV drugs (IFX vs. ABA 
vs. TCZ) 
Johnston  (60) US claims data TCZ 
Cycle vs swap Zhou (51) US claims data Cycle 
McBride (61) US claims data Cycle 
Baser (62) US claims data Cycle 
 
Cost effectiveness 
Joensuu et al (63) reviewed cost-utility analyses of biologics in RA across five 
categories of patients, one of which included studies that compared biologics in patients with 
an inadequate response to TNFi’s. Four studies met their inclusion criteria all of which 
compared rituximab to one or more TNFi’s (adalimumab, etanercept and/or infliximab), one 
also included abatacept as a treatment option. All of them are European studies. Three studies 
(64-66) included indirect costs while Merkesdal et al (64) and Kielhorn et al (67) were the 
only analyses of treatment sequences although in both cases the only difference in the 
sequences presented was the inclusion of rituximab as the first biological after initial TNFi 
failure in one arm. The analyses including rituximab conclude that RTX compared to TNF’s 
is either cost-effective at the €30,000 incremental cost effectiveness ratio (ICER) threshold or 
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is the dominant option (cheaper and more effective). The ICERs for abatacept ranged from 
€47,663 to over 1.2 million euros. No clear best choice emerges among the three TNFi’s 
included in the models.  
 
Sullivan et al (68) conclude from their review of 15 articles that cycling to a second 
TNFi is less likely to be cost-effective whereas swapping to abatacept or rituximab results in 
an ICER below willingness to pay thresholds and may even be cost-saving. 
 
An initial literature search revealed a further five cost-utility (19, 65, 69-71) and four 
cost-effectiveness (72-75) analyses all comparing treatment arms consisting of TNFi’s, 
abatacept and/or rituximab. Three studies were performed in Central America, the rest are 
based on European populations. The overall conclusion appears to be that swapping to a non-
TNFi biological is more cost-effective than cycling to a second TNFi. Four cost-utility 
analyses (CUA) favored rituximab whereas half of the six cost-effectiveness analyses (CEA) 
did so. The incomplete SWITCH study concluded that an alternative TNFi might be cost-
effective when compared to rituximab but that abatacept is unlikely to be cost-effective when 
compared to TNFi (19). Given the substantial uncertainty inherent in assumptions about 
disease progression under the different treatment options complicated by the diverse 
populations of the nine countries represented and the different modelling assumptions and 
structures used, it is not possible to reach an unequivocal conclusion.  
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Table 2: Comparative cost-utility of second-line targeted drugs 
 
Drug Comparator Study Country ICER 
RTX TNFi Brodszky (65) Hungary RTX dominant 
TNFi TNFi Carlos (69) Mexico RTX dominant 
TNFi Diamantopolous (70) Netherlands RTX dominant 
ABA Diamantopolous (70) Netherlands RTX dominant 
TNFi Manders (71) Netherlands RTX dominant 
 TNFi Brown (76) United Kingdom TNFi: £5,332/QALY 
ABA TNFi Brown (76) United Kingdom ABA: £253,967/QALY 
 
Table 3: Comparative cost-effectiveness of second-line targeted drugs 
 
Drug Comparator Study Country Result 
RTX 
 
TNFi Carlos (73) Costa 
Rica 
RTX: lowest cost/ACR70 
TNFi Carlos (75) Mexico RTX: lowest cost/ACR70 
TNFi Ryazhenov (74) Russia RTX: lowest cost/unit DAS reduction 
ABA Ryazhenov (74) Russia RTX: lowest cost/unit DAS reduction 
ABA (3rd line) RTX Emery (72) UK £8/day in LDAS* 
* LDAS: low disease activity state 
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Public Health Significance 
Annual health care costs in the United States have exceeded the $3 trillion mark 
accounting for 17.5% of Gross National Product in 2014 (77) which is approximately double 
the OECD per capita average. Americans are paying more for health care but this is not 
reflected in superior health outcomes. One of the primary goals of the Patient Protection and 
Affordable Care Act (ACA) of 2010 was to improve the efficiency of the US health care 
system. The increase in the number of insured individuals as well as the overall aging of the 
population mean not only that more people will have access to targeted disease-modifying 
anti-rheumatic drugs, but they will be needing them for longer. There is no consensus on the 
most effective second line treatment, and a paucity of information on the most cost-effective.  
The uncertainty of treatment success, coupled with risk and high expense make these 
therapies an important target for economic evaluations as it is important for patients that their 
physicians have guidance on the most cost-effective options for controlling their disease. 
This study aims to provide such a tool by providing a systematic synthesis of the relative 
costs and benefits of alternative rheumatoid arthritis treatments for patients who have failed 
their initial TNFi agent. 
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Hypothesis, Research Question, Specific Aims or Objectives 
The essential purpose of this research project is to build a cost-utility model that will assist 
physicians and rheumatoid arthritis patients in treatment selection after failing their initial 
TNFi. In order to be relevant and valid, the model needs to be based on best decision analysis 
practices. To that end a systematic methodological review of analyses on the topic is 
necessary to glean those approaches and parameter sources that most successfully model real 
world situations. To inform cycle lengths and possibly group treatments, it was thought 
prudent to examine actual usage of second line targeted therapies, length of time on them and 
their per person costs. Thus, this analysis will consist of three linked aims: 
 
1. Systematic review of modeling methodologies for the cost-effectiveness of targeted 
drugs as second line treatment for rheumatoid arthritis. 
2. Determine real world utilization patterns and costs of targeted drugs. 
3. Cost-utility analysis of RA treatment options after initial TNFi failure. 
 
The question to be answered is this: What is the most cost-effective treatment for rheumatoid 
arthritis patients who have failed their first TNFi drug? 
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METHODS 
Human Subjects, Animal Subjects, or Safety Considerations  
This study was approved by the University of Texas M.D. Anderson Cancer Center 
Institutional Review Board (PA17-0789) under expedited review. Waivers of informed 
consent and authorization were granted as only de-identified and previously published data 
was used. 
The project was also determined as qualifying for exempt status by the Committee for 
Protection of Human Subjects of University of Texas Health Science Center at Houston 
(HSC-SPH-18-0164).  
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JOURNAL ARTICLE 1 
Systematic review of economic evaluations of cycling versus swapping in patients with 
rheumatoid arthritis after failure to tumor necrosis factor inhibitors  
Annals of Rheumatologic Disease 
 
ABSTRACT 
Objective: To systematically review the modeling approaches and quality of economic 
analyses comparing cycling tumor necrosis factor-alpha inhibitors (TNFi) to swapping to a 
therapy with a different mode of action in patients with rheumatoid arthritis whose initial 
TNFi failed. 
 
Methods: We searched electronic databases, gray literature, and references of included 
publications until July 2017. Two reviewers independently screened citations. Reporting 
quality was assessed using the Consolidated Health Economic Evaluation Reporting 
Standards (CHEERS) statement. Data regarding modeling methodology were extracted. 
 
Results: We included 7 articles comprising 19 comparisons. Three studies scored ≥ 16/24 on 
the CHEERS checklist. Most models used a lifetime horizon, took a payer perspective, 
employed a 6-month cycle length, and measured treatment efficacy in terms of the American 
College of Rheumatology improvement criteria. We noted possible sources of bias in terms 
of transparency and study sponsorship. In the cost-utility comparisons, the median 
incremental cost-effectiveness ratio (ICER) was US $70,332/quality-adjusted life-year 
(QALY) for swapping versus cycling strategies. Rituximab was more effective and less 
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expensive than TNFi in 7 of 11 comparisons. Abatacept (intravenous) compared to TNFi was 
less cost-effective than rituximab. Common influential parameters in sensitivity analyses 
were the rituximab dosing schedule, assumptions regarding disease progression, and 
estimation of utilities. 
 
Conclusion: Differences in the design, key assumptions, and model structure chosen had a 
major impact on the individual study conclusions. Despite the existence of multiple reporting 
standards, there continues to be a need for more uniformity in the methodology reported in 
economic evaluations of cycling versus swapping after TNFi in patients with RA. 
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SIGNIFICANCE AND INNOVATION 
• First study to review cost-effectiveness analyses comparing cycle versus swap 
strategies in rheumatoid arthritis patients who have failed their first tumor necrosis 
alpha inhibitor. 
• Reiterates need for standardization and transparency in cost-effectiveness studies. 
• Highlights the need of further studies evaluating cost-effectiveness with swapping 
choices other than rituximab or intravenous abatacept that better reflect current 
clinical practices. 
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Therapy with tumor necrosis factor inhibitors (TNFi) has greatly improved the management 
of patients with rheumatoid arthritis (RA); however, substantial numbers of patients do not 
experience an adequate response to these drugs, necessitating a change in treatment regimen. 
The choice of a subsequent therapy is controversial for many reasons, among them doubts 
about efficacy, concerns about safety, and pervasive resource constraints; adalimumab and 
etanercept together accounted for over 5% of US pharmaceutical spending in 2013 (1). 
 
 Two basic approaches are used after TNFi failure: patients can switch either to 
another TNFi (cycling strategy) or to a drug with a new mechanism of action (MOA) 
(swapping strategy). While systematic reviews of randomized controlled trials show that 
targeted drugs have similar effectiveness and safety profiles (2, 3), evidence from a 
randomized controlled trial (4) and multiple observational studies (5-13) has supported a 
swapping strategy. Despite this, physicians tend to cycle rather than swap (10, 14-16), though 
this trend may be changing (14, 17). 
 
Results from economic evaluations comparing the cycling and swapping strategies 
have been inconclusive. Cycling appears to be the cheaper strategy (16, 18, 19), but cost-
effectiveness analyses show that swapping has an incremental cost-effectiveness ratio (ICER) 
below willingness-to-pay thresholds and may, in some circumstances, be cost-saving (20, 
21).  
 Our objective was to systematically review the modelling approaches and quality of 
economic evaluations comparing cycling versus swapping in patients with RA who have 
failed TNFi therapy. 
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METHODS 
 We followed the 27-item checklist of the Preferred Reporting Items for Systematic 
Reviews and Meta-analyses (PRISMA) statement to report our results (22). 
 
Eligibility criteria 
 We included: 1) economic evaluations (cost-effectiveness, cost-utility, or cost-benefit 
analyses); 2) published before July 2017; 3) comparing TNFi (adalimumab, certolizumab, 
etanercept, golimumab, or infliximab) to non-TNFi biologics (abatacept, anakinra, rituximab, 
tocilizumab) or tofacitinib (oral small molecule inhibitor); and 4) consisting of patients with 
RA who had failed a TNFi. We excluded studies: 1) if the comparator group was a disease-
modifying anti-rheumatic drug (DMARD); 2) if they were conference abstracts or poster 
presentations; or 3) if model details were not provided. 
 
Information sources 
 The search aimed to find published and unpublished studies and was developed with 
the assistance of a health sciences librarian experienced in developing strategies for 
systematic reviews. Searches were not limited by year or type of publication but were 
restricted to articles published in English. The databases searched were MEDLINE (Ovid), 
EMBASE (Ovid), Cumulative Index to Nursing and Allied Health Literature, Cochrane 
Library, Database of Abstracts of Reviews of Effects, Health Technology Assessments, Web 
of Science, National Guideline Clearing House, National Institute for Health and Clinical 
Excellence, Agency for Healthcare Research and Quality, Turning Research into Practice, 
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Health Economic Evaluations Database, EconLit, National Health System Economic 
Evaluations Database, and Academy of Managed Care Pharmacy Abstracts. In addition, the 
reference lists of included articles were hand-searched. DistillerSR software (Evidence 
Partners) was used to store all citations for duplicate checking and screening.  
 
Search 
 The initial keywords included “rheumatoid arthritis,” the generic and brand names of 
the 10 drugs of interest, their mechanisms of action, “comparative effectiveness research,” 
“costs,” and “cost analysis.” The detailed MEDLINE search strategy can be found in 
Appendix B. 
 
Study selection 
 Two reviewers (ARK, MLO) performed eligibility assessments independently, 
blinded to author and journal. Disagreements at all stages were resolved through discussion. 
If agreement could not be reached, a third reviewer (SBC) made a final decision.  
 
Data collection process 
 To systematically extract data, we developed a form based on the Guide to 
Community Preventive Services’ standard abstraction document (23) and RA-specific 
guidelines (24, 25). The form was pilot-tested on 5 randomly selected studies and refined 
accordingly. Data extraction was performed by one reviewer (ARK) and crosschecked by 
another (MLO).  
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Data items 
 We extracted: i) general information such as title, authors, publication year, country, 
study sponsor; ii) study characteristics: analytic technique, perspective of the study, funding 
source, reporting quality; iii) modeling features: participants’ characteristics, intervention 
characteristics, disease states (i.e., health states and pathways), cycle length, time horizon, 
parameters of effectiveness/safety, and costs (drug and non-drug costs), model outcomes 
(i.e., quality-adjusted life year (QALY) where one QALY is equivalent to one life year spent 
in full health- and/or cost per responder; iv) ICERs (i.e., the estimated difference in cost 
between the competing interventions divided by the difference in QALY's gained); and v) 
assessment of uncertainty and model validation. 
 
Quality appraisal 
 The selected studies were appraised for reporting quality using the Consolidated 
Health Economic Evaluation Reporting Standards (CHEERS) (26) checklist, which consists 
of 24 items evaluating 6 aspects of an economic study. Items were assessed as “true,” “false,” 
or “not applicable or partly true”. Because many items consisted of more than one question, 
if a sub-item was not reported, the entire item was marked as “partly true”. The reporting 
quality of the studies was assessed as the total number of “true” ratings and expressed as a 
percentage. 
 
Synthesis of results 
 Data were analyzed using narrative synthesis. Extracted data were tabulated from the 
studies. Quantitative meta-estimates were not calculated given the heterogenic nature of 
24 
 
economic evaluations. However, we estimated the median and provide the maximum and 
minimum values as reference. To facilitate comparability, all ICERs were adjusted to 2017 
US dollars according to rules specified by the Community Guide (27): costs per QALY were 
first converted to US dollars using purchasing power parity rates as published by the World 
Bank (28) and then revised to 2017 values using the U.S. Department of Labor’s medical 
care consumer price index (MCPI) (base period 1982-1984) (29).  
   
We considered an intervention cost-effective if the incremental cost-effectiveness 
ratio (ICER) fell below a threshold of $100,000/QALY (30). A threshold of $50,000/QALY 
has been used historically but, recently, thresholds of $100,000 - $300,000 per QALY gained 
are being considered more appropriate (30-32). Strategies costing less and at least as 
effective as the comparator are dominating. 
 
RESULTS 
 
Study selection 
 After exclusion of duplicates, 5221 citations were screened. The 7 included 
publications comprised 19 comparisons, as four articles examined more than one treatment 
strategy. Figure 1 shows the study selection flowchart. 
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Figure 1.1. Flowchart illustrating the study screening and eligibility evaluation.  
This flowchart is modeled after the PRISMA statement (22) 
  
  
Records identified through 
database searching
N = 8204
EMBASE = 3914
Web of Science = 1293
CINAHL = 1147
Medline = 960
Cochrane = 487
TRIP = 130
NHS EED = 68
PubMed = 60
EconLit = 45
CEA Registry = 41
HTA = 34
DARE = 22
NGC = 3
Unique records
N = 5221
Records excluded
N = 4864
Not full economic evaluation = 2943
Not RA = 663
Wrong population = 165
Wrong comparison = 103
Review = 99
Non-English = 10
More than one exclusion reason = 881
Full-text articles assessed 
for eligibility
N = 357
Full-text articles excluded
N = 350
TNFi naïve = 209
Abstract only = 114
Cannot determine TNFi failure = 3
More than one exclusion reason = 24
Studies included in 
qualitative synthesis
N = 7
Duplicates
N = 3056
Hand search
N = 73
References of included studies = 
3
NICE = 13
Conference proceedings:
ISPOR = 16
AMCP = 41
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Study characteristics 
 The 7 included studies represented 4 European countries and the United States. There 
was one decision tree, three microsimulations, two discrete event simulations and one trial-
based study. Four studies were from the perspective of a third-party payer, two took a 
societal perspective and the 7th did not report perspective. Six models were cost-utility 
analyses, the last was a cost-effectiveness analysis. Five studies were sponsored by the 
pharmaceutical industry; all reporting favorable ICERs for their marketed strategy (Table 1). 
 
Table 1.1. Methods and modeling features of the included studies. 
 
Study, year Country Model type Sponsor Perspective Horizon Outcome Comparisons 
Claxton, 2016 (38) USA Decision tree Pfizer Private payer 1 year Cost/responder 1 
Hallinen, 2010 (39) Finland Microsimulation Roche Oy Society Lifetime QALY 6 
Kielhorn, 2008 (37) UK Microsimulation F. Hoffman-La Roche AG Public payer Lifetime QALY 1 
Lindgren, 2009 (33) Sweden DES Roche AB Society Lifetime QALY 1 
Malottki 2011 (34) UK DES 
National Institute for Health and 
Clinical Excellence 
Public payer 
Not 
reported 
QALY 6 
Manders, 2015 (35) Netherlands Trial-based 
Netherlands Organisation for Health 
Research and Development 
Not reported 1 year QALY 2 
Merkesdal, 2010 
(36) 
Germany Microsimulation 
Roche Pharma 
AG, Grenzach- Wyhlen and F. 
Hoffmann- La Roche Ltd 
Public payer Lifetime QALY 2 
  
Quality of reporting 
 While most studies reported their parameters as required by CHEERS (Figure 2), few 
justified their choices as also recommended by the guideline; for example, most described the 
study perspective (5 studies), time horizon (6 studies), discount rate (5 studies), health 
outcomes (all studies) and choice of model (6 studies), but not all gave reason for their 
choices. No study explained their selection of model. Characterization of uncertainty was 
another weak point; only 2 studies characterized population heterogeneity. The mean score 
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(number of “true” answers on the 24-item checklist) was 15 (63.7%), with a range of 11 to 
18. 
 
 
Figure 1.2. Results of CHEERS quality of reporting checklist. 
 
Modeling features 
 
Patient characteristics 
 Study cohorts were modelled on registries (33, 34), clinical trials (35-37) or 
epidemiological data (38, 39). Cohorts modelled a population that was predominantly female 
(median 81%, range, 67-81%), with a median age of 52 years (range, 48-56), disease 
duration of 10.2 years (range, 6.3-14.1) and baseline Health Assessment Questionnaire 
Disability Index (HAQ-DI) of 1.88 (range, 1.4-1.9), and weight of 73.8 kg (range, 70.0-77.7). 
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No study reported all characteristics; 2 studies reported 4 (33, 35), three studies did not report 
baseline HAQ-DI and one study did not report any patient characteristics at all (38).  
 
Treatment Strategies 
 Eleven of nineteen comparisons evaluated rituximab versus TNFi, either as a class 
(33, 35) or individually, with adalimumab being the most common comparator (34, 36, 37, 
39). Seven comparisons evaluated abatacept versus TNFi. In one study, tofacitinib was 
compared to adalimumab.  
 
Health states and pathways 
 The three microsimulations and two discrete event simulations had at least two health 
states/events: “on treatment” and “death” (33, 34, 36, 37, 39). Patients on treatment could 
have varying degrees of response, those not responding moved to the next treatment in 
sequence or to palliative treatment. One study (33) allowed patients to be off treatment and 
another (36) had a separate state for palliative treatment. In all cases, costs and utilities were 
not allocated based on the disease state itself, but on the specific drug, cycle (first vs 
subsequent) and the associated HAQ-DI score. In all cost-utility analyses the HAQ-DI 
improved upon new treatment initiation and deteriorated over time, rebounding to its original 
value upon treatment discontinuation.  
One study (35) was not a decision analysis model but was based on a pragmatic 
randomized controlled trial. In the decision tree study, (38) patients experiencing an ACR20 
response would continue treatment for the next 6 months before being reassessed. 75% of 
those not responding or experiencing an adverse drug related reaction would switch to the 
next treatment in sequence and the pattern would then be repeated. 
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Discontinuation was either after a predetermined treatment time (36, 37, 39) or 
determined based on observational data (33, 34). Only one study explicitly modeled 
probability of serious adverse events as a reason for discontinuation (38). 
 
Cycle length 
 Cycle length represents the minimum amount of time an individual will spend in a 
health state before the possibility of transition to another. The length of the cycle needs to 
reflect the underlying disease process such that it can represent the frequency of clinical 
events and interventions. The three microsimulations and one decision tree used a 6-month 
cycle length. Of these, only one study stated that the cycle length was determined based on 
the effectiveness data (6-month clinical trials) (37). 
 
Time horizon 
 Four of the seven included studies used a lifetime horizon and one is presumed to 
have done so (34). This is consistent with the International Society for Pharmacoeconomics 
and Outcomes Research (ISPOR) best practices (40). One study (35) tracked outcomes over 
one year, and one study (38) used both one- and two-year frameworks. Shorter frameworks 
are preferred by the Outcome Measures in Rheumatology initiative (25) which cautioned 
against extrapolating beyond the duration of the clinical trial, stating that efficacy estimates 
past 10 years are unlikely to be clinically acceptable. 
 
Effectiveness and safety 
 ACR criteria were used by four studies to determine treatment efficacy (36-39). One 
study (38) only considered whether patients achieved at least an ACR20 response or not. One 
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study (33) used HAQ-DI scores only, and another (33) combined the HAQ-DI with the 
DAS28 score. One study (35) used the EuroQol 5-dimensional questionnaire (EQ-5D), a 
standardized instrument for measurement of health-related quality of life (QoL) that can be 
converted to utilities. In six studies, the effectiveness measures were based on clinical trial 
data (34-39); however, one used registry data (33) (Appendix C). 
 Three studies mentioned adverse events: one (33) explicitly excluded them from the 
model, one (38) incorporated adverse event data from a meta-analysis into the model 
structure and costed them, and the third (34) reported using them in the sensitivity analysis 
without providing further detail. Six models (33, 34, 36-39) did consider treatment 
discontinuations, which are considered particularly important because they can affect the 
total treatment cost and thereby the overall cost-effectiveness of treatment.  
 
Costs 
 Cost parameters were unevenly included across studies: in terms of direct medical 
costs, all studies included drug costs and at least one other component. Two studies each 
mentioned direct non-medical costs (38, 39) or indirect costs (33, 36). Drug costs were 
sourced from national price lists while other medical costs and expected resource use were 
derived from surveys, literature reviews, national fee schedules and guidelines (Appendix C). 
Given the large disparity in reporting, it was not possible to reconcile amounts for nondrug 
cost components. 
Drug costs. Medication costs were recorded per dose in five studies, and two simply 
recorded annual (Appendix D). Regarding the latter, studies often differentiated the first and 
subsequent years/cycles to accommodate loading doses. Drug costs reported in the only study 
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from the United States were consistently twice the reported by studies from the European 
countries. Table 2 shows the per (subsequent) 6-month cycle costs of the 5 most commonly 
reported biologic drugs in the included studies. Rituximab and infliximab were consistently 
the least expensive drugs, whereas adalimumab and etanercept were the most expensive. One 
study did not report drug costs (33). 
 
Table 1.2. Distribution of drug costs per 6-month cycle in 2017 US dollars. 
 
 Drug 
Value Abatacept IV Adalimumab Etanercept Infliximab Rituximab 
Mean 11,289  15,325  15,140  8,214  8,471  
Median 10,050  11,513  10,986  7,335  7,216  
Minimum 8,787  8,647  8,649  6,078  4,482  
Maximum 16,268  26,260  25,786  12,107  16,471  
Standard deviation 3,394 7,472  9,293  2,674  4,183  
Number of studies  4  5   3   4  6  
*Only includes drugs that were analyzed in at least 3 studies 
 
 Non-medication cost components. Costs other than those of targeted drugs were 
categorized into 22 different components (Table 3) and studies reported 1-10 of them 
(median: 8). The most commonly reported direct medical costs were laboratory tests and 
primary care visits (5 of 7 studies), followed by administration, monitoring, and radiology 
costs (4 studies each). However, in some studies, administration and monitoring were 
bundled with medication costs, increasing the difficulty of reconciling the study parameter 
outputs. Direct nonmedical costs, such as patient time costs and training and education costs, 
were only included in one model each (38, 39). In general, costs were portrayed broadly; few 
studies noted the cost assigned per item, and fewer still described the derivation of that cost. 
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Exacerbating the situation was the studies’ use of disparate definitions of each of the 
components. For example, the radiology category might have included only x-rays in one 
study, but computed tomography scans, magnetic resonance imaging, ultrasonography, and 
bone densitometry in another study. 
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Table 1.3. Reported cost components 
 
 Study 
Cost component Claxton  Hallinen  Kielhorn  Lindgrena Malottki  Manders  Merkesdal  
Direct medical 
Drugs ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Administration ✓ - ✓ - ✓ - ✓ 
Monitoring ✓ - ✓ - ✓ - ✓ 
Primary care visits ✓ ✓ ✓ - ✓ - ✓ 
Rheumatologist visits ✓ ✓ - -  - ✓ 
Other specialist visits - - - - - - - 
Allied health - ✓ - - ✓ - - 
Phone consultation - ✓ - -  -  
Outpatient ✓  - - ✓ - ✓ 
Inpatient - ✓ - - ✓ - ✓ 
Home care - - - -  - - 
Palliative care - - - - ✓ - - 
Adverse events ✓ - - b c - - 
Aids, devices, and home 
equipment 
- - - - - - - 
Non-bDMARD 
prescriptions 
✓ 
- - - - - - 
Intra-articular injections - - - - - - - 
Joint replacement  - - - ✓ - - 
Radiology ✓ ✓ - - ✓ ✓ - 
Lab tests ✓ ✓ ✓ - ✓  ✓ 
Direct nonmedical 
Training/education ✓ - - - - - - 
Patient travel - ✓ - - - - - 
Patient time - - - - - - - 
Indirect 
Productivity - - - ✓ - - ✓ 
Abbreviation: bDMARD, biologic disease-modifying antirheumatic drug 
aIncluded “direct and indirect costs” with no further details  
bExcluded: assumed similar in both arms 
cOnly included in sensitivity analysis 
 
Model outcomes 
 Quality-adjusted life-years (QALYs) were the model outcome in all cost-utility 
analyses. They are derived by multiplying the life-years gained from an intervention by the 
utility of those years. No study reported total life-years gained. Utilities were derived from 
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the EQ-5D (35) or from regression formulae predicated on HAQ-DI, the most common (36, 
37, 39) was Bansback’s equation (41). The outcome of the single cost-effectiveness analysis 
(38) was measured in terms of cost per responder. 
 
ICERs 
 In the 18 cost-utility analyses, the median ICER was $70,332/QALY for the 
swapping strategy, with a range of $24,770 to $239,104/QALY. In 7 of the 11 comparisons 
between rituximab and TNFi, rituximab dominated TNFi, that is, rituximab was both more 
effective and less expensive than TNFi (Appendix E). The median ICER for the remaining 4 
comparisons of rituximab and TNFi was $24,934/QALY. The comparison of intravenous 
abatacept and TNFi yielded a higher median ICER of $86,334/QALY. The abatacept ICERs 
fell into 2 distinct groups: one composed of 4 comparisons from two studies (34, 35), with a 
median ICER of $73,961/QALY (minimum $42,058/QALY, maximum $86,334/QALY), 
and the other comprising three comparisons from one study (39), with a median ICER of 
$223,850/QALY (minimum $195,443/QALY, maximum $223,850/QALY). The source of 
this discrepancy could not be ascertained because the models differed in terms of their type, 
structure, assumptions, and variables. Table 4 shows the ICERs for the cost-utility analyses 
comparisons, including the adjustment rates for conversion to 2017 US dollars. In the single 
cost-effectiveness analysis comparison (38), swapping to tofacitinib dominated cycling to 
adalimumab in both the one- and two-year-time horizons. 
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Table 1.4. Incremental cost-effectiveness ratios (ICERs). “Final ICER” is reported in 2017 
US dollars.  
 
Study Swap Cycle 
Original 
ICER 
Currency, 
year 
PPPa  
MC 
inflation 
factorb 
Final 
ICER 
Hallinen (39) RTX IFX 18,179 €, 2008 0.91 364.07 $26,021 
Hallinen (39) RTX ADA 
RTX 
dominant 
€, 2008 0.91 364.07 
RTX 
dominant 
Hallinen (39) RTX ETN 
RTX 
dominant 
€, 2008 0.91 364.07 
RTX 
dominant 
Hallinen (39) ABA IFX 156,388 €, 2008 0.91 364.07 $223,850 
Hallinen (39) ABA ADA 136,542 €, 2008 0.91 364.07 $195,443 
Hallinen (39) ABA ETN 167,044 €, 2008 0.91 364.07 $239,104 
Kielhorn (37) RTX ADA 11,601 £, 2004 0.69 310.10 $25,847 
Lindgren (33) RTX TNFi 
RTX 
dominant 
€, 2008 0.91 364.07 
RTX 
dominant 
Malottki (34) RTX ADA 
RTX 
dominant 
£, 2008 0.70 364.07 
RTX 
dominant 
Malottki (34) RTX ETN 
RTX 
dominant 
£, 2008 0.70 364.07 
RTX 
dominant 
Malottki (34) RTX IFX 
RTX 
dominant 
£, 2008 0.70 364.07 
RTX 
dominant 
Malottki (34) ABA ADA 46,400 £, 2008 0.70 364.07 $86,334 
Malottki (34) ABA ETN 37,800 £, 2008 0.70 364.07 $70,332 
Malottki (34) ABA IFX 41,700 £, 2008 0.70 364.07 $77,589 
Manders (35) RTX TNFi 
RTX 
dominant 
€, 2013 0.80 425.13 
RTX 
dominant 
Mandersc (35) ABA TNFi 29,998 €, 2013 0.80 425.13 $8351 
Merkesdadc 
(36) 
RTX ADA 15,565 €, 2008 0.82 364.07 $24,770 
Merkesdale 
(36) 
RTX ADA 24,517 €, 2008 0.82 364.07 $39,017 
 
Assessment of uncertainty 
 Methodological uncertainty, which pertains to the appropriateness of analytic 
decisions, was addressed by six (33, 34, 36-39) studies; the most common items (3 of 6 
studies) addressed were the HAQ-DI-to-QoL equation, rebound effect, allowing negative 
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QoL (states worse than death), and discount rate (adjustment for differential timing of 
events). Structural uncertainty, which pertains to the theory and assumptions underlying the 
model, was addressed by changing rituximab scheduling (33, 34, 37, 39) and drug dosage 
(36) assumptions. One study (34) addressed heterogeneity (first-order uncertainty), which 
accounts for variability among individuals, by running the model separately for different 
populations. Six models (33, 34, 36-39) included sensitivity analyses to assess parameter 
(second-order) uncertainty, which focuses on the imprecision of data inputs: six performed 
one-way sensitivity analyses, including one (38) that also performed a two-way analysis, and 
half (33, 34, 36, 37) performed probabilistic sensitivity analysis. One study included a 2-
dimensional simulation that combined first- and second-order uncertainty (33). The 
rituximab dosing schedule (repeated treatments being given every 4-9 months) significantly 
affected results in five of the six studies evaluating the drug. Other influential parameters 
were assumptions regarding HAQ-DI, such as progression, rebound effects, and the 
conversion-to-preference weights. 
 
Validation 
 Internal and external consistency are important in determining model validity (42). 
Only one study (34) demonstrated the internal validity of the model by verifying its 
mathematical logic. No studies established the external validity of their models; no model 
was calibrated against independent data or tested for predictive validity. All model results did 
appear valid given the data presented (face validity), and five studies (34, 36-39) reported 
that their results were consistent with previous models (cross-validity). 
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DISCUSSION 
 This systematic review included seven studies that made 19 comparisons between 
TNFi and agents with other mechanisms of action. Adherence to the CHEERS reporting 
standard among these studies was moderate, with clear, detailed explanation of modeling 
choices, methodology, and data sources being suboptimal. Despite the substantial uncertainty 
inherent in assumptions about disease progression under different treatment options, the 
included publications agreed that swapping to a non-TNFi targeted agent is a cost-effective 
alternative to cycling to another TNFi at the $100,000/QALY threshold. 
 
 This consensus can, at least partly, be attributed to the largely homogenous structure 
and efficacy parameters of the included models. The efficacy estimates, while expressed 
differently, were derived from the same set of randomized clinical trials (Appendix F). 
However, studies did not take into account safety data as most models are based on results 
from individual trials comparing an experimental drug to a csDMARD and not on meta-
analyses and as such, there is a paucity of data comparing safety differences among the 
different treatments. The validity of the efficacy parameters would be enhanced had it been 
possible to base them on meta-analyses rather than on single trials.  
 
Drug’s relative ranking per study did differ. While this may reflect price differences 
across time and countries it may also indicate sponsorship bias (43, 44). More problematic 
are the large discrepancies and lack of transparency in both the reporting and the inclusion of 
other cost components which further impedes understanding of differences in results. This 
opacity around cost estimates and the preponderance of studies funded by one 
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pharmaceutical company leads to concerns regarding bias: in general assessments performed 
by independent organizations have been found to result in less favorable ICERs than those 
funded by pharmaceutical companies (45).  
 
The choice of comparator may be another source of bias: 11 of the 19 comparisons 
evaluated rituximab versus TNFi which is interesting given that, at least in the United States, 
70% of patients who swap to an agent with other mechanisms of action switch to abatacept 
(19). Furthermore, although golimumab and certolizumab pegol have been on the market 
since 2009, only the latter was analyzed as an alternative to agents with other mechanisms of 
action (46); however, new non-TNFi drugs, tocilizumab (model excluded because the 
patients were TNFi-naïve at entry to model (47)) and tofacitinib, have been explicitly 
considered. A recent analysis reported non-biologic triple therapy (methotrexate, 
sulfasalazine, and hydroxychloroquine) to be cost-effective in comparison to etanercept when 
used as first line therapy (48). However, no publications have reported on this approach in 
patients who have already failed biologic therapy.  
 
Whereas previous systematic reviews (21, 34, 49, 50) have looked at treatment 
options after the failure of the initial TNFi, the current study is the first to specifically 
compare the cycling and swapping strategies and the only one to comprehensively assess 
reporting quality and to investigate modeling differences. Our study was, however, limited 
by the inherent heterogeneity of the economic evaluations and the need to include only those 
that could be comparable. Furthermore, while we recognize that it is not always possible to 
present model details in full, we could only compare information explicitly reported in the 
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papers this may have resulted in more negative quality assessments than the actual models 
warrant. Also, only one study from US met our eligibility criteria, therefore, the cost per 
QALY range reported may not entirely reflect US populations-based cost-utility studies.  
 
 Future research should determine the treatment sequences used in real-world clinical 
practice and the length of time patients continue taking each agent. More detailed analysis of 
the associated nondrug costs would be helpful, as would guidelines regarding the cost 
components to be included and standardization of efficacy estimate adjustments. Much of the 
uncertainty in the models could be attributed to a lack of knowledge regarding how 
commonly used disease activity, disability, and QoL measures change over time, in reaction 
to new treatment, and with disease progression as well as how these measures should be 
converted to utilities. Lastly, as noted, adverse events, a major issue of concern, had not been 
adequately assessed in the majority of these models owing to a lack of evidence on long-term 
safety. This is yet another fruitful area for investigation.  
 
 
CONCLUSION 
Despite the findings showing that swapping to non-TNFi targeted agents is cost-effective at 
the $100,000/QALY threshold, our study highlights the need for further studies evaluating 
cost-effectiveness with swapping choices other than rituximab or intravenous abatacept that 
better reflect current clinical practices, of longer-term studies on the progression of RA, of 
RA costs over time and for greater standardization and transparency in the reporting of 
economic evaluation studies. 
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JOURNAL ARTICLE 2 
Real-world treatment sequences, effectiveness and costs of tumor necrosis factor alpha 
inhibitor (TNFi) cycling versus swapping to a disease-modifying anti-rheumatic drug 
with a new mechanism of action among rheumatoid arthritis patients who have failed 
their first TNFi 
Arthritis Care and Research 
  
ABSTRACT 
 
Objective: Use a large, commercial administrative claims database, Truven Health 
MarketScan®, to evaluate sequences of therapeutic drugs used by rheumatoid arthritis (RA) 
patients who failed their initial tumor necrosis factor inhibitor (TNFi) therapy, mean time 
until therapy discontinuation and the costs associated with TNFi versus non-TNFi drugs.  
Methods: Using the Truven Health MarketScan® Research database we analyzed claims of 
adult RA patients who switched to their second biological or targeted DMARD (disease-
modifying antirheumatic drug) between January 2008 and December 2015. We determined 
the most common treatment sequences and used survival analysis techniques to estimate 
time to therapy discontinuation. We compared costs between adherent and non-
adherent patients considering drug and other healthcare costs.  
Results: Of the 10,442 RA patients identified to have failed TNFi, 36.4% swapped to a non-
TNFi, of which, a majority (66.8%) switched to abatacept. The remaining 63.5% switched to 
a cycling regimen (second TNFi), a plurality of whom received adalimumab (41.1%). For 
subsequent lines, non-TNFi was more frequent. Patients who swapped were significantly (p< 
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0.001) older and sicker than those who cycled. Survival analysis showed longer time to 
discontinuation for second line non-TNFi versus TNFi (median: 471 versus 370 days, p < 
0.001) but no difference in subsequent lines.  
While non-TNFi drugs were less expensive for adherent patients, cycling was associated with 
lower costs overall. 
Conclusion: Our study reinforces previous work which found that, while patients are more 
likely to cycle to a second TNFi, those who swap to a non-TNFi, are more likely to persist on 
second line treatment. However, cycling appears to be the less expensive strategy overall.  
 
MeSH terms: arthritis, rheumatoid/drug therapy; treatment failure; biological 
products/therapeutic use  
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INTRODUCTION 
Rheumatoid arthritis (RA) is a chronic inflammatory disease of the joints affecting 
0.4-1.3% of the United States population (1). Total annual societal costs of the disease are 
approximately $39.2 billion (2) and are rising faster than medical inflation (3). Compared to 
the general population, RA is associated with increased all-cause mortality and greater 
morbidity. Currently, there is no curative treatment and, as such, therapy to control 
symptoms is usually required for life.  
The discovery of tumor necrosis factor alpha inhibitors (TNFi) and other biological 
and targeted synthetic therapies brought new hope to RA patients. More people respond to 
these drugs, and the response is superior to that attained by conventional synthetic disease 
modifying anti-rheumatic drugs (csDMARDs). However, biologic and targeted therapies are 
associated with increased side effects and can cost over $20,000 per year (4).  
 
Over the course of their lifetime, most patients are required to switch medication 
several times due to the side effects of the drug or lack or loss of efficacy in managing 
symptoms. A systematic review of studies of TNFi discontinuation rates, based on registry 
and administrative databases, calculated a mean discontinuation rate of 27% (range 23-32%) 
after one year and increasing to 52% (46-57%) after five years (5).  
There are two basic approaches for TNFi failure: cycling (switching to another TNFi: 
adalimumab, certolizumab, etanercept, infliximab, golimumab) or swapping (to a drug with 
another mechanism of action: abatacept, anakinra, rituximab, tocilizumab, tofacitinib) but 
neither strategy conclusively affects the cost-effectiveness of the second-line drug. As new 
drugs are showing efficacy and being approved (sarilumab and baracitinib were approved in 
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2017 and 2018 respectively. Filgotinib, upadacitinib, perficitinib, olokizumab are among 
those in Phase III trials) there is increased controversy regarding the most effective regimen. 
There is also much concern over the rising price of these drugs: wholesale acquisition costs 
for etanercept, adalimumab and tofacitinib increased 80.3%, 68.6% and 44.3% respectively 
between 2013 and 2016 (6). It is increasingly important to address the issue of value and 
arrive at a consensus regarding the most cost-effective second-line therapeutic option. 
 
Time to discontinuation of treatment, calculated from administrative data sets have 
become an acceptable proxy for effectiveness in the absence of randomized clinical trials (7, 
8). Many studies have calculated survival times and cost of various treatment strategies based 
on utilization date but they have been limited in terms of length of follow-up (9-12) and 
sample size (10, 13-15). Only one study was found that investigated all ten drugs approved 
by the FDA as of 2017 (13).   
Furthermore, existing studies have used a limited lead time which makes it difficult to 
differentiate between second and subsequent line therapies, instead categorizing treatment as 
first or non-first line (9, 12, 14, 15).   
The objectives of this study were to describe sequences of use of treatment strategies, 
time to drug discontinuation, drug and other healthcare costs for adult patients with RA who 
have failed initial TNFi therapy.  
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METHODS 
 
Data source 
This retrospective observational cohort study utilized individual-level, de-identified, 
fully adjudicated healthcare claims information from employers and health plans 
collected from 1998-2016 in the Truven Health Marketscan® Commercial Claims & 
Encounters database. The Marketscan claims databases are fully compliant with the 
health insurance portability and accountability act of 1996 (HIPPS) (16) hence an 
institutional waiver from IRB approval was granted. 
 
Study cohort 
We used a validated claims-based algorithm (17-20) to identify adult enrollees (age ≥ 
18) with RA, using at least two claims, greater than two months apart, with RA diagnosis 
codes (ICD-9-CM: 714.x; ICD-10- CM: M05.x, M06.x) (Appendix G) who received their 
first TNFi between January 1, 2008 and December 31, 2015. 
All patients were required to have at least one year of continuous enrolment prior to 
the first claim for a TNFi and at least one year after initiation of the second drug. The index 
date was the first claim for a TNFi. Because of left censoring, we cannot account for possible 
biologic use prior to inclusion in the MarketScan database.  
Of this initial cohort, we included only those who subsequently switched to a new 
drug of interest between January 1st 2008 and December 31st 2015 (Appendix H) . This 
timeframe was chosen to maximize sample size while mitigating the bias caused by not all 
ten drugs of interest being available on the market (certolizumab, and golimumab were 
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approved in 2009 while subcutaneous (SC) abatacept was approved in July 2011 and 
tofacitinib in November 2012).  
We excluded patients with overlapping episodes of targeted drugs (defined as more 
than one drug within the effective period for that drug) as both American and European 
guidelines explicitly discourage this concomitant dual therapy (21, 22). Furthermore, we 
excluded ra patients who, at any time, had at least 2 claims, 60 days apart for non-ra 
indications of biologic drugs (ankylosing spondylitis, chronic lymphocytic leukemia , non-
Hodgkin’s lymphoma, Crohn’s disease, juvenile idiopathic arthritis,  multiple sclerosis, 
polyarteris nodosa, psoriasis, psoriatic arthritis, spondyloarthropathy, systemic lupus 
erythematosus, ulcerative colitis, Wegener's granulomatosis) as well as those with severe co-
morbidities involving immune-suppression such as HIV, organ transplant and malignancies 
(Appendix I). 
Lastly, we deleted claims with a zero or negative allowed amount. If a patient’s index 
claim was deleted, we removed the patient from analysis. 
 
Study measures 
The primary study outcome was time to discontinuation for TNFi (cyclers) versus 
non-TNFi (swappers) after failure of the first TNFi. Secondary outcomes were time to 
discontinuation of third through sixth treatment lines, the determination of common treatment 
sequences after tnfi-failure, drug and all-cause healthcare costs associated with each therapy 
for all versus adherent and non-adherent patients. 
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Baseline characteristics 
We assessed patient age, gender, year of index TNFi, geographic region, plan type 
and mean follow-up time. We calculated the Deyo-Charlson comorbidity index (23), from 
claims in the six months prior to index. Rheumatologic diseases were not counted towards 
the index.  
Sequences 
We determined the frequency of patients using different drug sequences to establish 
the most commonly used treatment patterns after TNFi failure. 
 
Treatment persistence 
 We compared time to discontinuation between TNFi and non-TNFi drugs. This was 
calculated as the number of days from initiation to drug switching or discontinuation. Switch 
date was the date of a new biologic minus one day.  
A patient was considered to have discontinued treatment if there was greater than 
180-day gap in treatment. We defined the discontinuation date as the last claim date plus 
days’ supply. For claims with a procedure code from the Healthcare Common Procedure 
Coding System (HCPCS), days’ supply was imputed as the dosing interval for intravenous 
(IV) administration as stated in the product insert. For drugs administered subcutaneously 
(SC) only, the SC dosing interval was used. For claims using a National Drug Code (NDC), 
the “DAYSUPP” field was used to determine days’ supply.  In cases where DAYSUPP was 
zero or one day, we imputed days’ supply as the recommended dosing interval. In cases 
where the dosing interval was variable, the smallest interval was used. 
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Previous studies (24-36) used gaps of 30-90 days to determine drug discontinuation 
but this precludes the possibility of patients stopping treatment due to remission (37) or side 
effects and restarting after a flare or the side effect has resolved. Many studies reported 
patients restarting TNFi after 140-207 days (38-40).  We chose 180 days based on our 
preliminary results showing that more than 25% of patients had gaps longer than 90 
days. 
 
Costs 
We calculated two categories of costs comparing adherent and non-adherent patients 
who cycled versus switched after TNFi failure: 1) Direct drug-related costs comprised drug 
acquisition costs for the drugs of interest; 2) other healthcare costs consisted of all other 
claims. Adherent patients were those with a medication possession ratio (MPR) of over 80%. 
For oral and subcutaneous drugs MPR was calculated as the total number of days’ supply 
within the six-month period, divided by 183 days. For intravenous drugs, which do not have 
days’ supply variable, we followed Popp et al and defined adherence as receiving at least 
80% of the expected doses, based on the dosing schedules for these drugs (see Appendix 5.) 
(41). Net payments as reported by the carrier were the primary source for calculating the 
costs. 
Statistical Analysis 
We stratified the cohort based on mechanism of action of the second targeted drug 
(cycling versus swapping) and evaluated unadjusted associations with covariates using t-tests 
and the Wilcoxon rank-sum test (for non-normally distributed variables) for continuous 
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measures and the Pearson Χ2 test for categorical measures. All calculations were based on 
two-tailed significance level set at 0.05. 
Covariates that differed significantly between cyclers and swappers were entered in a 
Cox Proportional Hazards model as detailed below. 
 
Survival analysis 
Differences between cyclers and swappers in time to discontinuation were compared 
using the non-parametric Kaplan Meier method. When the difference was statistically 
significant (p < 0.05) we ran a Cox Proportional Hazards model to determine to what extent 
covariates affect time to discontinuation.  
Patients were censored if they were continuously treated with the second (or 
subsequent) drug. Where we were unable to ascertain discontinuation, patients were censored 
at the end of the study period or disenrollment. 
Because rituximab is given every six to nine months, results may be biased in favor of 
non-TNFi’s, hence the models were run both with and without rituximab. 
 
Cost per treated patient per six months 
Six-month healthcare costs were calculated for the first and second 180-day post-
index period by aggregating payment for individual claims for each of the second line 
targeted drugs and dividing by the number of patients receiving each drug for the full period. 
We calculated these costs for all patients as well as subgroups of adherent and non-adherent 
patients.  
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All data analysis was conducted using SAS ® Enterprise Guide, Version 7.15. (SAS 
Institute Inc., Cary, NC, USA). 
 
RESULTS 
 
Baseline characteristics 
A total of 10,442 patients with a mean follow-up time of almost three years (1,059 
days, SD = 583.1) met the study criteria (Figure 1). Of these, 6,626 (63.46%) people cycled 
to a new TNFi while 3,816 (36.54%) swapped to a drug with a different mechanism of 
action.  Patients who swapped to non-TNFi drugs were significantly older (53.4 years, versus 
51.1, p < 0.001) and had higher Deyo-Charlson scores (8.44% with two or more 
comorbidities, versus 4.63%, p < 0.001) than those who cycled. Their mean follow-up time 
was shorter than patients who cycled (1,023.4 days versus 1,079.9, p < 0.001). There were 
also significant differences in start year of first TNFi, region and plan type (Table 1.) but 
none in terms of gender. 
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Figure 2.1: Patient selection flowchart 
 
  
<18 at initiation of first TNFi n = 41
Patients with ≥ 2 RA diagnoses on different 
dates during 2008-2016
n = 890,198
n = 572,633
TNFi (cyclers) non-TNFi (swappers)
n = 6626 n = 3816
Patients available for analysis
n = 10,442
≥ 2 diagnoses for competing biologic 
agent indication or severe comorbidity
n = 317,565
≤ 1 previous targeted drug n = 543,757
n = 28,876
Index claim deleted in data cleaning n=264
Received a different TNFi or a non-TNFi 
biological prior to 2008
n = 4,163
n = 24,713
n = 10,706
Not continuously enrolled 1 year prior to 
1st TNFi and 1 year post 2nd line 
n = 13,966
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Table 2.1: Demographic characteristics 
 
Variable  Cycle 
n = 6626 
Swap 
n = 3816 
P value 
Age: mean (SD) 51.1 (11.59) 53.64 (11.87) <0.001 
% female 79.43 80.69 NS* 
Deyo-Charlson score 
0 
1 
2+ 
 
80.35% 
15.02% 
4.63% 
 
73.22% 
18.34% 
8.44% 
<0.001 
Region 
North Central 
Northeast 
South 
West 
Unknown 
 
23.17% 
15.51% 
40.51% 
19.44% 
1.37% 
 
24.74% 
15.67% 
40.41% 
17.16% 
2.02% 
0.0037 
Plan type 
Comprehensive 
Exclusive Provider Organizations 
Health Maintenance 
Organization 
Point-Of-Service  
Preferred Provider Organization 
Point-Of-Service – Capitated 
Consumer-Directed Health Plans 
 High Deductible Health Plans 
Unknown 
 
8.10% 
1.09% 
13.34% 
8.12% 
57.29% 
0.36% 
5.58% 
2.60% 
3.52% 
 
12.16% 
1.15% 
9.38% 
7.36% 
58.25% 
0.31% 
5.61% 
2.18% 
3.59% 
<0.001 
Year of first TNFi 
2008 
2009 
2010 
2011 
2012 
2013 
2014 
2015 
 
26.91% 
14.08% 
14.20% 
11.68% 
10.20% 
11.24% 
8.68% 
3.00% 
 
30.97% 
12.08% 
12.29% 
11.48% 
10.06% 
12.34% 
8.23% 
2.54% 
<0.001 
Adherent patients 
First 6 months 
Second 6 months 
 
53.62% 
33.17% 
 
52.75% 
34.72% 
 
NS* 
NS* 
Follow-up time in days: mean (SD) 1079.85 
(590.21) 
1023.36 
(568.84) 
<0.0001 
*NS = not significant 
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Sequences 
Etanercept (n=4551, 43.6%) and adalimumab (n=3305, 31.6%) accounted for 75.2% 
of first-line drugs. Sixty-three percent of patients cycled to a second TNFi (Figure 2), with a 
plurality switching to adalimumab (41.2%) followed by etanercept (24.3%) (Figure 3). 
Slightly more than half of cyclers (52.9%) subsequently switched to a third-line drug, the 
most common being abatacept (30.1%) and etanercept (14.2%).  
More than half of swappers (54.2%) switched to abatacept and under half (46.3%) 
went on to a third-line drug, of which 18.5% switched to tocilizumab and 11.8-14.3% 
switched to etanercept, tofacitinib or adalimumab. Overall, while TNFi were most often 
prescribed as second line treatment for RA patients who had failed their initial TNFi, non-
TNFi drugs were most common in subsequent lines for both cyclers and swappers (Tables 2 
& 3) In all treatment lines approximately 25% of both cyclers and swappers who 
discontinued treatment did not switch to a new biological or targeted DMARD. 
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Figure 2.2: Most common sequences by drug class 
2nd line 3rd line 4th line 5th line 6th line
nonTNFi
n=21 (21.9%)
non-TNFi
n=96 (18.5%) TNFi
n=20 (20.8%)
non-TNFi TNFi
n=518 (26.2%) n=68 (13.1%) None
non-TNFi n=15 (15.6%)
n=1978 (29.8%) TNFi None
n=283 (14.3%) n=117 (22.6%) Censored
TNFi n=40 (41.7%)
TNFi n=1535 (23.1%) None Censored
n=6,635 n=379 (19.2%) n=237 (45.8%)
63.5% None
n=1459 (22%) Censored
n=798 (40.3%)
Censored
n=1,663 (25.1%)
non-TNFi
n=6 (15.8%)
TNFi
n=38 (20%) TNFi
non-TNFi n=4 (10.5%)
n=190 (21.3%) non-TNFi
non-TNFi n=28 (14.7%) None
non-TNFi n=894 (23.5%) TNFi n=11 (28.9%)
n=3,807 n=124 (13.9%) None
36.5% TNFi n=44 (23.2%) Censored
n=869 (22.8%) None n=17 (44.7%)
n=215 (24%) Censored
None n=80 (42.1%)
n=893 (23.5%) Censored
n=365 (40.8%)
Censored
n=1,151 (30.2%)
cycle (TNFi) or swap (non-TNFi)
n=10,442
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Figure 2.3: Most common sequences by drug 
  
2nd line 3rd line 4th line 5th line 6th line
Other
TNFi=5 (9.3%)
non-TNFi=2 (3.7%) rituximab
Other n=5 (45.5%)
TNFi=61 (13.9%) tofacitinib
Other non-TNFi=33 (7.5%) n=12 (22.2%) None
TNFi=336 (12.3%) n=2 (18.2%)
non-TNFi=390 (14.3%) tocilizumab certolizumab
n=54 (12.3%) n=4 (7.4%) Censored
abatacept n=5 (45.5%)
n=438 (16%) tofacitinib None
n=41 (9.4%) n=11 (20.4%)
etanercept
adalimumab n=310 (11.4%) None Censored
n=2,729 n=83 (18.9%) n=20 (n=37%)
26.10% None
n=631 (23.1%) Censored
n=166 (37.9%)
Censored
n=624 (22.9%)
Other Other
TNFi=51 (19%) TNFi=2 (8.3%)
Other non-TNFi=6 (2.2%)
TNFi=468 (22.7%) tofacitinib Censored
non-TNFi=130 (6.3%) rituximab n=3 (12.5%) n = 3
n=24 (9%)
tocilizumab infliximab
abatacept n=268 (13%) tofacitinib n=2 (8.3%)
n=2062 n=23 (8.6%)
19.70% tofacitinib None
n=156 (7.6%) None n=7 (29.2%)
n=58 (21.6%)
None Censored
n=466 (22.6%) Censored n=10 (41.7%)
n=106 (40%)
Censored TNFi
n=574 (27.8%) non-TNFi
cycle (TNFi) or swap (non-TNFi)
n=10,442
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Table 2.2: Second to third line transitions 
 
 Third line TNFi 
adalimumab certolizumab etanercept golimumab infliximab TOTAL 
Second line N % N % N % N % N % N % 
TNFi 303 6.5% 242 5.2% 499 10.7% 251 5.4% 240 5.2% 1,535 14.7% 
adalimumab - - 120 6.3% 310 16.3% 107 5.6% 109 5.7% 646 6.2% 
certolizumab 59 11.9% - - 64 12.9% 29 5.8% 18 3.6% 170 1.6% 
etanercept 139 12.0% 71 6.1% 2 0.2% 81 7.0% 66 5.7% 359 3.4% 
golimumab 62 9.8% 40 6.3% 95 15.0% - - 37 5.8% 234 2.2% 
infliximab 43 9.2% 11 2.4% 28 6.0% 34 7.3% 10 2.1% 126* 1.2% 
 
non-TNFi 209 24.1% 105 12.1% 253 29.1% 111 12.8% 191 22.0% 869 8.3% 
abatacept 110 23.5% 74 15.8% 119 25.4% 66 14.1% 99 21.2% 468 4.5% 
anakinra 2 40.0% 1 20.0% 1 20.0% 1 20.0% - - 5 0.0% 
rituximab 28 26.9% 11 10.6% 30 28.8% 10 9.6% 25 24.0% 104 1.0% 
tocilizumab 22 18.0% 9 7.4% 33 27.0% 20 16.4% 38 31.1% 122 1.2% 
tofacitinib 47 27.6% 10 5.9% 70 41.2% 14 8.2% 29 17.1% 170 1.6% 
TOTAL 512 21.3% 347 14.4% 752 31.3% 362 15.1% 431 17.9% 2,404 23.0% 
* Ten infliximab patients restarted infliximab after >180 days 
 
Third line non-TNFi  
abatacept anakinra rituximab tocilizumab tofacitinib TOTAL 
Second line N % N % N % N % N % N % 
TNFi 
1,05
9 
53.5
% 5 
0.3
% 195 9.9% 362 18.3% 357 18.0% 1,978 18.9% 
adalimumab 438 
52.9
% 3 0.4% 69 8.3% 150 18.1% 168 20.3% 828 7.9% 
certolizumab 121 
49.6
% - - 19 7.8% 53 21.7% 51 20.9% 244 2.3% 
etanercept 259 
57.0
% 2 0.4% 38 8.4% 70 15.4% 85 18.7% 454 4.3% 
golimumab 114 
52.3
% - - 34 
15.6
% 39 17.9% 31 14.2% 218 2.1% 
infliximab 127 
54.3
% - - 35 
15.0
% 50 21.4% 22 9.4% 234 2.2% 
 
non-TNFi 
154 
17.2
% 2 
0.2
% 178 
19.9
% 326 36.5% 234 26.2% 894 8.6% 
abatacept - - 1 0.2% 129 
23.3
% 268 48.4% 156 28.2% 554 5.3% 
anakinra 3 
75.0
% - - 1 
25.0
% - - - - 4 0.0% 
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rituximab 44 
43.1
% - - - - 30 29.4% 28 27.5% 102 1.0% 
tocilizumab 71 
43.3
% 1 0.6% 44 
26.8
% - - 48 29.3% 164 1.6% 
tofacitinib 36 
51.4
% - - 4 5.7% 28 40.0% 2 2.9% 70* 0.7% 
TOTAL 
1,21
3 
42.2
% 7 0.2% 373 
13.0
% 688 24.0% 591 20.6% 2872 27.5% 
* Two tofacitinib patients restarted tofacitinib after >180 days 
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No third line 
Censored None TOTAL 
Second line N % N % N % 
TNFi 1,663 53.3% 1459 46.7% 3,122 29.9% 
adalimumab 624 49.7% 631 50.3% 1255 12.0% 
certolizumab 165 50.6% 161 49.4% 326 3.1% 
etanercept 434 54.3% 365 45.7% 799 7.7% 
golimumab 229 57.3% 171 42.8% 400 3.8% 
infliximab 211 61.7% 131 38.3% 342 3.3% 
non-TNFi 1,151 56.3% 893 43.7% 2,044 19.6% 
abatacept 574 55.2% 466 44.8% 1,040 10.0% 
anakinra 1 14.3% 6 85.7% 7 0.1% 
rituximab 181 54.2% 153 45.8% 334 3.2% 
tocilizumab 220 62.1% 134 37.9% 354 3.4% 
tofacitinib 175 56.6% 134 43.4% 309 3.0% 
TOTAL 2,814 26.9% 2,352 22.5% 5,166 49.5% 
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Table 2.3: Drug frequency by treatment line 
 
TNFi 
LINE adalimumab certolizumab etanercept golimumab infliximab TOTAL 
2 2,729 41.1% 740 11.2% 1,612 24.3% 852 12.8% 702 10.6% 6,635 
3 512 21.3% 347 14.4% 752 31.3% 362 15.1% 431 17.9% 2,404 
4 186 23.3% 129 16.1% 180 22.5% 167 20.9% 137 17.1% 799 
5 45 16.8% 62 23.1% 53 19.8% 61 22.8% 47 17.5% 268 
6 15 15.3% 22 22.4% 19 19.4% 27 27.6% 15 15.3% 98 
7 6 15.8% 7 18.4% 7 18.4% 8 21.1% 10 26.3% 38 
8 - - 1 16.7% - - 3 50.0% 2 33.3% 6 
9 1 33.3% 1 33.3% - - 1 33.3% - - 3 
  
Non-TNFi 
LINE abatacept anakinra rituximab tocilizumab tofacitinib TOTAL 
2 2,062 54.2% 16 0.4% 540 14.2% 640 16.8% 549 14.4% 3,807 
3 1,213 42.2% 7 0.2% 373 13.0% 688 24.0% 591 20.6% 2,872 
4 416 30.0% 5 0.4% 212 15.3% 385 27.8% 369 26.6% 1,387 
5 109 22.3% 5 1.0% 77 15.8% 144 29.5% 153 31.4% 488 
6 27 14.8% 1 0.5% 46 25.1% 46 25.1% 63 34.4% 183 
7 6 13.6% 3 6.8% 7 15.9% 10 22.7% 18 40.9% 44 
8 2 11.1% - - 6 33.3% 2 11.1% 8 44.4% 18 
9 1 50.0% - - - - - - 1 50.0% 2 
 
Looking across treatment lines we found a significant (p < 0.0001) trend to shorter 
time to discontinuation for lines two through five (Appendix K). There was no difference for 
lines five and six. 
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Table 2.4: Median time to discontinuation (in days) for drugs 
  
2nd line 3rd line 4th line 5th line 6th line 
n = 10,442 n = 5,276 n = 2,186 n = 756 n = 281 
Median 
(IQR) 
Median 
(IQR) 
Median 
(IQR) 
Median 
(IQR) 
Median 
(IQR) 
ALL 399 (149-760) 313 (147-644) 252 (112 -539) 200 (93-405) 194 (112-389) 
p (compared to previous line) <0.0001 <0.0001 <0.0001 NS 
TNFi 
370 (133-1,175) 504 (166-
1,374) 
402 (144-1,235) 304 (118-653) 379 (139-
1,150) 
adalimumab 
331 (120-1,007) 439 (151-
1,157) 
392 (123-1,122) 238 (92-820) n/a (847-n/a) 
certolizumab 339 (128-1,003) 273 (104-813) 237 (83-1,000) 232 (59-507) 210 (139-798) 
etanercept 
398 (124-1,343) 722 (223-
1,649) 
447 (189-1,015) 353 (175-552) 189 (90-n/a) 
golimumab 
394 (149-1,263) 461 (183-
1,027) 
419 (189-1,926) 265 (147-942) 308 (168-
1,150) 
infliximab 
542 (214-1,509) 619 (200-
2,011) 
550 (178 – n/a) 417 (248 – n/a) 553 (130-759) 
 
non-TNFi 
471 (180-1,321) 441 (186-
1,438) 
426 (173-1,217) 339 (156-979) 397 (156-
1,013) 
abatacept 
457 (178-1,316) 393 (175-
1,415) 
377 (160-885) 244 (153-634) 244 (155-n/a) 
anakinra 87 (44-799) 88 (54-162) 84 (84-181) 111 (71-158) n/a 
rituximab 
634 (195-1,776) 768 (201-
2,306) 
1,157 (341-2,051) 1,102 (366- 
n/a) 
830 (683-
1,237) 
tocilizumab 
493 (169-1,384) 466 (171-
1,408) 
384 (145-1,1254) 287 (137 – n/a) 260 (84-951) 
tofacitinib 
391 (83-1,049) 431 (125-
1,132) 
339 (102-1,116) 333 (111-901) 352 (116-985) 
 
Survival analysis 
Following Peduzzi et al (42), the minimum sample size for a cox proportional hazards 
regression is 10k/p where k is the number of predictor variables and p is the proportion of 
positive cases (failure events) in the population. A further suggestion is that this number be at 
least 100 (43).  We included five predictor models and there were 7,580/10,442, 3,108/5,230, 
1,229/2,234, 425/767 and 137/282 failure events for the second through sixth line analyses 
respectively, hence models could be run for all of them. 
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The resulting formula for the Cox model for estimating the hazard ratio for 
discontinuation can be presented as follows: 
h(t) = H0(t)*exp(β*drug group + β*age + β*age2 + β*TNF_start_year + β*region + 
β*deyo)  
where H0(t) represents the baseline hazard, the failure rate when all covariates are set to zero. 
 
The median time to discontinuation for second line TNFi was significantly lower 
(p<0.0001) than that for second line non-TNFi: 370 days (Interquartile range (IQR): 133-
1,1175) versus 471 days (IQR: 180-1,321). The Cox model corroborated this. Furthermore, 
patients with more than two comorbidities were less likely to continue taking their second 
line drug while older patients were more likely. Thirteen patients did not have verified 
discontinuation dates and were assumed to be censored. 
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Figure 2.4: Kaplan Meier survival curve for cycling vs swapping  
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Table 2.5: Cox PH analysis of predictors for second line drug discontinuation 
 
Variable Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > Chi
Sq 
Hazard 
Ratio 
95% Confidence 
Intervals 
Drug group (ref = 
TNFi cyclers) 
       
non-TNFi swappers -0.14017 0.02481 31.9252 <.0001 0.869 0.828 0.913 
Age -0.01745 0.00604 8.3505 0.0039 . . . 
Age2 0.0001466 0.0000589 6.1872 0.0129 . . . 
Comorbidity score 
(ref=0) 
       
1 0.03253 0.03256 0.9987 0.3176 1.033 0.969 1.101 
2+ 0.15666 0.05009 9.7806 0.0018 1.17 1.06 1.29 
Region (ref = North 
West) 
       
Northeast -0.03011 0.04026 0.5592 0.4546 0.97 0.897 1.05 
South 0.0808 0.03035 7.0903 0.0078 1.084 1.022 1.151 
Unknown -0.02215 0.09818 0.0509 0.8215 0.978 0.807 1.186 
West 0.07956 0.03661 4.7234 0.0298 1.083 1.008 1.163 
Year of first TNFi 
(ref=2008) 
       
2009 0.08623 0.03945 4.7776 0.0288 1.09 1.009 1.178 
2010 0.11462 0.03916 8.5686 0.0034 1.121 1.039 1.211 
2011 0.2769 0.04062 46.4726 <.0001 1.319 1.218 1.428 
2012 0.23981 0.04308 30.9925 <.0001 1.271 1.168 1.383 
2013 0.26708 0.04224 39.9732 <.0001 1.306 1.202 1.419 
2014 0.44033 0.04692 88.066 <.0001 1.553 1.417 1.703 
2015 0.63067 0.07298 74.6749 <.0001 1.879 1.628 2.168 
Plan type (ref = 
Preferred Provider 
Organization) 
       
Consumer Directed 
Health Plan 
-0.09435 0.05192 3.3015 0.0692 0.91 0.822 1.007 
Comprehensive -0.0356 0.04531 0.6173 0.432 0.965 0.883 1.055 
Exclusive Provider 
Organization 
-0.27452 0.12185 5.0759 0.0243 0.76 0.598 0.965 
High Deductible 
Health Plan 
0.10691 0.07414 2.0794 0.1493 1.113 0.962 1.287 
Health maintenance 
Organization 
0.02418 0.03696 0.4279 0.513 1.024 0.953 1.101 
Point of Service -0.0196 0.04409 0.1976 0.6566 0.981 0.899 1.069 
Point of Service - 
Capitated 
0.16411 0.19708 0.6934 0.405 1.178 0.801 1.734 
 
There was no significant difference in time to discontinuation for third-, fourth- or 
sixth-line drug classes. Fifth line non-TNFi (n=495) did have a significantly longer time to 
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discontinuation in the Kaplan Meier model (median 339 days, 95% IQR: 156-979) than TNFi 
(n=272, median 304 days, 95% IQR: 118-653) but this disappeared when taking covariates 
into account in the multivariate model. 
We conducted a sensitivity analysis by removing the 367 patients who received 
rituximab. The results changed conclusions for the third line non-parametric analysis, making 
time to discontinuation significantly longer for patients on third line TNFi. This difference 
disappeared in the Cox model and seems to be largely accounted for by age and year of first 
TNFi (See Appendix L. for full results). Conclusions were unchanged for other treatment 
lines. 
 
For specific second line drugs, the longest-lasting was etanercept among TNFi (mean 
= 398 days, IQR: 124-1,343) and rituximab among the non-TNFi (mean = 634 days, IQR: 
195-1,176). When comparing the most common second line drugs, median time to 
discontinuation was significantly longer for abatacept (457 days (IQR: 178-1,1316)) 
compared to adalimumab (331 days (IQR 120-1,007).  
Among the most prescribed third line drugs, etanercept (n=752) had a significantly 
longer median time to discontinuation (722 days (IQR: 223-1,649) than abatacept (n=1213) 
(393 days (IQR: 175-1,415). 
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Cost per treated patient 
Mean costs across most categories were significantly lower for patients who cycled to 
a second TNFi. Among patients with a medication possession ratio of at least 80%, mean 
drug costs were lower for non-TNFi swappers, both for the first six months (not statistically 
significant) and the second six-month period (p <0.001): $16,128 (SD $6,742) and $15,645 
(SD $8.213) for TNFi versus $16,046 (SD $7,129) and $14,454 (SD $6324) for non-TNFi. 
Other costs tended to be significantly lower for adherent cyclers (for full details see 
Appendices M & N.) This trend was replicated when looking at the most common second-
line-drugs: adalimumab (TNFi) and abatacept (non-TNFi) and could not be accounted for by 
the higher number of comorbidities among swappers (see Appendix O).  
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Table 2.6: Mean cost differences between cyclers and swappers 
 
Adherent   Variable   Cycle  Swap   Difference (swap-cycle)  p 
ALL 
Drug cost: first 6 months  $12,709 $13,053 $344 0.023 
Other costs: first 6 months  $6,138 $8,228 $2,089 <0.001 
Total costs: first 6 months $18,847 $21,281 $2,433 <0.001 
Drug cost: second 6 months  $7,683 $7,886 $203 NS 
Other costs: second 6 months  $5,100 $7,474 $2,374 <0.001 
Total costs: second 6 months $12,783 $15,360 $2,577 <0.001 
Annual drug cost  $20,392 $20,939 $547 NS 
Annual other costs  $11,238 $15,702 $4,464 <0.001 
Total annual costs $31,631 $36,641 $5011 <0.001 
YES  
Drug cost: first 6 months  $16,128  $16,046  -$82 NS* 
Other costs: first 6 months  $5,594  $8,053  $2,458 <0.001 
Total costs: first 6 months $21,723 $24,097 $2,376 <0.001 
Drug cost: second 6 months  $15,665  $14,455  -$1,210 <0.001 
Other costs: second 6 months  $5,746  $8,035  $2,289 <0.001 
Total costs: second 6 months $21,411 $22,490 $1,079 0.047 
Annual drug cost  $31,301  $29,906  -$1,396 0.0035 
Annual other costs  $11,482  $15,435  $3,953 <0.001 
Total annual costs $42,784 $45,341 $2,557 0.002 
 NO  
Drug cost: first 6 months  $8,756  $9,711  $956 <0.001 
Other costs: first 6 months  $6,767  $8,423  $1,656 0.002 
Total costs: first 6 months $15,523 $18,134 $2,611 <0.001 
Drug cost: second 6 months  $3,721  $4,393  $671 <0.001 
Other costs: second 6 months  $4,779  $7,176  $2,397 <0.001 
Total costs: second 6 months $8,501 $11,568 $3,068 <0.001 
Annual drug cost  $14,977  $16,170  $1,193 <0.001 
Annual other costs  $11,117  $15,844  $4,726 <0.001 
 Total annual costs $26,094 $32,01 $5,919 <0.001 
* NS = not significant 
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Table 2.7: Mean cost differences between adalimumab and abatacept 
 
Adherent   Variable  Adalimumab  Abatacept   Difference (swap-cycle)  p 
ALL 
 Drug cost: first 6 months   $12,873   $13,244   $370  0.0208 
 Other costs: first 6 months   $5,553   $7,851   $2,299  <0.001 
 Drug cost: second 6 months   $7,900   $7,756   -$144 0.0213 
 Other costs: second 6 months   $4,543   $7,479   $2,936  <0.001 
 Annual drug cost  $20,773 $21,000 $227  NS 
 Annual other costs  $10,096 $15,331 $5,235  <0.001 
 YES  
 Drug cost: first 6 months   $16,842   $15,513  -$1,329 <0.001 
 Other costs: first 6 months   $5,328   $7,593  $2,266 <0.001 
 Drug cost: second 6 months   $17,620   $13,669  -$3,950 <0.001 
 Other costs: second 6 months   $5,202   $7,654  $2,453 <0.001 
 Annual drug cost   $34,159   $28,812  -$5,348 <0.001 
 Annual other costs   $10,484   $14,844  $4,361 <0.001 
 NO  
 Drug cost: first 6 months   $7,654   $9,776  $2,122 <0.001 
 Other costs: first 6 months   $5,849   $8,246  $2,397 <0.001 
 Drug cost: second 6 months   $3,600   $3,420  -$180 NS* 
 Other costs: second 6 months   $4,252   $7,351  $3,099 <0.001 
 Annual drug cost   $14,851   $15,271  $420 NS* 
 Annual other costs   $9,925   $15,687  $5,763 <0.001 
* NS = not significant 
 
When looking at all ten drugs there were stark differences among adherent and non-
adherent patients with tocilizumab and golimumab being the least costly for adherent patients 
but the costliest for non-adherent patients in the first 6 months.  A somewhat more 
ambiguous pattern was seen when looking at the second six-months and at annual costs, with 
adalimumab being the costliest for adherent patients (Appendix 9.). 
 
DISCUSSION 
This claims-based retrospective analysis assessed treatment sequences, time to 
discontinuation and costs for 10,442 patients for up to eight years. Our initial results 
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corroborate those of previous authors who found non-TNFi to be associated with higher 
persistence despite being prescribed less (9, 11, 13-15, 44). We found one other report of 
high overall discontinuation rates for biologicals (44). Similarly, while we reported lower 
drug costs for adherent swappers, like other studies (11, 12, 14, 15), we found that other 
categories of cost favored TNFi cycling. Despite other studies reporting improved adherence 
among swappers (9, 14) we found similar adherence between cyclers and swappers.  
 
Patients who began their first TNFi in later calendar years, when there was a greater 
variety of choices, had shorter times until discontinuation. Prescribing patterns and access 
issues may explain why patients in the Western and Southern part of the United States were 
also more likely to discontinue treatment earlier. 
 
The advantages of this study include a larger sample as well as an extended follow-up 
time and inclusion of all ten targeted DMARDs available on the market at the end of the 
study period. The most significant strength is the clear identification of second-line versus 
non-first-line or continuing treatment. Previous publications that made this differentiation 
were limited by other factors such as reliance on self-report (45) small sample size (n<201) 
(46), follow-up of less than three years (38, 47) or few drugs (47, 48).  
 
As with any data source, MarketScan claims data have limitations. Some have to do 
with the nature of claims data and others with the nature of the MarketScan sample 
population. The usefulness of all administrative data sets is constrained in that their purpose 
is to support reimbursement and not to serve as a research tool; as such there is no 
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information regarding baseline disease activity, disease severity or response to treatment. The 
lack of clinical and demographic information precludes propensity score matching which 
could theoretically compensate for channeling bias whereby specific groups of patients may 
be more likely to receive (or not receive) certain drugs than others such that results are 
incorrectly attributed to the drug instead of unmeasured characteristics of the patients. While 
multivariate modeling does control for some patient characteristics, the nonrandomized 
allocation of the study groups and baseline heterogeneity introduces bias and confounding. 
Our study was limited by the number of covariates analyzed compared to similar studies, 
such as concurrent and pre-index use of csDMARDs, pre-index costs and a greater number of 
treatment effectiveness criteria. 
 Accuracy is also a concern in that the diagnosis and procedure codes that do exist 
may be subject to up-coding, miscoding or may simply be missing if they are not 
reimbursable. In that vein, Fisher et al (49) report errors in recording days’ supply – this 
supports using a more conservative (shortest possible) cut-off to determine failure.   
Regarding MarketScan specifically, because it underrepresents medium and small 
firms in favor of large employers, the sample is not random, possibly leading to biases and 
impaired generalizability.  
The sample may undercount the newer drugs as claims for newly licensed 
medications use a non-specific HCPCS code (e.g., J3490 and J3590) until a unique HCPCS 
code specific to each drug is assigned – this can take up to two years. Because physicians 
tend to prescribe more familiar drugs first, we believe that this is unlikely to impact results 
significantly. 
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Lastly, while time to drug discontinuation is commonly used as a surrogate marker 
for efficacy, there are other factors that influence retention rates, such as cost (in terms of 
absolute cost and also patient co-payments), insurance coverage, access to alternative 
treatments and patient/provider preferences (50). Studies have shown a lowering of the 
threshold of disease activity before switch over time (50) and a trend of decreasing time to 
switch (5, 35, 45), specifically, an increasing rate of discontinuations due to inefficacy with 
no concomitant change in discontinuation rate due to adverse events (51), supporting the 
contention that the availability of more choices leads to increased switch rates.  
 
Areas for future research include expanding the covariates used in the analysis while 
preserving the long-follow-up time and analyzing clinical databases which will allow for 
better matching of patients using more pertinent characteristics such as sero-marker status. 
Another avenue for study is to determine how, if at all, reasons for switching, affect time to 
discontinuation of subsequent lines of treatment. Additional data analysis is required first, to 
corroborate our finding regarding discontinuation of biological and targeted treatment 
altogether and, secondly, to determine what alternative treatments patients are prescribed. We 
would also like to further examine reasons for differences in costs between the treatment 
options. 
 
CONCLUSION 
The retrospective claims-based analysis of commercially insured patients adds to the 
knowledge base by demonstrating how RA patients change treatment over an extended 
period of time with TNFi being the treatment of choice for second-line treatment while non-
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TNFi’s are preferred after that. We showed that patients who swap to a drug with a different 
mechanism of action have longer times to discontinuation compared to those who cycle to a 
second TNFi. No differences were found for subsequent treatment lines. We report a 
tendency to lower costs for cycling with the exception of drug costs for adherent patients 
which were lower for swappers. Our analysis substantiates previous studies that support the 
use of non-TNFi biological DMARDS for patients who have failed their first TNFi. Patient-
specific clinical factors, not available in administrative databases, are needed for more 
unequivocal evidence.  
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JOURNAL ARTICLE 3 
Failed initial tumor necrosis inhibitor (TNFi) therapy – what next? Cost-utility analysis 
of cycling versus swapping to a disease-modifying anti-rheumatic drug with a new 
mechanism of action among rheumatoid arthritis patients who have failed their first 
TNFi 
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ABSTRACT 
Objective:  To analyze sequences of therapeutic drugs used by rheumatoid arthritis (RA) 
patients who failed their initial tumor necrosis factor inhibitor (TNFi) therapy in terms of 
cost-utility, using a microsimulation model following best practice guidelines with parameter 
inputs based on real-world data. 
Methods: We simulated 10,000 RA patients beginning second line biological treatment with 
adalimumab or abatacept and followed them for up to ten years. In each strategy, patients 
could either respond or fail to respond to therapy. Those not responding switched to the next 
drug in a sequence of three. Costs and utilities were assigned based on patients’ changing 
disability status over time. Demographics, treatment sequences, direct medical costs and 
transition probabilities derived from a cohort of RA patients in the Truven Health 
MarketScan® Research database were entered into a Markov model using TreeAge Pro 
2019. 
Results: Switching to a sequence that begins with abatacept versus adalimumab results in an 
incremental discounted cost of just over $8,000 over ten years and achieves a discounted 
QALY benefit of 0.14. The incremental cost-effectiveness ratio (ICER) of $61,245/QALY is 
within current willingness to pay thresholds (WTP). Scenario analysis produced an ICER 
range of $40,659/QALY to $129,587/QALY. Probabilistic sensitivity analysis results showed 
that swapping to abatacept after TNFi failure has a 80.6% likelihood of being cost-efficient at 
a WTP of $100,000/QALY. 
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Conclusion: Swapping to a treatment sequence beginning with the non-TNFi abatacept was 
estimated to be a cost-effective strategy for RA patients who have failed their first TNFi 
therapy. 
MeSH terms: cost-utility analysis, arthritis, rheumatoid/drug therapy; treatment failure; 
biological products/therapeutic use 
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INTRODUCTION 
The promise of rheumatoid arthritis (RA) remission, first seen as a possibility two 
decades ago when etanercept was approved, has not quite been realized. While many patients 
do respond and sustain a response to their initial TNFi, many do not (1-4). As of March 2019, 
there are ten biological and two targeted synthetic disease modifying anti-rheumatic drugs 
(bDMARDs and tsDMARDs respectively) competing to be a second line agent, all proven 
efficacious in randomized clinical trials compared to placebo or conventional synthetic 
disease modifying anti-rheumatic drugs (csDMARDs) and all expensive. In the absence of, 
and extreme difficulty in designing, head-to-head randomized controlled trials of 
complicated treatment sequences, decision analytic models are able to synthesize and 
extrapolate from the available data. To-date few cost-effectiveness models have considered 
options after failure of initial TNF-inhibitor. The 30% of patients (1) experiencing this 
scenario is faced with an expanding range of choices which greatly complicates clinical 
decision making. There are two basic approaches for TNFi failure: cycling (switching to 
another TNFi: adalimumab, certolizumab, etanercept, infliximab, golimumab) or swapping 
(to a drug with another mechanism of action: abatacept, anakinra, baracitinib, sarilumab, 
rituximab, tocilizumab, tofacitinib) but neither strategy conclusively affects the cost-
effectiveness of the second-line drug.  
The uncertainty of treatment success, coupled with risk and high expense make these 
therapies an important target for economic evaluations. These can help fill knowledge gaps 
regarding population-level effects of the alternative therapies, providing a framework for the 
comparison of competing interventions thereby assisting decision makers to determine which 
best serves their needs. 
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This study aims to provide such a tool by applying best practices to evaluate real-
world practice in terms of incremental cost per quality adjusted life year (QALY) of 
alternative treatments for adult RA patients in the United States who have failed their first 
TNFi. 
 
METHODS 
Philips et al’s (5) guidelines for good practice in decision-analytic modeling were 
followed, with model structure based on best practices as set out in the reference case 
recommendations made by the U.S. Panels on Cost Effectiveness in Health and Medicine (6, 
7). Both of these are, by design, broad and as such, RA-specific methodology will follow 
Modelling and the Outcome Measures in Rheumatology Clinical Trials (OMERACT) 
consensus-based reference case for rheumatoid arthritis (8, 9) with input from a systematic 
review of the rheumatoid arthritis cost-effectiveness literature (10). 
 
Model description and structure 
A probabilistic cost-utility microsimulation Markov (state-transition) model was 
developed in TreeAge Software (TreeAge Software Inc, Williamstown, Mass.). 
Microsimulation, as opposed to cohort models, allows for the incorporation of heterogeneity 
and the tracking of events. Markov models are particularly suited to chronic diseases as they 
allow the mapping of long periods of time while taking into consideration disease 
progression and varying probabilities. Patients transition between mutually exclusive health 
states representing clinically and economically distinct events in the disease course. The state 
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transition diagram (Figure 1) shows the transitions among health states with the arrows on 
the arc representing the direction of the possible movements. These transitions can occur 
once per ‘Markov cycle’. Figure 2 demonstrates the full Markov model. In keeping with most 
literature on the subject, cycles were six months long. The first cycle of new treatment is 
associated with higher cost due to loading doses of the drugs. It is also potentially associated 
with the highest utility. Under these circumstances we chose not to implement a half-cycle 
correction which would entail eliminating half of the upfront cost and utility of a new 
treatment. 
Treatment sequences and model input parameters were determined from an analysis 
of 10,442 patients derived from the Truven Health MarketScan® Commercial Claims & 
Encounters Databases. The model begins after failure of the patients’ first TNFi. Patients 
pass through sequences of up to three biological drugs after which they shift to palliative 
treatment. 
The analysis was from the perspective of a U.S. private health care payer and, as such 
only included costs incurred by insurers. The model followed patients from initiation of the 
second bDMARD for ten years or until death. For the sensitivity analysis we used a lifetime 
perspective. Theorists prefer a lifetime perspective to reflect the chronic nature of the disease 
(5) but, for RA specifically, the OMERACT consensus conference cautions against 
extrapolating beyond available data (8). 
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Figure 3.1: State transition diagram 
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Figure 3.2: Model structure 
 
 
Population and setting 
The cohort consisted of 10,000 individuals, demographically similar to that seen in a 
large U.S. administrative claims data base in terms of age and gender, who have failed their 
initial TNFi therapy. Baseline HAQ-DI was derived from a computation of patients’ age 
adjusted comorbidity index (CCIa) which has been shown to correlate with HAQ-DI (11-14). 
Each CCIa score was mapped to a corresponding HAQ-DI distribution (11) such that patients 
with the same CCIa could have a range of HAQ-DI scores.   Scenario analyses were run 
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using HAQ values derived from the Birmingham Rheumatoid Arthritis Model (BRAM) (15) 
and ROC (16) and ATTAIN (17) clinical trials, all of which comprised patients who were 
refractory to at last one prior TNFi (Table 2). 
 
Table 3.1: Baseline demographic characteristics of the model cohort 
 
Demographical variables Value  Source 
Females (%) 79.9% MarketScan 
Age (mean ± SD) years 52.03 (11.76) MarketScan 
HAQ-DI score (mean ± SD) 1.46 (0.29) MarketScan 
 
Treatment sequences 
Both the U.S. Panels on Cost Effectiveness in Health and Medicine (6, 7) and the 
OMERACT consensus-based reference case for rheumatoid arthritis (8, 9) recommend 
modelling treatment sequences as this is more realistic, with the proviso that these sequences 
be based on actual practice.  
The literature on patterns has mostly concentrated on TNFi’s and even then, there is 
no consensus on the most common second line TNFi: adalimumab (18-21), etanercept (22-
24) or infliximab (25). This is likely due to several factors including methodology (self-
report versus registry or patient records), country of origin and its treatment guidelines, 
payment rules and population preferences, as well as availability of alternatives at the time 
the study was performed. Only one study (18) was found that examined non-TNFi drugs: 
Baser et al (18) examined data from 3,497 patients starting a second-line agent between 
2004-2010 in the Truven Health MarketScan Commercial Claims and Encounters Database 
and the Medicare Supplemental and Coordination of Benefits database and report that 
abatacept was used 19% of the time, compared to adalimumab, etanercept and infliximab 
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(31%, 23% and 15% of patients, respectively) and over 70% of the time in those swapping to 
a non-TNFi. This is a particularly interesting finding given that most studies have 
concentrated on rituximab as a second line drug (10). 
The comparators for this study consist of the most common sequence in each of the 
cycle and swap categories as ascertained by the analysis of administrative claims data.   
• Strategy A: Cycle: adalimumab (ADA) > abatacept (ABA) > tocilizumab (TCZ) 
• Strategy B: Swap: abatacept (ABA) > tocilizumab (TCZ) > rituximab (RTX) 
We found that while most patients cycle to a second TNFi after initial TNFi failure, non-
TNFi drugs predominate in subsequent treatment lines.  
Patients who survive the full treatment sequence will continue with palliation. Given 
the paucity of evidence on the efficacy of csDMARDs following biological or targeted 
DMARDs, we have not specified what form palliation takes (26). 
 
 
Health outcomes 
Initial and continued treatment response (transition) probabilities were determined 
from the claims data on a six-monthly basis. They were calculated by dividing the number of 
patients still on treatment at the end of each six-month treatment by the total number of 
patients still being followed up in that period. Rates were assumed to be constant after four 
years. 
Responding patients experienced a once-off improvement in disability (HAQ-DI 
reduction) followed by a disease progression until loss of efficacy (return to baseline HAQ-
DI) at which point they switch to the next treatment in sequence.  
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The HAQ-DI is measured in most RA trials, it is assessed in clinical practice and has 
been shown to be a close approximation of patients’ own evaluation of their health (27), 
having a fundamental relationship to utility, and a strong correlation with costs and mortality 
(28, 29) 
The term ‘utility’ refers to cardinal values that represent the strength of an 
individual’s preferences for specific outcomes under conditions of uncertainty. Health 
utilities specifically, are preferences for distinctive health states or treatments and they allow 
for the comprehensive measurement of health-related quality of life (30).  
QALY’s take into consideration both the duration of the effect and its utility.  While 
the validity of QALYs is not uncontroversial it remains the most commonly used measure of 
health states that facilitates comparisons across diseases.  
 
We converted HAQ-DI to utilities using the formula utilized by the Birmingham 
Rheumatoid Arthritis Model (BRAM) (15). Sensitivity analyses used 2 other formulas: 
Bansback (31) because is it the most commonly used and Carreño (32) because it gives much 
higher values than these and other commonly used formulas (Table 2).  
 
Resource use 
Cost parameters and their distributions were gleaned from the analysis of 
administrative claims data. Net payments as reported by the carrier were the primary source 
for the calculation. We calculated two categories of costs: 1) Direct drug-related costs 
comprised drug acquisition costs for the drugs of interest; 2) other healthcare costs consisted 
of all other claims. Each category was further subdivided into initial cycle versus subsequent 
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cycles to account for loading doses and extra monitoring associated with starting a new 
treatment. Total costs for each cycle was the sum of drug and other healthcare costs. For 
palliation, costs were other healthcare costs only. These include costs for csDMARDs and 
symptomatic treatment.  
Costs for the 33 individuals aged over 80 with two or more comorbidities (CCIa=6) 
were excluded from the base case analysis as they were more than double the next highest 
CCIa category and likely include end-of-life costs. This impact of this was checked in 
scenario analysis. 
As with utilities, other health related costs were attributed to each individual based on 
their functional disability score in each cycle. This correlation has been demonstrated in the 
literature (33, 34). 
 
Given the paucity of studies on productivity losses for the target population, the technical 
challenges of aggregating outcomes and the debate over methodology and social welfare, this 
economic evaluation will be from a health-system perspective and as such, will focus on direct 
medical costs (7, 8, 35). 
Table 3.2: Health Assessment Questionnaire Parameters 
 
HAQ to utility formula 
Source Conversion to utilities 
Birmingham Rheumatoid Arthritis Model (base case) 
(15) 
utility = 0.804 -0.203*HAQ-DI – 0.045*HAQ-DI^2 
Bansback (31) utility = 0.76 - 0.28*HAQ+0.05*female 
Carreño (32) Utility = 0.9567 - 0.309*HAQ-DI 
 
Baseline HAQ 
Source Mean SD 
Truven MarketScan (base case) 1.46  0.29 
BRAM (15) 2.0 0.56 
ATTAIN trial (17) 1.8 0.6 
ROC trial (16) 1.3 0.6 
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HAQ changes   
Initial response -0.4 -0.3 
Subsequent cycles 0.017 0.01 
 
Table 3.3: Transition probabilities 
 
Strategy A: Cycle: adalimumab (ADA) > abatacept (ABA) > tocilizumab (TCZ) 
β 
distribution 
Adalimumab (2nd line) Abatacept (3rd line) Tocilizumab (4th line) 
Mean SD Mean SD Mean SD 
Cycle 1 0.6448 0.2500 0.6850 0.1620 0.5876 0.0970 
Cycle 2 0.7356 0.1850 0.5858 0.1422 0.6360 0.0727 
Cycle 3 0.7133 0.1627 0.6701 0.1039 0.6621 0.0570 
Cycle 4 0.7010 0.1391 0.7370 0.0796 0.6979 0.0450 
Cycle 5 0.7264 0.1134 0.7344 0.0686 0.7313 0.0363 
Cycle 6 0.7468 0.0943 0.6780 0.0622 0.5510 0.0348 
Cycle 7 0.7578 0.0803 0.7667 0.0463 0.7778 0.0216 
Cycle 8+ 0.6992 0.0748 0.6522 0.0457 0.7143 0.0207 
 
Strategy B: Swap: abatacept (ABA) > tocilizumab (TCZ) > rituximab (RTX) 
β 
distribution 
Abatacept (2nd line) Tocilizumab (3rd line) Rituximab (4th line) 
Mean SD Mean SD Mean SD 
Cycle 1 0.7424 0.1995 0.6459 0.1255 0.9009 0.0435 
Cycle 2 0.7573 0.1685 0.6225 0.1023 0.5759 0.0683 
Cycle 3 0.7137 0.1546 0.6895 0.0770 0.7364 0.0462 
Cycle 4 0.6850 0.1342 0.6335 0.0666 0.7284 0.0400 
Cycle 5 0.7535 0.1031 0.6942 0.0507 0.6610 0.0364 
Cycle 6 0.7030 0.0949 0.7143 0.0414 0.6410 0.0300 
Cycle 7 0.7657 0.0737 0.6000 0.0379 0.6800 0.0233 
Cycle 8+ 0.7026 0.0696 0.6667 0.0283 0.8235 0.0157 
 
Relative risk of mortality due to RA 
Standard US Life tables 2015 (36) * RA risk modifier (29) 
 
 
Table 3.4: Drug cost parameters 
 
First cycle drug cost 
γ distribution 
Strategy A: Cycle  Strategy B: Swap 
Drug Mean Std Dev  Drug Mean Std Dev 
Second line ADA $12,873 $7,277  ABA $13,244 $7,228 
Third line ABA $13,244 $7,228  TCZ $11,984 $7,466 
100 
 
Fourth line TCZ $11,984 $7,465  RTX $16,469 $8,713 
        
Subsequent cycle drug cost 
γ distribution 
Strategy A: Cycle  Strategy B: Swap 
Drug Mean Std Dev  Drug Mean Std Dev 
Second line ADA $7,900 $9,214  ABA $7,7556 $7,676 
Third line ABA $7,756 $7,676  TCZ $8,365 $8,280 
Fourth line TCZ $8,365 $8,280  RTX $8,437 $8,952 
 
 
Costs and outcomes were discounted at a rate of three percent per annum as 
recommended by Second Panel on Cost-Effectiveness in Health and Medicine (7). 
 
Model Assumptions  
Certain assumptions are required as modelers need to find a balance between 
accuracy, computability and comprehensibility. In the current analysis, like others (10), we 
assume that there is an immediate loss of treatment effect after discontinuation. This is based 
on the expectation that the withdrawal is due to loss of effect or adverse events, both of 
which imply loss of therapeutic effect. Furthermore, there is no information on differential 
returns to baseline between the competing agents. 
Due to limited long-term data, and evidence demonstrating similar safety profiles 
between abatacept and adalimumab (37) the costs and disutilities of adverse events have not 
been explicitly included in the model. There is also little consensus and standardization 
within clinical trials and observational studies on how, or even which, adverse events should 
be reported. Our analysis captured them in the calculation of overall healthcare costs and 
discontinuation probabilities (38). 
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Analysis 
TreeAge’s microsimulation sums the utilities and costs of individual patients (trials) 
taking a random walk through the model’s chance nodes. It uses a Monte Carol pseudo-
random series to generate a new state configuration from the current one. A key assumption 
of Markov models is that this is a memory-less system: the new configuration does not 
depend on any history prior to the current cycle.  This is circumvented somewhat by the use 
of trackers which count how many new treatments patients have been on and how many 
cycles they have been in the ‘Respond’ state. Drug costs differ per treatment, and transition 
probabilities depend on treatment as well as number of cycles. For the first eight cycles in the 
‘Respond’ state, the Markov chain can thus be said to be non-stationary. Subsequently, the 
transition probabilities are constant and the chain can be considered stationary although the 
probability of dying increases over time, with increasing patient age. 
Two-dimensional simulation was used to account for both first-order i.e. variability 
among individuals (trials) and second-order uncertainty i.e. parameter uncertainty 
(sampling), 
Pairwise comparisons were made between treatment sequences and the model 
outcome will be expressed in terms of the incremental cost effectiveness ratio (ICER), i.e. the 
marginal cost per Quality Adjusted Life Year gained.  
 
Sensitivity Analysis 
An essential step in the modelling process is the sensitivity analyses. Conflicting 
source data, poor internal or external validity and the necessity of extrapolating or making 
assumptions lead to uncertainty in most economic evaluations. It is thus necessary to 
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systematically vary the input parameters and probabilities across their possible ranges and 
calculate the ICERs based thereon. If the conclusion remains unchanged the result can be 
said to be robust. If the results are not robust, the sensitivity analysis can point to areas where 
more information is needed, where uncertainty is most crucial and to variables that have 
greatest bearing on the conclusion  
 
Threshold analysis seeks to identify the critical value of parameter that would need to 
be achieved in order for an intervention to be deemed cost-effective. Debate exists over the 
appropriate benchmark for societal willingness to pay (WTP) per quality-adjusted life year 
(QALY) gained as well as the appropriateness of the measure itself.  It is generally 
acknowledged that the prevalent $50,000/QALY cost-effectiveness threshold criterion, one 
that has not been revised to allow for inflation and national variation, is not based on well-
formulated justifications for a specific dollar value. For the purposes of this analysis, we have 
thus also used a $100,000/QALY threshold. 
 
Probabilistic Sensitivity Analysis (PSA) assesses the joint uncertainty across all 
parameters. Costs, transition probabilities and HAQ-DI changes were assigned distributions 
and the Monte Carlo simulation recalculated expected values for repeatedly sampling 
parameter values from these distributions. By iterating this process thousands of times 
distributions of the incremental costs and effects were obtained. 
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RESULTS 
The model comparing two common strategies after initial TNFi failure show that 
switching to a sequence that begins with abatacept, an anti-T lymphocyte 
recombinant fusion protein, will cost approximately $224,000 (discounted) over ten years, 
compared to $216,000 for the sequence that begins with cycling to adalimumab, a tumor 
necrosis factor inhibitor. The incremental cost of just over $8,000 achieves a discounted 
QALY benefit of 0.14 over those ten years for an ICER of $61,245/QALY for the basecase 
(Table 4). 
Scenario analysis resulted in an ICER range from $40,659/QALY to $129,587/QALY 
with a median of $67,483/QALY (Table 5). This is within the realm of current willingness to 
pay thresholds. These results calibrate nicely with the BRAM model, keeping in mind their 
higher baseline disability (15). Their comparison of abatacept versus adalimumab resulted in 
an ICER of £46,4000 (95% credible interval: £23,100-£152,000) which is equivalent to 
$86,334 ($42,981 - $282,818) (2017 USD).  
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Table 3.5: Scenario analysis 
 
 ADA>ABA>TCZ ABA>TCZ>RTX Incrementa
l 
Costs 
Incrementa
l 
QALYs 
ICER Cohort = 
10,000 
Costs 
QALY
s 
Costs 
QALY
s 
Base-case $215,851 3.22 $224,182 3.36 $8,331 0.14 $61,245/QALY 
Lifetime horizon $356,350 2.71 $367,335 2.98 $10,985 0.27 $40,659/QALY 
5-year horizon $139,588 2.12 $146,492 2.17 $6,904 0.05 $129,587/QALY 
Including CCIa6 $217,252 3.13 $225,617 3.25 $8,365 0.12 $71,830/QALY 
Bansback HAQ-
QALY 
$241,844 3.87 $251,394 4.07 $9,550 0.20 $48,215/QALY 
Carreño HAQ-
QALY 
$215,244 4.05 $224,234 4.19 $8,990 0.14 $64,755/QALY 
No negative 
QALY 
$216,234 3.23 $224,440 3.36 $8,205 0.13 $64,175/QALY 
ATTAIN HAQ  $225,611 2.22 $235,838 2.37 $10,227 0.14 $71,050/QALY 
ROC HAQ $205,158 3.59 $214,692 3.72 $9,534 0.14 $69,186/QALY 
BRAM HAQ $236,208 1.92 $246,504 2.02 $10,296 0.10 $102,076/QALY 
 
 
Probabilistic sensitivity analysis suggests that the swapping strategy has an 80.6% 
probability of having an ICER below $100,000 compared with a 37.1% probability at the 
more conservative $50,000/QALY threshold.  
 
The cost-effectiveness acceptability curve (Figure 2) summarizes some of the 
uncertainty in the analysis by demonstrating the probability of an alternative being cost-
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effective across a range of willingness-to-pay thresholds – given the available data. The 
abatacept strategy becomes more likely to be cost-effective at just under $60,000/QALY. 
 
Figure 3.3: Cost-Effectiveness Acceptability Curve 
 
Looking at the incremental cost effectiveness scatterplots, one sees that while the 
ABA>TCZ>RTX can be cost-effective at the $50,000/QALY threshold (Figure 3a), it is 
more likely to be so with a higher willingness-to-pay threshold (Figure 3b). 
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Figure 3.4: ICE Scatterplots  
(A: WTP=$50,000/QALY B: WTP = $100,000/QALY) 
 
DISCUSSION 
Few studies have compared cycling to swapping, those that have utilized a variety of 
methodologies and parameters, resulting in a wide range of ICERs. None were based on a US 
population. In addition, transparency regarding data sources and methodological details is an 
issue. This leads to concern about biases, particularly since it has been found that 
assessments performed by independent organizations result in less favorable ICERs than 
those funded by pharmaceutical companies (39). Publicly funded studies are not yet available 
for all agents, indeed, for the newer agents, no analysis of their cost-effectiveness as second-
line treatment was found at all. 
  
Our baseline mean HAQ-DI was lower than that of other CUAs (10) and this can be 
explained by their reliance of clinical trial data and, in one case, a British cohort: people 
enrolling in randomized clinical trials tend to have higher disease activity than those in 
general practice (40, 41) and biologic drugs are used less frequently in the United Kingdom 
(41). As the primary outcome is incremental effectiveness, this is unlikely to affect direction 
of results. 
 
The ICER of the swapping strategy was lower over a longer time period and was higher 
when baseline HAQ-DI was higher. Both can be explained by the greater probability of 
continuing treatment in the ABA>TCZ>RTX arm. In the former case, the advantages of 
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staying on treatment and continued lower HAQ-DI leads to decreased costs over time. 
However, when HAQ-DI is high, the higher costs associated with this strategy counter this.  
 
Joensuu et al (42) reviewed cost-utility analyses of biologics in RA including four 
studies comparing rituximab or abatacept to one of more TNFi’s. All were European studies. 
The analyses including rituximab conclude that, compared to TNF’s, it is either cost-effective 
at the €30,000 incremental cost effectiveness ratio (ICER) threshold or is the dominant 
option (cheaper and more effective). The ICERs for abatacept ranged from €47,663 to over 
1.2 million euros.  
Sullivan et al (43) conclude from their review of 15 articles that cycling to a second 
TNFi is less likely to be cost-effective whereas swapping to abatacept or rituximab results in 
an ICER below willingness to pay thresholds and may even be cost-saving. 
Our systematic review also found that swapping to a non-TNFi agent is a cost-
effective alternative to cycling to a second TNFi, at the $100,000/QALY threshold (10). The 
median ICER was $70,332/QALY, compared to this model’s $67,483/QALY. 
 
Decision-analysis models are, by definition, simplifications of complex processes and 
as such cannot capture the full nuance of real-life situations. For example, trials have not had 
the statistical power necessary to determine differences in treatment-specific mortality and 
adverse event between arms. Likewise, models are only as good as the data that are available 
to be incorporated into it. So, while population risk stratification is recommended for 
increased generalizability and application of the model to sub-groups (e.g. seropositivity), the 
lack of individual demographic and clinical data hampers this. Similarly, treatment sequences 
were fixed and do not account for the fact that the choice of the next drug may depend on the 
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reason for failure of its predecessor: adverse event or primary versus secondary non-
response. It is difficult to predict how this would affect results. 
The HAQ-DI deterioration rate has been shown to have an impact on study results, 
and like many others, this study modelled slow, universal HAQ-DI deterioration while on 
therapy. Lack of data on HAQ-DI progression per second line agent likely impacts the 
accuracy of the model. Similarly, pain has been shown to be an independent predictor of 
health-related quality of life and should be incorporated into the HAQ-DI to utility 
conversion formula (44). This information is not available from administrative databases. 
 
The greatest strength of this model lies in its use of real-world data. Firstly, treatment 
sequences were chosen in an objective manner with no implicit preference for a particular 
outcome. This is in contrast to most cost-effectiveness analyses performed. Our systematic 
review found these to be largely funded by pharmaceutical companies and, either by design 
or due to publication bias, to favor the sponsor’s product. Our analysis allows clinicians to 
assess actual clinical practice thereby making conclusions particularly pertinent and valid.  
An additional advantage of real-world data is the longer-term follow-up which 
reduces reliance on extrapolation. Randomized clinical trials are limited to one drug and are 
usually conducted over 6 months. Optional long-term extension studies of up to two years do 
exist but, overall, there is a paucity of head-to-head studies for second line drugs.  
Administrative data also gives access to a more diverse population than that available 
from strictly controlled clinical trials. Our costs and discontinuation probabilities are derived 
from community practice. These factors increase the generalizability of our findings to the 
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larger population. It has also been reported that using data from randomized controlled trials 
results in lower ICERs than community-based settings (45). 
 
 
CONCLUSION 
To our knowledge, this is the first full cost-utility analysis investigating cycling to a second 
TNFi versus swapping to a non-TNFi biological drug after failure of first-line TNFi that 
synthesizes evidence from a United States commercial claims database. Our independent 
study determined treatment sequences based on an appraisal of real-life prescribing patterns 
with no preconceived notions of what drugs those sequences should consist of. Similarly, 
parameter inputs were derived solely from the data. Despite being limited in terms of clinical 
data our results support and add credence to the existing literature that shows swapping to be 
a cost-effective strategy for this population.  
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APPENDICES 
Appendix A:  Summary of biological and targeted synthetic therapies 
Drug Target and structure FDA license Given Dose Loading 
dose 
Frequency 
Etanercept 
(Enbrel) 
TNFi 
Soluble fusion protein 
Nov 1998 SC 25mg   Fortnightly 
Infliximab+MTX 
(Remicade) 
TNFi 
Chimeric (mouse) MAb 
Nov 1999 IV 3mg/kg  
 
w0, w2, w2 q8w 
Anakinra 
(Kineret) 
Anti-IL1 Nov 2001 SC 100mg  Daily 
Adalimumab 
(Humira) 
TNFi 
Recombinant human MAb 
Dec 2002 SC 40mg  Fortnightly 
Abatacept 
(Orencia) 
Anti-T lymphocyte 
Recombinant fusion protein 
Dec 2005  
Jul 2011 
IV 
SC 
500-1000mg  
125mg 
w0 w2 w4 monthly 
Weekly 
Rituximab 
(Rituxan) 
Anti-CD20 
Chimeric human/mouse MAb 
Mar 2006 
TNFii failure 
IV 100mg  
 
 d1 d15 -as needed 6-
monthly 
Certolizumab 
(Cimzia) 
TNFi 
Pegylated humanized MAb 
Mar 2009 SC 400mg  
then 200mg q2w  
OR 400mg  
w0 w2 w4  
 
Monthly 
Golimumab 
(Simponi) 
TNFi 
Human recptor MAb 
Apr 2009 
Jul 2013 
SC 
IV 
50mg 
2mg/kg 
 
w0 w4 
Monthly 
q8w 
Tocilizumab 
(Actemra) 
IL-6 receptor 
Humanized MAb 
Jan 2010 
Oct 2013 
IV 
SC 
4mg/kg up to 
8mg/kg 
162mg  
 Monthly 
Weekly or fortnightly 
Tofacitinib Anti-JAK Nov 2012 
Feb 2016 
PO 
XR 
5mg x2/d 
11mg x1/d 
 Twice daily 
Daily 
MAb = monoclonal antibody IL = interleukin JAK =  
SC = subcutaneous IV = Intravenous PO = per os XR = extended release 
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Appendix B:  Search strategy. Database(s): Ovid MEDLINE(R) In-Process & Other Non-
Indexed Citations and Ovid  
 
# Searches 
1 exp ARTHRITIS, RHEUMATOID/ 
2 ((rheumatoid or reumatoid) and arthriti*).ti. 
3 ((rheumatoid or reumatoid) adj5 arthriti*).mp. 
4 ra.ti. 
5 (rheumatism* or rheumarthriti*).mp. 
6 ((rheumatic or reumatic) and (arthriti* or polyarthriti*)).ti. 
7 ((rheumatic or reumatic) adj5 (arthriti* or polyarthriti*)).mp. 
8 (rheumatoid and nodul*).ti. 
9 (rheumatoid adj5 nodul*).mp. 
10 (rheumatoid and vasculit*).ti. 
11 (rheumatoid adj5 vasculit*).mp. 
12 
((Caplan* or Felty* or Stills* or "Still's" or Sjogren* or Sjoegren* or sicca) and 
(syndrome* or disease*)).ti. 
13 
((Caplan* or Felty* or Stills* or "Still's" or Sjogren* or Sjoegren* or sicca) adj5 
(syndrome* or disease*)).mp. 
14 or/1-13 
15 exp TUMOR NECROSIS FACTORS/ 
16 (tumo?r necrosis factor* adj5 (inhibit* or block* or antagonist* or modulator*)).mp. 
17 (TNF* adj5 (inhibit* or block* or antagonist* or modulator*)).mp. 
18 (anti-tnf* or antitnf* or TNFi).mp. 
19 (anti-tumo?r necrosis factor* or antitumor necrosis factor*).mp. 
20 exp RECEPTORS, TUMOR NECROSIS FACTOR/ 
21 (TNF* adj3 receptor* adj3 (antibod* or anti-bod* or MAb)).mp. 
22 (tumo?r necrosis factor* adj3 receptor* adj3 (antibod* or anti-bod* or MAb)).mp. 
23 (TNFR* adj3 (antibod* or anti-bod* or MAb)).mp. 
24 exp ANTIBODIES, MONOCLONAL/ 
25 ("anti-tumo?r necrosis factor-alpha" adj3 "monoclonal antibod*").mp. 
26 ETANERCEPT/ 
27 (etanercept* or Enbrel* or Embrel* or "TNR 001*" or TNR001*).mp. 
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28 ("tumo?r necrosis factor receptor*" adj3 Fc adj3 "fusion protein*").mp. 
29 (TNFR* adj3 Fc adj3 "fusion protein*").mp. 
30 
(Avent* or CHS-0214* or CHS0214* or Etacept* or Etanar* or GP2015* or GP 2015* 
or HD203* or HD 203* or LBEC0101* or LBEC 0101* or PRX-106* or PRX106* or 
Qiangke* or TNFcept* or TuNEX* or Yisaipu*).mp. [etanercept biosimilars] 
31 
(DWP 422* or DWP422* or SB-4* or SB4* or ENIA-11* or ENIA11* or BX-2922* 
or BX2922* or Davictrel* or Intacept*).mp. [more biosimilars] 
32 ADALIMUMAB/ 
33 (adalimumab* or Humira* or "D2E7 antibod*").mp. 
34 
(CTP13* or CT-P13* or SB2* or SB-2* or NI071* or NI-071* or PF06438179* or PF-
06438179* or BOW015* or BOW-015*).mp. [biosimilars] 
35 INFLIXIMAB/ 
36 
(infliximab* or Remicade* or Revellex* or "MAB cA2" or "monoclonal antibody 
cA2").mp. 
37 (avakine* or IFX or inflectra* or remsima*).mp. 
38 
(CTP13* or CT-P13* or SB2* or SB-2* or NI071* or NI-071* or PF06438179* or PF-
06438179* or BOW015* or BOW-015*).mp. [biosimilars] 
39 CERTOLIZUMAB PEGOL/ 
40 (certolizumab* or Cimzia* or cdp-870* or cdp870*).mp. 
41 (PF688* or PF-688*).mp. [biosimilars] 
42 (golimumab* or Simponi* or CNTO148 or (CNTO adj "148")).mp. 
43 (BOW100* or BOW-100*).mp. [biosimilars] 
44 
(ozoralizumab* or ATN103* or ATN-103* or PF5230896* or PF-5230896*).mp. 
[new? anti-TNF] 
45 BIOSIMILAR PHARMACEUTICALS/ 
46 biosimilar*.mp. 
47 or/15-46 
48 14 and 47 [RA + TNF terms] 
49 ECONOMICS/  [Begin NHS EED strategy] 
50 exp "COSTS AND COST ANALYSIS"/ 
51 ECONOMICS, DENTAL/ 
52 exp "ECONOMICS, HOSPITAL"/ 
53 ECONOMICS, MEDICAL/ 
54 ECONOMICS, NURSING/ 
55 ECONOMICS, PHARMACEUTICAL/ 
133 
 
56 
(economic$ or cost or costs or costly or costing or price or prices or pricing or 
pharmacoeconomic$).ti,ab. 
57 (expenditure$ not energy).ti,ab. 
58 (value adj1 money).ti,ab. 
59 budget$.ti,ab. 
60 or/49-59 
61 ((energy or oxygen) adj cost).ti,ab. 
62 (metabolic adj cost).ti,ab. 
63 ((energy or oxygen) adj expenditure).ti,ab. 
64 or/61-63 
65 60 not 64 
66 Letter.pt. 
67 Editorial.pt. 
68 Historical article.pt. 
69 Animals/ not humans/ 
70 or/66-69 
71 65 not 70 [End of NHS EED strategy] 
72 48 and 71 [RA + TNFi + NHS EED] 
73 exp ECONOMICS/ [Begin NHS QI Scotland filter] 
74 exp "FEES AND CHARGES"/ 
75 exp HOSPITALIZATION/ 
76 CONSUMER SATISFACTION/ 
77 PATIENT ACCEPTANCE OF HEALTH CARE/ 
78 DISEASE MANAGEMENT/ 
79 PHYSICIAN'S PRACTICE PATTERNS/ 
80 exp "PATIENT CARE PLANNING"/ 
81 HEALTH CARE RATIONING/ 
82 QUALITY OF LIFE/ 
83 VALUE OF LIFE/ 
84 QUALITY-ADJUSTED LIFE YEARS/ 
85 "OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE)"/ 
86 "OUTCOME ASSESSMENT (HEALTH CARE)"/ 
87 MODELS, ECONOMIC/ 
88 MARKOV CHAINS/ 
89 MONTE CARLO METHOD/ 
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90 DECISION TREE/ 
91 ec.fs. 
92 
(economic$ or cost? or costing? or costly or costed or price? or pricing? or 
pharmacoeconomic? or (pharmaco adj economic?) or budget$).tw. 
93 
(value adj1 money).mp. or (value adj1 monetary).tw. [mp=title, abstract, original title, 
name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique 
identifier] 
94 
(charge? or fee or fees or saving? or preference? or satisfaction or satisfied or ration$ or 
"quality of life" or qol? or hrqol? or "quality adjusted life year?" or qaly?).tw. 
95 
(cba or cea or cua or value? or model$ or markov$ or (monte adj carlo) or (decision 
adj2 (tree? or analys$)) or outcome? or utilit$ or pathway? or protocol?).tw. 
96 ((clinical or critical or patient) adj path?).tw. 
97 ((managed adj2 (care or clinical or network)) or (resource? adj1 allocat$)).tw. 
98 or/73-97 [End of NHS QI Scotland filter] 
99 48 and 98 [RA + TNF + NHS QI Scotland] 
100 
exp "COSTS AND COST ANALYSIS"/  [econ/cost from current Medline prelim 
strategy] 
101 ECONOMICS, PHARMACEUTICAL/ 
102 ec.fs. 
103 (cost*3 or economic* or pharmacoeconomic* or clinicoeconomic*).ti,kw,sh,jw. 
104 
(cost*3 adj5 (benefit* or analy* or control* or measur* or averag* or estimat* or 
evaluat* or annual* or minimiz* or minimis* or minimali* or utilit* or effectiveness or 
containment)).ab. 
105 
((econom* or cost*3 or financ* or expenditure* or spend* or spent) adj5 (impact* or 
model* or evaluat* or analy* or burden)).ab. 
106 (ICER* or QALY*).ti,kw. 
107 COMPARATIVE EFFECTIVENESS RESEARCH/ 
108 (comparativ* and (effective* or efficac*)).ti,kw. 
109 QUALITY-ADJUSTED LIFE YEARS/ 
110 or/100-109 [cost/econ terms from current Medline prelim] 
111 48 and 110 [RA + TNFi/drug + econ/cost] 
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Appendix C:  Parameter sources 
Study Effectiveness* 
Adverse 
events 
Drug costs Other medical costs Resource use 
Claxton 
2016 (38) 
RCTs (Keystone et al. 
2004; Burmester et al. 
2013; Genovese et al. 
2005; Cohen et al. 
2006) 
Meta-
analysis 
(Strand et 
al. 2015) 
Drug 
Package 
inserts 
RED BOOK 
online 
(Truven 
Health 
Analytics 
2015) 
U.S. Medicare fee 
schedule (InGauge Health 
Care Solutions 2015) 
The National (Nationwide) 
Inpatient Sample 
(Healthcare Cost and 
Utilization Project (HCUP) 
2012) 
ACR guidelines 
(Saag et al. 2008) 
Hallinen 
2010 (39) 
RCTs (Genovese et al. 
2008; Maini et al. 
1999; Weinblatt et al. 
1999; Cohen et al. 
2006; Keystone et al. 
2004) 
n/a 
Finnish 
Medicine 
Tariff 
(11/2008) 
National health are unit 
costs in Finland (Hujanen 
et al. 2008) 
National health 
are unit costs in 
Finland (Hujanen 
et al. 2008) 
Kielhorn 
2008 (37) 
RCTs (Maini et al. 
1999; Cohen et al. 
2006; Keystone et al. 
2004) 
n/a 
British 
National 
Formulary 
Personal Social Services 
Research Unit (PSSRU) 
(Curtis and Netten 2003, 
2004) 
Office for National 
Statistics (Office for 
National Statistics 2005) 
National Health Service 
(Department of Health & 
Social Care 2004) 
Literature review (Barton 
et al. 2004; Nuijten et al. 
2001; Yelin and Wanke 
1999) 
Norfolk Arthritis 
Register (Wiles, 
Cooper, and 
Symmons 2005) 
Lindgren 
2009 (33) 
Southern Swedish 
Arthritis Treatment 
Group Registry, RCT 
(Cohen et al. 2006) 
excluded 
Swedish 
official price 
list 
Swedish Survey 
(Jacobsson et al. 2007) 
Swedish Survey 
(Jacobsson et al. 
2007) 
Malottki 
2011 (34) 
RCTs (Bingham et al. 
2009; Bombardieri et 
al. 2007; Burmester et 
al. 2007; Genovese et 
al. 2005; Keystone et 
al. 2008; Keystone et 
al. 2009; Westhovens 
et al. 2006; Bristol-
Meyers Squibb 2004; 
Chen et al. 2006; 
Cohen et al. 2006; 
Emery 2005; Hassett 
et al. 2008; National 
Audit Office 2009) 
RCT’s 
(Bingham 
et al. 2009; 
Burmester 
et al. 2007) 
British 
National 
Formulary 
Systematic review (Chen 
et al. 2006) 
Survey (National Audit 
Office 2009) 
Systematic review 
(Chen et al. 2006) 
Survey (National 
Audit Office 
2009) 
Manders 
2015 (35) 
Economic evaluation done alongside pragmatic clinical trial: Netherlands Trial Register number 
NTR1605. 
Merkesdal 
2010 (36) 
RCTs (Bansback, 
Brennan, and 
Ghatnekar 2005; 
Weinblatt et al. 1999; 
Edwards et al. 2004; 
n/a 
German drug 
retail 
prices for 
pharmacists 
German recommendations 
(Deutsche Gesellschaft 
fur Rheumatologie, DGRh) 
German 
recommendations 
(Deutsche 
Gesellschaft 
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Study Effectiveness* 
Adverse 
events 
Drug costs Other medical costs Resource use 
Maini et al. 1999; 
Genovese et al. 2005; 
Keystone et al. 2004) 
Roche internal file 
fur 
Rheumatologie) 
*Effectiveness for all included economic evaluations was derived from specific trials of specific 
medications (in all cases it was biological DMARD vs conventional synthetic DMARD).  
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Appendix D:  Drug costs 
First author Cost Unit Dose 
Freque
ncy 
6-month 
cost 
Curre
ncy 
Base 
year 
PPPa USD 
MCPI
b 
2017 
USD 
ABATACEPT IV   
Claxton (38) 849 
250 
mg 
vial 
Weight 
depende
nt 
  15,290 $ 2015 1.00 15,290 446.75 16,268 
Hallinen 
(39) 
1116 Dose 
750 
mg 
q4w 6696 € 2008 0.91 7341 364.07 9,584 
Malottki 
(34) 
242 
250 
mg 
750 
mg 
q4w 4722 £ 2008 0.70 6730 364.07 8,786 
Manders 
(35) 
15,000 Year     7500 € 2013 0.80 9405 425.13 10,515 
                        
ABATACEPT SC  
Claxton (38) 864 
125 
mg/mL 
syringe 
125 
mg 
Weekly 22,466 $ 2015 1.00 
22,46
6 
446.75 23,903 
                        
ADALIMUMAB  
Claxton (38) 1898 
40 
mg/0.8 
ml pen 
40 mg q2w 24,681 $ 2015 1.00 24,681 446.75 26,259 
Hallinen 
(39) 
618 Dose 40 mg q2w 8043 € 2008 0.91 8818 364.07 11,512 
Kielhorn 
(37) 
358 40 mg 40 mg q2w 4660 £ 2004 0.69 6774 310.10 10,382 
Malottki 
(34) 
358 Dose   q2w 4648 £ 2008 0.70 6623 364.07 8,648 
Merkesdal 
(36) 
24,914 Year 40 mg q2w 12,457 € 2008 0.82 15,184 364.07 19,824 
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First author Cost Unit Dose 
Freque
ncy 
6-month 
cost 
Curre
ncy 
Base 
year 
PPPa USD 
MCPI
b 
2017 
USD 
CERTOLIZUMAB PEGOL   
Claxton (38) 
3344.5
9 
400 
mg/2 
ml 
syringe 
200 
mg 
q2w 21,740 $ 2015 1.00 21,740 446.75 23,130 
            
ETANCERCEPT 
   
Claxton (38) 932.16 
50 
mg/ml 
syringe 
50 mg Weekly 24,236 $ 2015 1.00 24,236 446.75 25,786 
Hallinen 
(39) 
295.19 Dose 50 mg Weekly 7675 € 2008 0.91 8414 364.07 10,986 
Malottki 
(34) 
178.78 Dose 50 mg Weekly 4648 £ 2008 0.70 6623 364.07 8,649 
                        
INFLIXIMAB                     
Hallinen 
(39) 
1306.6
2 
Dose 
210 
mg 
q8w 4247 € 2008 0.91 4656 364.07 6,079 
Kielhorn 
(37) 
419.62 
100 
mg 
3 
mg/kg 
  3431 £ 2004 0.69 4987 310.10 7,644 
Malottki 
(34) 
149.62 Vial     3777 £ 2008 0.70 5382 364.07 7,028 
Merkesdal 
(36) 
15,215
.97 
Year 
3 
mg/kg 
q8w 7608 € 2008 0.82 9273 364.07 12,107 
                        
RITUXIMAB                      
Claxton (38) 774.07 
10 
mg/ml 
vial 
2*1000 
mg 
q6mo 15,481 $ 2015 1.00 15,481 446.75 16,472 
Hallinen 
(39) 
3061.0
2 
Dose 
2*1000 
mg 
q9mo 4592 € 2008 0.91 5034 364.07 6,573 
Kielhorn 
(37) 
873.15 
500 
mg 
2*1000 
mg 
q9mo 3493 £ 2004 0.69 5077 310.10 7,782 
Malottki 
(34) 
873.15 
500 
mg 
2*1000 
mg 
q8.7mo 2409 £ 2008 0.70 3433 364.07 4,482 
Manders 
(35) 
9487.2
0 
 Year 
2*1000 
mg 
q6mo 4744 € 2013 0.80 5948 425.13 6,651 
Merkesdal 
(36) 
11,146
.83 
Year 
2*1000 
mg 
q9mo 5573 € 2008 0.82 6794 364.07 8,869 
                        
TOCILIZUMAB IV                     
Claxton (38) 819.48 
80 
mg/ml 
vial 
400ml  once  4097 $ 2015 1.00 4097 446.75 4,359 
            
TOCILIZUMAB SC                     
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First author Cost Unit Dose 
Freque
ncy 
6-month 
cost 
Curre
ncy 
Base 
year 
PPPa USD 
MCPI
b 
2017 
USD 
Claxton (38) 819.48 
80 
mg/ml 
vial 
  Weekly 21,306 $ 2015 1.00 21,306 446.75 22,669 
                        
TOFACITINIB                      
Claxton (38) 52.82 
5 mg 
tablet 
5 mg *2/d 19,279 $ 2015 1.00 19,279 446.75 20,512 
                        
TNFi                       
Manders 
(35) 
13,205
.00 
Year     6603 € 2013 0.80 8280 425.13 9,258 
                        
GOLD SALTS                      
Hallinen 
(39) 
5.06 Dose 50 mg q4w 30 € 2008 0.91 33 364.07 43 
Kielhorn 
(37) 
2.94 10 mg 
25-50 
mg 
q2-3w 96 £ 2004 0.69 139 310.10 214 
Malottki 
(34) 
11.23 Dose 50 mg   67 £ 2008 0.70 96 364.07 125 
Merkesdal 
(36) 
327.22 Year     163.61 € 2008 0.82 199 364.07 260 
                        
AZATHIOPRINE                      
Malottki 
(34) 
0.40 Day 
150 
mg 
Daily 74 £ 2008 0.70 105 364.07 138 
                        
CYCLOSPORINE                     
Hallinen 
(39) 
9.54 Dose 
210 
mg 
Daily 1741 € 2008 0.91 1909 364.07 2,492 
Kielhorn 
(37) 
50.00 
100 
mg 
3.25 
mg/kg 
Daily 768 £ 2004 0.69 1116 310.10 1,711 
Malottki 
(34) 
5.37 Day 
225 
mg 
Daily 980 £ 2008 0.70 1397 364.07 1,823 
Merkesdal 
(36) 
5917.2
2 
Year     2959 € 2008 0.82 3606 364.07 4,709 
                        
Leflunomide                      
Kielhorn 
(37) 
51.13 20 mg 15.2 g Daily 247 £ 2004 0.69 359 310.10 550 
Malottki 
(34) 
1.70 Day 20 mg Daily 310 £ 2008 0.70 442 364.07 577 
                        
Methotrexate                      
Hallinen 
(39) 
1.32 Dose 15 mg Weekly 34 € 2008 0.91 38 364.07 49 
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First author Cost Unit Dose 
Freque
ncy 
6-month 
cost 
Curre
ncy 
Base 
year 
PPPa USD 
MCPI
b 
2017 
USD 
Kielhorn 
(37) 
3.27 2.5 mg 
7.5-20 
mg 
Weekly 18 £ 2004 0.69 27 310.10 40 
Malottki 
(34) 
0.12 Tablet 15 mg Weekly 18 £ 2008 0.70 26 364.07 33 
Merkesdal 
(36) 
155.74 Year     78 € 2008 0.82 95 364.07 124 
                        
Palliative                       
Malottki 
(34) 
284.00 
6 
months 
    284 £ 2008 0.70 405 364.07 528 
a Purchasing power parity, data from World Bank 
b Medical Consumer Price Index, data from US Bureau of Labor Statistics 
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Appendix E: Point estimates of the cost-utility comparisons 
 
 
Figure 4a represents the point estimates of the cost-utility comparisons of rituximab (RTX) – a swapping 
strategy. Health outcomes (incremental quality-adjusted life year (QALY)) are plotted on the x axis and the 
incremental costs on the y axis. The studies were rituximab generated more health gains reported higher costs. 
Rituximab was cost-saving in seven of the reported estimates. ADA, adalimumab; ETN, etanercept; IFX, 
infliximab; TNFi, RTX, rituximab; Tumor Necrosis Factor alpha inhibitor. 
 
 
 
 
Figure 4b represents the point estimates of the cost-utility comparisons of abatacept (ABA) – a swapping 
strategy. Health outcomes (incremental quality-adjusted life year (QALY)) are plotted on the x axis and the 
incremental costs on the y axis. The studies were intravenous abatacept generated more health gains reported 
higher costs. ABA, abatacept; ADA, adalimumab; ETN, etanercept; IFX, infliximab; TNFi, Tumor Necrosis 
Factor alpha inhibitor. 
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Appendix F: Efficacy and utility parameters 
Author(s) 
Claxton, 
2016 (38) 
Hallinen, 
2010 (39) 
Kielhorn, 2008 
(37) 
Lindgren, 2009 (33) 
Malottki, 
2011 (34) 
Manders, 
2015 (35) 
Merkesdal, 
2010 (36) 
Health Assessment Questionnaire (HAQ) 
HAQ 
progression: 
bDMARD 
n/a  
0.017/cycle 0.017/cycle 
Linear regression 
using:starting HAQ, 
months on treatment, 
treatment line and 
disease duration 
response 
maintained 
Not 
reported 
0.017/cycle 
HAQ 
progression: 
cDMARD 
n/a n/a n/a 0.045/year n/a n/a 
HAQ 
progression: 
palliation 
0.065/cycle 0.065/cycle n/a 0.06/year n/a 0.065/cycle 
HAQ 
progression: 
off treatment 
n/a n/a 0.03/year n/a n/a n/a 
HAQ after 
treatment 
end 
return to initial 
HAQ score 
 
return to initial HAQ 
score 
return to 
initial HAQ 
score 
 n/a 
HAQ-QoL 
conversion 
0.76 -  
0.28*HAQ+ 
0.05*Female 
0.76 - 0.28*HAQ+ 
0.05*Female  
-0.252*HAQ - 
0.107*disease 
activity - 0.05*male 
+ 0.915 
a-b1*HAQ-
b2*HAQ^2 
n/a 
0.76-
0.28*HAQ 
+0.05*Female 
Health Assessment Questionnaire (HAQ) change associated with ACR 
ACR0-20 
n/a 
 
0.1 0.1 
n/a n/a n/a 
0.1 
ACR20-50 0.45 0.45 0.45 
ACR50-70 0.85 0.85 0.85 
ACR70-100 1.11 1.11 1.1 
Efficacy 
ADA 
Keystone, 
2004 
Keystone, 
2004 
Keystone, 2004 
Comparator was 
TNFi in general. No 
efficacy information 
reported 
n/a Manders, 
2015 
Keystone, 
2004 
% achieving 
ACR20/50/70 
(degraded) 
adjusted ACR 
response rates 
(transition 
probabilities 
adjusted ACR 
response rates 
TNFi in 
general 
Good/mod 
EULAR 
response 
adjusted ACR 
response rates 
48.2/21.2/6.8 0.21/0.16/0.18 0.598/0.369/0.196 0.34/0.72 0.21/0.16/0.18 
ABA+MTX 
Genovese et 
al 2005 
Genovese et al 
2005 
n/a n/a n/a Manders, 
2015 
n/a % achieving 
ACR20/50/70 
adjusted ACR 
response rates 
(transition 
probabilities 
Good/mod 
EULAR 
response 
50/20/10 0.32/0.11/0.11 0.21/0.68 
ETN 
n/a 
Weinbaltt et al, 
1999 
n/a n/a n/a 
n/a  
adjusted ACR 
response rates 
(transition 
probabilities 
0.29/0.22/0.14 
IFX n/a Maini, 1999 Maini, 1999 n/a 
n/a n/a Maini, 1999 
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Author(s) 
Claxton, 
2016 (38) 
Hallinen, 
2010 (39) 
Kielhorn, 2008 
(37) 
Lindgren, 2009 (33) 
Malottki, 
2011 (34) 
Manders, 
2015 (35) 
Merkesdal, 
2010 (36) 
adjusted ACR 
response rates 
(transition 
probabilities) 
adjusted ACR 
response rates  
adjusted ACR 
response rates 
0.24/0.2/0.08 0.59/0.319/0.094 0.24/0.2/0.08 
RTX+MTX 
Cohen, 2006 Cohen, 2006 Cohen, 2006 
Cohen, 2006 
n/a Manders, 
2015 
Cohen, 2006 
% achieving 
ACR20/50/70  
adjusted ACR 
response rates 
(transition 
probabilities) 
adjusted ACR 
response rates 
% achieving 
ACR20/50/70 
Good/mod 
EULAR 
response 
adjusted ACR 
response rates 
51/27/12 0.27/0.17/0.13 0.631/0.334/0148 51/27/12 0.39/0.71 0.27/0.17/0.13 
TOF 
Burmester et 
al 2013 
n/a n/a n/a n/a 
n/a n/a % achieving 
ACR20/50/70 
51/37/16 
Adjustment 
 
Ref placebo 
OR/Trial 
placebo OR 
*Trial 
treatment OR 
Ref placebo 
OR/Trial placebo 
OR *Trial 
treatment OR 
n/a n/a 
 
(adjusted 
Trial 
Treatment = 
adjusted 
OR/(1 + 
adjusted OR) 
(adjusted OR 
= 
(OR\Average 
placebo 
rate/OR\Trial 
Placebo) 
+OR\Trial 
Treatment). 
Time on 
treatment 
Probabilistic 
Predefined 
time period 
Predefined time 
period 
Probabilistic Probabilistic  
Predefined 
time period 
RTX 
retreatment 
interval 
6 months 9 months 9 months 6 months 8.7 months 6 months 9 months 
Discount rate, 
effectiveness 
n/a 0.03 0.035 0.03 0.035  0.035 
Discount 
rate, cost 
n/a 0.03 0.035 0.03 0.035  0.035 
 
ACR, American College of Rheumatology; ADA, adalimumab; ABA, abatacept; bDMARD, biologic 
Disease Modifying Antirheumatic Drug; cDMARD, conventional Disease Modifying Antirheumatic 
Drug; ETN, etanercept; EULAR, European League Against Rheumatism; HAQ, Health Assessment 
Questionnaire; IFX, infliximab; MTX, methotrexate; n/a, not applicable; OR, odds ratio; RTX, 
rituximab; TNFi, Tumor necrosis factor alpha inhibitor; TOF, tofacitinib. 
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Appendix G – RA ICD-10 codes 
 
ICD-10 code Description 
M05.40  Rheumatoid myopathy with rheumatoid arthritis of unspecified site  
M05.411  Rheumatoid myopathy with rheumatoid arthritis of right shoulder  
M05.412  Rheumatoid myopathy with rheumatoid arthritis of left shoulder  
M05.419  Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder  
M05.421  Rheumatoid myopathy with rheumatoid arthritis of right elbow  
M05.422  Rheumatoid myopathy with rheumatoid arthritis of left elbow  
M05.429  Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow  
M05.431  Rheumatoid myopathy with rheumatoid arthritis of right wrist  
M05.432  Rheumatoid myopathy with rheumatoid arthritis of left wrist  
M05.439  Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist  
M05.441  Rheumatoid myopathy with rheumatoid arthritis of right hand  
M05.442  Rheumatoid myopathy with rheumatoid arthritis of left hand  
M05.449  Rheumatoid myopathy with rheumatoid arthritis of unspecified hand  
M05.451  Rheumatoid myopathy with rheumatoid arthritis of right hip  
M05.452  Rheumatoid myopathy with rheumatoid arthritis of left hip  
M05.459  Rheumatoid myopathy with rheumatoid arthritis of unspecified hip  
M05.461  Rheumatoid myopathy with rheumatoid arthritis of right knee  
M05.462  Rheumatoid myopathy with rheumatoid arthritis of left knee  
M05.469  Rheumatoid myopathy with rheumatoid arthritis of unspecified knee  
M05.471  Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot  
M05.472  Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot  
M05.479  Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot  
M05.49  Rheumatoid myopathy with rheumatoid arthritis of multiple sites  
M05.50  Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site  
M05.511  Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder  
M05.512  Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder  
M05.519  Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder  
M05.521  Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow  
M05.522  Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow  
M05.529  Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow  
M05.531  Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist  
M05.532  Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist  
M05.539  Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist  
M05.541  Rheumatoid polyneuropathy with rheumatoid arthritis of right hand  
M05.542  Rheumatoid polyneuropathy with rheumatoid arthritis of left hand  
M05.549  Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand  
M05.551  Rheumatoid polyneuropathy with rheumatoid arthritis of right hip  
M05.552  Rheumatoid polyneuropathy with rheumatoid arthritis of left hip  
M05.559  Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip  
M05.561  Rheumatoid polyneuropathy with rheumatoid arthritis of right knee  
M05.562  Rheumatoid polyneuropathy with rheumatoid arthritis of left knee  
M05.569  Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee  
M05.571  Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot  
M05.572  Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot  
M05.579  Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot  
M05.59  Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites  
M05.70  Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems 
involvement  
M05.711  Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement  
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ICD-10 code Description 
M05.721  Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement  
M05.722  Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement  
M05.729  Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems 
involvement  
M05.731  Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement  
M05.732  Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement  
M05.739  Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems 
involvement  
M05.741  Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement  
M05.742  Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement  
M05.749  Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems 
involvement  
M05.751  Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement  
M05.752  Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement  
M05.759  Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems 
involvement  
M05.761  Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement  
M05.762  Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement  
M05.769  Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems 
involvement  
M05.771  Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems 
involvement  
M05.772  Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems 
involvement  
M05.779  Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems 
involvement  
M05.79  Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement  
M05.80  Other rheumatoid arthritis with rheumatoid factor of unspecified site  
M05.811  Other rheumatoid arthritis with rheumatoid factor of right shoulder  
M05.812  Other rheumatoid arthritis with rheumatoid factor of left shoulder  
M05.819  Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder  
M05.821  Other rheumatoid arthritis with rheumatoid factor of right elbow  
M05.822  Other rheumatoid arthritis with rheumatoid factor of left elbow  
M05.829  Other rheumatoid arthritis with rheumatoid factor of unspecified elbow  
M05.831 Other rheumatoid arthritis with rheumatoid factor of right wrist 
M05.832  Other rheumatoid arthritis with rheumatoid factor of left wrist  
M05.839  Other rheumatoid arthritis with rheumatoid factor of unspecified wrist  
M05.841  Other rheumatoid arthritis with rheumatoid factor of right hand  
M05.842  Other rheumatoid arthritis with rheumatoid factor of left hand  
M05.849  Other rheumatoid arthritis with rheumatoid factor of unspecified hand  
M05.851  Other rheumatoid arthritis with rheumatoid factor of right hip  
M05.852  Other rheumatoid arthritis with rheumatoid factor of left hip  
M05.859  Other rheumatoid arthritis with rheumatoid factor of unspecified hip  
M05.861  Other rheumatoid arthritis with rheumatoid factor of right knee  
M05.862  Other rheumatoid arthritis with rheumatoid factor of left knee  
M05.869  Other rheumatoid arthritis with rheumatoid factor of unspecified knee  
M05.871  Other rheumatoid arthritis with rheumatoid factor of right ankle and foot  
M05.872  Other rheumatoid arthritis with rheumatoid factor of left ankle and foot  
M05.879  Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot  
M05.89  Other rheumatoid arthritis with rheumatoid factor of multiple sites  
M05.9  Rheumatoid arthritis with rheumatoid factor, unspecified  
M06.00  Rheumatoid arthritis without rheumatoid factor, unspecified site  
M06.011  Rheumatoid arthritis without rheumatoid factor, right shoulder  
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ICD-10 code Description 
M06.012  Rheumatoid arthritis without rheumatoid factor, left shoulder  
M06.019  Rheumatoid arthritis without rheumatoid factor, unspecified shoulder  
M06.021  Rheumatoid arthritis without rheumatoid factor, right elbow  
M06.022  Rheumatoid arthritis without rheumatoid factor, left elbow  
M06.029  Rheumatoid arthritis without rheumatoid factor, unspecified elbow  
M06.031  Rheumatoid arthritis without rheumatoid factor, right wrist  
M06.032  Rheumatoid arthritis without rheumatoid factor, left wrist  
M06.039  Rheumatoid arthritis without rheumatoid factor, unspecified wrist  
M06.041  Rheumatoid arthritis without rheumatoid factor, right hand  
M06.042  Rheumatoid arthritis without rheumatoid factor, left hand  
M06.049 Rheumatoid arthritis without rheumatoid factor, unspecified hand 
M06.051  Rheumatoid arthritis without rheumatoid factor, right hip  
M06.052  Rheumatoid arthritis without rheumatoid factor, left hip  
M06.059  Rheumatoid arthritis without rheumatoid factor, unspecified hip  
M06.061  Rheumatoid arthritis without rheumatoid factor, right knee  
M06.062  Rheumatoid arthritis without rheumatoid factor, left knee  
M06.069  Rheumatoid arthritis without rheumatoid factor, unspecified knee  
M06.071  Rheumatoid arthritis without rheumatoid factor, right ankle and foot  
M06.072  Rheumatoid arthritis without rheumatoid factor, left ankle and foot  
M06.079  Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot  
M06.08  Rheumatoid arthritis without rheumatoid factor, vertebrae  
M06.09  Rheumatoid arthritis without rheumatoid factor, multiple sites  
M06.20  Rheumatoid bursitis, unspecified site  
M06.211  Rheumatoid bursitis, right shoulder  
M06.212  Rheumatoid bursitis, left shoulder  
M06.219  Rheumatoid bursitis, unspecified shoulder  
M06.221  Rheumatoid bursitis, right elbow  
M06.222  Rheumatoid bursitis, left elbow  
M06.229  Rheumatoid bursitis, unspecified elbow  
M06.231  Rheumatoid bursitis, right wrist  
M06.232  Rheumatoid bursitis, left wrist  
M06.239  Rheumatoid bursitis, unspecified wrist  
M06.241  Rheumatoid bursitis, right hand  
M06.242  Rheumatoid bursitis, left hand  
M06.249  Rheumatoid bursitis, unspecified hand  
M06.251  Rheumatoid bursitis, right hip  
M06.252  Rheumatoid bursitis, left hip  
M06.259  Rheumatoid bursitis, unspecified hip  
M06.261  Rheumatoid bursitis, right knee  
M06.262  Rheumatoid bursitis, left knee  
M06.269  Rheumatoid bursitis, unspecified knee  
M06.271  Rheumatoid bursitis, right ankle and foot  
M06.272  Rheumatoid bursitis, left ankle and foot  
M06.279  Rheumatoid bursitis, unspecified ankle and foot  
M06.28  Rheumatoid bursitis, vertebrae  
M06.29  Rheumatoid bursitis, multiple sites  
M06.30  Rheumatoid nodule, unspecified site  
M06.311  Rheumatoid nodule, right shoulder  
M06.312  Rheumatoid nodule, left shoulder  
M06.319  Rheumatoid nodule, unspecified shoulder  
M06.321  Rheumatoid nodule, right elbow  
M06.322  Rheumatoid nodule, left elbow  
M06.329  Rheumatoid nodule, unspecified elbow  
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ICD-10 code Description 
M06.331 Rheumatoid nodule, right wrist 
M06.332  Rheumatoid nodule, left wrist  
M06.339  Rheumatoid nodule, unspecified wrist  
M06.341  Rheumatoid nodule, right hand  
M06.342  Rheumatoid nodule, left hand  
M06.349  Rheumatoid nodule, unspecified hand  
M06.351  Rheumatoid nodule, right hip  
M06.352  Rheumatoid nodule, left hip  
M06.359  Rheumatoid nodule, unspecified hip  
M06.361  Rheumatoid nodule, right knee  
M06.362  Rheumatoid nodule, left knee  
M06.369  Rheumatoid nodule, unspecified knee  
M06.371  Rheumatoid nodule, right ankle and foot  
M06.372  Rheumatoid nodule, left ankle and foot  
M06.379  Rheumatoid nodule, unspecified ankle and foot  
M06.38  Rheumatoid nodule, vertebrae  
M0639  Rheumatoid nodule, multiple sites  
M06.80  Other specified rheumatoid arthritis, unspecified site  
M06.811  Other specified rheumatoid arthritis, right shoulder  
M06.812  Other specified rheumatoid arthritis, left shoulder  
M06.819  Other specified rheumatoid arthritis, unspecified shoulder  
M06.821  Other specified rheumatoid arthritis, right elbow  
M06.822  Other specified rheumatoid arthritis, left elbow  
M06.829  Other specified rheumatoid arthritis, unspecified elbow  
M06.831  Other specified rheumatoid arthritis, right wrist  
M06.832  Other specified rheumatoid arthritis, left wrist  
M06.839  Other specified rheumatoid arthritis, unspecified wrist  
M06.841  Other specified rheumatoid arthritis, right hand  
M06.842  Other specified rheumatoid arthritis, left hand  
M06.849  Other specified rheumatoid arthritis, unspecified hand  
M06.851  Other specified rheumatoid arthritis, right hip  
M06.852  Other specified rheumatoid arthritis, left hip  
M06.859  Other specified rheumatoid arthritis, unspecified hip  
M06.861  Other specified rheumatoid arthritis, right knee  
M06.862  Other specified rheumatoid arthritis, left knee  
M06.869  Other specified rheumatoid arthritis, unspecified knee  
M06.871  Other specified rheumatoid arthritis, right ankle and foot  
M06.872  Other specified rheumatoid arthritis, left ankle and foot  
M06.879  Other specified rheumatoid arthritis, unspecified ankle and foot  
M06.88  Other specified rheumatoid arthritis, vertebrae  
M06.89  Other specified rheumatoid arthritis, multiple sites  
M06.9  Rheumatoid arthritis, unspecified  
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Appendix H – RA drug codes 
 
Drug  GPI Codea HCPCS Code NDC code 
Medicare payment 
limit 
TNFi  S9359   
ABATACEPT 66400010* J0129 00003-2187-10 44.75/10MG 
   C9230 00003-2188-11   
    0003-2188-21   
    00003-2188-31   
    0003-2188-51   
      0003-2188-91   
ADALIMUMAB 66270015* J0135 0074-0554-01 861.447/20MG 
    0074-0554-02   
    0074-0554-04   
    0074-0554-06   
    
0074-0554-71 
  
0074-0554-73 
    0074-0554-74   
    0074-2540-01   
    
0074-2540-03 
  
0074-3797-01 
    0074-3799-02   
    0074-3799-03   
    0074-3799-06   
    0074-3799-71   
    0074-4339-01   
    0074-4339-02   
    0074-4339-06   
    0074-4339-07   
    0074-4339-71   
    0074-4339-72   
    0074-4339-73   
    0074-4339-74   
    0074-6347-02   
    0074-9374-02   
      0074-9374-71   
ANAKINRA 66260010* NA 66658-234-07   
      66658-234-07   
CERTOLIZUMAB 52505020* J0717 50474-700-61 7.056/MG 
   J0718 50474-700-62   
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Drug  GPI Codea HCPCS Code NDC code 
Medicare payment 
limit 
   C9249 50474-710-79   
    50474-710-80   
      50474-710-81   
ETANERCEPT 66290030* J1438 58406-425-34   
    58406-435-04   
    58406-445-04   
    58406-455-04   
GOLIMUMAB 66270040* J1602 57894-070-01 24.787/MG 
    57894-070-02   
    57894-070-89   
    57894-070-90   
    57894-071-01   
    57894-071-02   
    57894-071-89   
    57894-071-90   
    57894-350-01   
     57894-350-89   
INFLIXIMAB 52505040* 
J1745 
0069-0809-01 82.872/10MG 
S9359 
And biosimilars  EJ 57894-0030-01  
  J1745   
  Q5102   
  Q5103   
    Q5104 57894-0030-01   
RITUXIMAB 21353060* J9310 50242-051-21 792.92/100MG 
      50242-053-06   
TOFACITINIB 66603065100320 J8499 0069-0501-14   
    0069-0501-30   
    0069-1001-01   
    0069-1001-02   
    0069-1001-03   
      63539-012-02   
TOCILIZUMAB 66500070* J3262 50242-135-01 4.103/MG 
   C9264 50242-135-04   
    50242-136-01   
    50242-136-04   
    50242-137-01   
    50242-137-04   
      50242-138-01   
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Appendix I – Excluded conditions 
 
Condition ICD9 ICD10 
Ankylosing spondylitis 720.0X M45 
M45.X 
M08.1 
M46.90 
M46.80 
M49.80 
Crohn’s disease 555.XX K50.00 
K50.10 
K50.80 
K50.90 
K52.9 
Juvenile idiopathic arthritis 714.3X M08.00 
M08.3 
M08.40 
Multiple sclerosis 340.XX G35 
Polyarteris nodosa 446.0X M30.0 
Psoriasis 696.0 
696.1X 
L40.0 
L40.1 
L40.2 
L40.3 
L40.4 
L40.8 
L40.54 
L40.59 
Psoriatic arthritis   696.0X L40.52 
L40.54 
Spondyloarthropathy 721.9X M47.819 
M47.10 
Systemic lupus 
erythematosus 
710.0X 
695.4 
M32 
M32.0 
M32.1 
M32.1X 
M32.8 
M32.9 
L93.0 
Ulcerative colitis 556.XX K51.80 
K51.20 
K51.30 
K51.40 
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Condition ICD9 ICD10 
K51.50 
K51.00 
K51.80 
K51.811 
K51.812 
K51.814 
K51.818 
K51.819 
K51.90 
K51.911 
K51.912 
K51.913 
K51.914 
K51.918 
K51.919 
K52.9 
K52.89 
Wegener's granulomatosis 446.4X M31.3 
M31.30 
M31.31 
HIV  B20 
Organ transplant   
Malignancies  Any malignancy 140-172.9; 
174-195.8; 200-208.9 / C00-
C97 
Metastatic malignancy 196-
199.1/C76-C80 
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Appendix J – Adherence criteria for IV drugs 
drug 
HCPCS 
code 
Month 0-6 Month 7-12 
expected 
claims 
minimum for 
adherence 
expected 
claims 
minimum for 
adherence 
ABATACEPT J0129 8 6 6 5 
ADALIMUMAB J0135 13 10 13 10 
CERTOLIZUMAB J0717 8 6 6 5 
CERTOLIZUMAB J0718 8 6 6 5 
ETANERCEPT J1438 13 10 13 10 
GOLIMUMAB J1602 8 6 6 5 
INFLIXIMAB J1745 5 4 3 2 
INFLIXIMAB S9359 5 4 3 2 
RITUXIMAB J9310 2 2 2 2 
TOCILIZUMAB J3262 13 10 13 10 
TOCILIZUMAB C9264 13 10 13 10 
TOFACITINIB J8499 6 5 6 5 
 
 
  
155 
 
Appendix K – Time to discontinuation comparison per treatment line 
2nd vs 3rd line  
 
The NPAR1WAY Procedure 
 
Wilcoxon Scores (Rank Sums) for Variable duration 
Classified by Variable line 
line N 
Sum of 
Scores 
Expected 
Under H0 
Std Dev 
Under H0 
Mean 
Score 
2 10442 84013859.0 82068899.0 268611.225 8045.76317 
3 5276 39521762.0 41466722.0 268611.225 7490.85709 
Average scores were used for ties. 
Wilcoxon Two-Sample Test 
Statistic Z Pr < Z Pr > |Z| 
t Approximation 
Pr < Z Pr > |Z| 
39521762 -7.2408 <.0001 <.0001 <.0001 <.0001 
Z includes a continuity correction of 0.5. 
Kruskal-Wallis Test 
Chi-Square DF Pr > ChiSq 
52.4292 1 <.0001 
 
 
 
 
 
3rd vs 4th line  
 
The NPAR1WAY Procedure 
 
Wilcoxon Scores (Rank Sums) for Variable duration 
Classified by Variable line 
line N 
Sum of 
Scores 
Expected 
Under H0 
Std Dev 
Under H0 
Mean 
Score 
3 5276 20265657.0 19687394.0 84682.0030 3841.10254 
4 2186 7578796.0 8157059.0 84682.0030 3466.96981 
Average scores were used for ties. 
Wilcoxon Two-Sample Test 
Statistic Z Pr < Z Pr > |Z| 
t Approximation 
Pr < Z Pr > |Z| 
7578796 -6.8286 <.0001 <.0001 <.0001 <.0001 
Z includes a continuity correction of 0.5. 
Kruskal-Wallis Test 
Chi-Square DF Pr > ChiSq 
46.6303 1 <.0001 
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4th vs 5thline  
 
The NPAR1WAY Procedure 
 
Wilcoxon Scores (Rank Sums) for Variable duration 
Classified by Variable line 
line N 
Sum of 
Scores 
Expected 
Under H0 
Std Dev 
Under H0 
Mean 
Score 
4 2186 3306034.0 3216699.0 20126.6480 1512.36688 
5 756 1023119.0 1112454.0 20126.6480 1353.33201 
Average scores were used for ties. 
Wilcoxon Two-Sample Test 
Statistic Z Pr < Z Pr > |Z| 
t Approximation 
Pr < Z Pr > |Z| 
1023119 -4.4386 <.0001 <.0001 <.0001 <.0001 
Z includes a continuity correction of 0.5. 
Kruskal-Wallis Test 
Chi-Square DF Pr > ChiSq 
19.7015 1 <.0001 
 
 
 
 
 
 
 
5th vs 6th line  
 
 
 
The NPAR1WAY Procedure 
 
Wilcoxon Scores (Rank Sums) for Variable duration 
Classified by Variable line 
line N 
Sum of 
Scores 
Expected 
Under H0 
Std Dev 
Under H0 
Mean 
Score 
5 756 391557.0 392364.0 4285.44977 517.932540 
6 281 146646.0 145839.0 4285.44977 521.871886 
Average scores were used for ties. 
Wilcoxon Two-Sample Test 
Statistic Z Pr < Z Pr > |Z| 
t Approximation 
Pr < Z Pr > |Z| 
146646.0 0.1882 0.4254 0.8507 0.4254 0.8508 
Z includes a continuity correction of 0.5. 
Kruskal-Wallis Test 
Chi-Square DF Pr > ChiSq 
0.0355 1 0.8506 
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Appendix L – Survival analysis results 
Including rituximab 
Second line 
 
Kaplan Meier 
  TNFi non-TNFi 
Percent 
Point 95% Confidence Interval Point 95% Confidence Interval 
Estimate Transform [Lower Upper) Estimate Transform [Lower Upper) 
75 1175 LOGLOG 1086 1260 1321 LOGLOG 1232 1424 
50 370 LOGLOG 354 392 471 LOGLOG 443 506 
25 133 LOGLOG 126 140 180 LOGLOG 176 191 
 
Summary of the Number of Censored and Uncensored Values 
Stratum group Total Failed Censored 
Percent 
Censored 
1 TNFi 6635 4940 1695 25.55 
2 non-TNFi 3807 2640 1167 30.65 
Total  10442 7580 2862 27.41 
 
 
Test of Equality over Strata 
Test Chi-Square DF Pr >Chi-Square 
Log-Rank 34.7749 1 <.0001 
Wilcoxon 46.7342 1 <.0001 
-2Log(LR) 34.0832 1 <.0001 
 
 
Third line 
 
Kaplan Meier 
 
  TNFi non-TNFi 
Percent 
Point 95% Confidence Interval Point 95% Confidence Interval 
Estimate Transform [Lower Upper) Estimate Transform [Lower Upper) 
75 1374 LOGLOG 1245 1582 1438 LOGLOG 1332 1632 
50 504 LOGLOG 462 561 441 LOGLOG 406 483 
25 166 LOGLOG 155 181 186 LOGLOG 178 194 
 
Summary of the Number of Censored and Uncensored Values 
Stratum group Total Failed Censored 
Percent 
Censored 
1 TNFi 2404 1473 931 38.73 
2 non-TNFi 2872 1635 1237 43.07 
Total  5276 3108 2168 41.09 
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Test of Equality over Strata 
Test Chi-Square DF 
Pr > 
Chi-Square 
Log-Rank 0.3446 1 0.5572 
Wilcoxon 0.191 1 0.6621 
-2Log(LR) 3.3196 1 0.0685 
 
Third line Cox Proportional Hazards Model 
 
Variable Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > ChiS
q 
Hazard 
Ratio 
95% Confidence 
Limits 
Drug group (ref = 
TNFi cyclers) 
       
non-TNFi swappers -0.02159 0.03702 0.34 0.5598 0.979 0.91 1.052 
Age -0.03707 0.00966 14.7222 0.0001 . . . 
Age2 0.0003349 0.0000951 12.3948 0.0004 . . . 
Comorbidity score 
(ref=0) 
       
1 0.02626 0.05128 0.2623 0.6085 1.027 0.928 1.135 
2+ 0.11001 0.0816 1.8173 0.1776 1.116 0.951 1.31 
Region (ref = North 
West) 
       
Northeast 0.08188 0.06393 1.6404 0.2003 1.085 0.958 1.23 
South 0.0948 0.048 3.9011 0.0483 1.099 1.001 1.208 
Unknown 0.28248 0.1602 3.1091 0.0779 1.326 0.969 1.816 
West 0.02539 0.05752 0.1949 0.6589 1.026 0.916 1.148 
Year of first TNFi 
(ref=2008) 
       
2009 0.14242 0.06253 5.1885 0.0227 1.153 1.02 1.303 
2010 0.2151 0.06161 12.1881 0.0005 1.24 1.099 1.399 
2011 0.29601 0.06347 21.7521 <.0001 1.344 1.187 1.523 
2012 0.42511 0.06716 40.0613 <.0001 1.53 1.341 1.745 
2013 0.4984 0.06487 59.0222 <.0001 1.646 1.45 1.869 
2014 0.53872 0.07603 50.2104 <.0001 1.714 1.477 1.989 
2015 0.87267 0.11462 57.9691 <.0001 2.393 1.912 2.996 
Plan type (ref = 
Preferred Provider 
Organization) 
       
Consumer Directed 
Health Plan 
0.00956 0.08515 0.0126 0.9106 1.01 0.854 1.193 
Comprehensive -0.08485 0.07215 1.3832 0.2396 0.919 0.798 1.058 
Exclusive Provider 
Organization 
0.05533 0.19823 0.0779 0.7802 1.057 0.717 1.559 
High Deductible 
Health Plan 
-0.16323 0.11909 1.8786 0.1705 0.849 0.673 1.073 
Health maintenance 
Organization 
0.04015 0.05636 0.5075 0.4762 1.041 0.932 1.163 
Point of Service 0.04811 0.06593 0.5324 0.4656 1.049 0.922 1.194 
Point of Service - 
Capitated 
-0.02634 0.30342 0.0075 0.9308 0.974 0.537 1.765 
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Fourth line 
 
Kaplan Meier 
 
  TNFi non-TNFi 
Percent 
Point 95% Confidence Interval Point 95% Confidence Interval 
Estimate Transform [Lower Upper) Estimate Transform [Lower Upper) 
75 1235 LOGLOG 1087 1452 1217 LOGLOG 1109 1497 
50 402 LOGLOG 350 493 426 LOGLOG 379 489 
25 144 LOGLOG 121 172 173 LOGLOG 155 185 
 
Summary of the Number of Censored and Uncensored Values 
Stratum group Total Failed Censored 
Percent 
Censored 
1 TNFi 799 468 331 41.43 
2 non-TNFi 1387 761 626 45.13 
Total  2186 1229 957 43.78 
 
Test of Equality over Strata 
Test Chi-Square DF 
Pr > 
Chi-Square 
Log-Rank 0.1346 1 0.7137 
Wilcoxon 1.5662 1 0.2108 
-2Log(LR) 0.0127 1 0.9101 
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Cox Proportional Hazards Model 
 
Variable Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > ChiS
q 
Hazard 
Ratio 
95% Confidence 
Limits 
Drug group (ref = 
TNFi cyclers) 
       
non-TNFi swappers -0.04488 0.06051 0.5501 0.4583 0.956 0.849 1.076 
Age -0.02547 0.01591 2.5604 0.1096 . . . 
Age2 0.0002418 0.0001564 2.3895 0.1222 . . . 
Comorbidity score 
(ref=0) 
       
1 -0.01047 0.08421 0.0155 0.901 0.99 0.839 1.167 
2+ 0.14023 0.12363 1.2865 0.2567 1.151 0.903 1.466 
Region (ref = North 
West) 
       
Northeast 0.05585 0.10297 0.2941 0.5876 1.057 0.864 1.294 
South 0.08535 0.07741 1.2158 0.2702 1.089 0.936 1.268 
Unknown 0.43728 0.23958 3.3312 0.068 1.548 0.968 2.477 
West 0.00175 0.09216 0.0004 0.9848 1.002 0.836 1.2 
Year of first TNFi 
(ref=2008) 
       
2009 -0.05789 0.09385 0.3805 0.5373 0.944 0.785 1.134 
2010 0.09659 0.09569 1.0188 0.3128 1.101 0.913 1.329 
2011 0.16443 0.09813 2.8079 0.0938 1.179 0.972 1.429 
2012 0.05255 0.11039 0.2266 0.634 1.054 0.849 1.309 
2013 0.19393 0.10556 3.3749 0.0662 1.214 0.987 1.493 
2014 0.52038 0.12738 16.6894 <.0001 1.683 1.311 2.16 
2015 0.5009 0.20605 5.9092 0.0151 1.65 1.102 2.471 
Plan type (ref = 
Preferred Provider 
Organization) 
       
Consumer Directed 
Health Plan 
-0.18155 0.14424 1.5842 0.2082 0.834 0.629 1.106 
Comprehensive 0.02418 0.11578 0.0436 0.8346 1.024 0.816 1.285 
Exclusive Provider 
Organization 
-0.18309 0.38147 0.2304 0.6313 0.833 0.394 1.759 
High Deductible 
Health Plan 
-0.34453 0.20801 2.7435 0.0976 0.709 0.471 1.065 
Health maintenance 
Organization 
-0.05099 0.0867 0.3459 0.5565 0.95 0.802 1.126 
Point of Service -0.22967 0.10858 4.474 0.0344 0.795 0.642 0.983 
Point of Service - 
Capitated 
0.02127 0.50396 0.0018 0.9663 1.022 0.38 2.743 
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Fifth line 
 
Kaplan Meier 
 
  TNFi non-TNFi 
Percent 
Point 95% Confidence Interval Point 95% Confidence Interval 
Estimate Transform [Lower Upper) Estimate Transform [Lower Upper) 
75 653 LOGLOG 516 1106 979 LOGLOG 881 . 
50 304 LOGLOG 248 371 339 LOGLOG 280 411 
25 118 LOGLOG 87 156 156 LOGLOG 133 178 
 
 
Summary of the Number of Censored and Uncensored Values 
Stratum group Total Failed Censored 
Percent 
Censored 
1 TNFi 268 158 110 41.04 
2 non-TNFi 488 267 221 45.29 
Total  756 425 331 43.78 
 
 
Test of Equality over Strata 
Test Chi-Square DF 
Pr > 
Chi-Square 
Log-Rank 3.1774 1 0.0747 
Wilcoxon 2.6913 1 0.1009 
-2Log(LR) 3.8054 1 0.0511 
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Cox Proportional Hazards Model 
 
Variable Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > ChiS
q 
Hazard 
Ratio 
95% Confidence 
Limits 
Drug group (ref = 
TNFi cyclers) 
       
non-TNFi swappers -0.15993 0.104 2.3645 0.1241 0.852 0.695 1.045 
Age -0.04873 0.02699 3.2601 0.071 . . . 
Age2 0.0005446 0.0002753 3.9137 0.0479 . . . 
Comorbidity score 
(ref=0) 
       
1 0.11592 0.14453 0.6433 0.4225 1.123 0.846 1.491 
2+ 0.06574 0.24868 0.0699 0.7915 1.068 0.656 1.739 
Region (ref = North 
West) 
       
Northeast 0.01826 0.17513 0.0109 0.917 1.018 0.723 1.435 
South -0.18661 0.12999 2.0609 0.1511 0.83 0.643 1.071 
Unknown -0.173 0.59533 0.0844 0.7714 0.841 0.262 2.702 
West -0.18955 0.16011 1.4015 0.2365 0.827 0.604 1.132 
Year of first TNFi 
(ref=2008) 
       
2009 0.18728 0.15149 1.5282 0.2164 1.206 0.896 1.623 
2010 0.36435 0.15564 5.4803 0.0192 1.44 1.061 1.953 
2011 0.38819 0.16398 5.6039 0.0179 1.474 1.069 2.033 
2012 0.07126 0.203 0.1232 0.7256 1.074 0.721 1.599 
2013 0.30298 0.18794 2.5988 0.1069 1.354 0.937 1.957 
2014 0.15232 0.26371 0.3336 0.5635 1.165 0.695 1.953 
2015 0.21681 0.51818 0.1751 0.6757 1.242 0.45 3.429 
Plan type (ref = 
Preferred Provider 
Organization) 
       
Consumer Directed 
Health Plan 
0.20848 0.24814 0.7059 0.4008 1.232 0.757 2.003 
Comprehensive -0.33541 0.22663 2.1904 0.1389 0.715 0.459 1.115 
Exclusive Provider 
Organization 
0.36514 0.51639 0.5 0.4795 1.441 0.524 3.964 
High Deductible 
Health Plan 
0.17674 0.45927 0.1481 0.7004 1.193 0.485 2.936 
Health maintenance 
Organization 
-0.15406 0.14784 1.0859 0.2974 0.857 0.642 1.145 
Point of Service 0.23028 0.17327 1.7662 0.1839 1.259 0.896 1.768 
Point of Service - 
Capitated 
0.14464 1.01338 0.0204 0.8865 1.156 0.159 8.422 
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Sixth line 
 
Kaplan Meier 
 
  TNFi non-TNFi 
Percent 
Point 95% Confidence Interval Point 95% Confidence Interval 
Estimate Transform [Lower Upper) Estimate Transform [Lower Upper) 
75 1150 LOGLOG 759 . 1013 LOGLOG 778 . 
50 379 LOGLOG 206 759 397 LOGLOG 350 710 
25 139 LOGLOG 90 190 156 LOGLOG 117 193 
 
Summary of the Number of Censored and Uncensored Values 
Stratum group Total Failed Censored 
Percent 
Censored 
1 TNFi 98 51 47 47.96 
2 non-TNFi 183 86 97 53.01 
Total  281 137 144 51.25 
 
Test of Equality over Strata 
Test Chi-Square DF 
Pr > 
Chi-Square 
Log-Rank 0.1556 1 0.6933 
Wilcoxon 0.1672 1 0.6826 
-2Log(LR) 0.0775 1 0.7807 
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Cox Proportional Hazards Model 
 
Variable Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > ChiS
q 
Hazard 
Ratio 
95% Confidence 
Limits 
Drug group (ref = 
TNFi cyclers) 
       
non-TNFi swappers -0.07113 0.18825 0.1428 0.7055 0.931 0.644 1.347 
Age 0.1497 0.07358 4.1397 0.0419 . . . 
Age2 -0.00177 0.0007654 5.3601 0.0206 . . . 
Comorbidity score 
(ref=0) 
       
1 -0.10536 0.28642 0.1353 0.713 0.9 0.513 1.578 
2+ -0.05954 0.60789 0.0096 0.922 0.942 0.286 3.102 
Region (ref = North 
West) 
       
Northeast 0.13572 0.3186 0.1815 0.6701 1.145 0.613 2.139 
South 0.12092 0.24237 0.2489 0.6179 1.129 0.702 1.815 
Unknown -12.65014 569.61743 0.0005 0.9823 0 0 . 
West 0.13504 0.28628 0.2225 0.6371 1.145 0.653 2.006 
Year of first TNFi 
(ref=2008) 
       
2009 -0.13002 0.28066 0.2146 0.6432 0.878 0.507 1.522 
2010 -0.05151 0.26258 0.0385 0.8445 0.95 0.568 1.589 
2011 0.23421 0.29691 0.6222 0.4302 1.264 0.706 2.262 
2012 -0.07412 0.39475 0.0353 0.8511 0.929 0.428 2.013 
2013 -0.35093 0.43959 0.6373 0.4247 0.704 0.297 1.666 
2014 -0.22967 0.53143 0.1868 0.6656 0.795 0.28 2.252 
2015 -13.11555 3469 0 0.997 0 0 . 
Plan type (ref = 
Preferred Provider 
Organization) 
       
Consumer Directed 
Health Plan 
-0.47363 0.53305 0.7895 0.3743 0.623 0.219 1.77 
Comprehensive 0.42252 0.38131 1.2278 0.2678 1.526 0.723 3.222 
Exclusive Provider 
Organization 
-1.26251 1.02619 1.5136 0.2186 0.283 0.038 2.114 
High Deductible 
Health Plan 
-1.13963 1.04733 1.184 0.2765 0.32 0.041 2.492 
Health maintenance 
Organization 
-1.04782 0.309 11.499 0.0007 0.351 0.191 0.643 
Point of Service -0.47088 0.31315 2.261 0.1327 0.624 0.338 1.154 
Point of Service - 
Capitated 
-13.40172 786.46855 0.0003 0.9864 0 0 . 
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Excluding rituximab 
Second line 
 
Kaplan Meier 
 
  TNFi non-TNFi 
Percent 
Point 95% Confidence Interval Point 95% Confidence Interval 
Estimate Transform [Lower Upper) Estimate Transform [Lower Upper) 
75 1175 LOGLOG 1086 1260 1255 LOGLOG 1147 1380 
50 370 LOGLOG 354 392 455 LOGLOG 427 486 
25 133 LOGLOG 126 140 156 LOGLOG 145 169 
 
Summary of the Number of Censored and Uncensored Values 
Stratum group Total Failed Censored 
Percent 
Censored 
1 TNFi 6635 4940 1695 25.55 
2 non-TNFi 3267 2285 982 30.06 
Total  9902 7225 2677 27.03 
 
 
Test of Equality over Strata 
Test Chi-Square DF 
Pr > 
Chi-Square 
Log-Rank 14.9073 1 0.0001 
Wilcoxon 19.7824 1 <.0001 
-2Log(LR) 11.792 1 0.0006 
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Cox Proportional Hazards Model 
 
Variable Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > ChiS
q 
Hazard 
Ratio 
95% Confidence 
Limits 
Drug group (ref = 
TNFi cyclers) 
       
non-TNFi swappers -0.10317 0.02602 15.7169 <.0001 0.902 0.857 0.949 
Age -0.01673 0.00616 7.3696 0.0066 . . . 
Age2 0.0001368 0.0000603 5.1411 0.0234 . . . 
Comorbidity score 
(ref=0) 
       
1 0.02189 0.0335 0.427 0.5135 1.022 0.957 1.092 
2+ 0.15236 0.05258 8.3977 0.0038 1.165 1.051 1.291 
Region (ref = North 
West) 
       
Northeast -0.028 0.04132 0.4592 0.498 0.972 0.897 1.054 
South 0.0754 0.0311 5.8787 0.0153 1.078 1.015 1.146 
Unknown -0.01157 0.10142 0.013 0.9092 0.989 0.81 1.206 
West 0.08999 0.03755 5.7438 0.0165 1.094 1.017 1.178 
Year of first TNFi 
(ref=2008) 
       
2009 0.08686 0.04075 4.5444 0.033 1.091 1.007 1.181 
2010 0.11082 0.04036 7.5396 0.006 1.117 1.032 1.209 
2011 0.27038 0.04144 42.5598 <.0001 1.31 1.208 1.421 
2012 0.23928 0.04398 29.5953 <.0001 1.27 1.165 1.385 
2013 0.2576 0.04314 35.663 <.0001 1.294 1.189 1.408 
2014 0.42466 0.04764 79.4602 <.0001 1.529 1.393 1.679 
2015 0.62477 0.07342 72.4124 <.0001 1.868 1.617 2.157 
Plan type (ref = 
Preferred Provider 
Organization) 
-0.0952 0.05277 3.2548 0.0712 0.909 0.82 1.008 
Consumer Directed 
Health Plan 
-0.04414 0.04683 0.8883 0.3459 0.957 0.873 1.049 
Comprehensive -0.32627 0.12553 6.7557 0.0093 0.722 0.564 0.923 
Exclusive Provider 
Organization 
0.09964 0.07554 1.7398 0.1872 1.105 0.953 1.281 
High Deductible 
Health Plan 
0.01579 0.03801 0.1726 0.6778 1.016 0.943 1.094 
Health maintenance 
Organization 
-0.02421 0.0454 0.2843 0.5939 0.976 0.893 1.067 
Point of Service 0.12467 0.20099 0.3847 0.5351 1.133 0.764 1.68 
Point of Service - 
Capitated 
-0.0952 0.05277 3.2548 0.0712 0.909 0.82 1.008 
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Third line 
 
Kaplan Meier 
 
  TNFi non-TNFi 
Percent 
Point 95% Confidence Interval Point 95% Confidence Interval 
Estimate Transform [Lower Upper) Estimate Transform [Lower Upper) 
75 1374 LOGLOG 1245 1582 1395 LOGLOG 1245 1530 
50 504 LOGLOG 462 563 407 LOGLOG 378 448 
25 166 LOGLOG 155 182 166 LOGLOG 154 176 
 
 
Summary of the Number of Censored and Uncensored Values 
Stratum group Total Failed Censored 
Percent 
Censored 
1 TNFi 2404 1473 931 38.73 
2 non-TNFi 2499 1444 1055 42.22 
Total  4903 2917 1986 40.51 
 
Test of Equality over Strata 
Test Chi-Square DF 
Pr > 
Chi-Square 
Log-Rank 4.7032 1 0.0301 
Wilcoxon 4.7128 1 0.0299 
-2Log(LR) 13.6033 1 0.0002 
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Cox Proportional Hazards Model 
 
Variable Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > ChiS
q 
Hazard 
Ratio 
95% Confidence 
Limits 
Drug group (ref = 
TNFi cyclers) 
       
non-TNFi swappers 0.02415 0.03839 0.3957 0.5293 1.024 0.95 1.104 
Age -0.03759 0.00989 14.4469 0.0001 . . . 
Age2 0.0003442 0.0000975 12.4727 0.0004 . . . 
Comorbidity score 
(ref=0) 
       
1 0.02907 0.0528 0.3032 0.5819 1.029 0.928 1.142 
2+ 0.07468 0.08485 0.7746 0.3788 1.078 0.912 1.273 
Region (ref = North 
West) 
       
Northeast 0.05491 0.06583 0.6957 0.4042 1.056 0.929 1.202 
South 0.07589 0.04959 2.342 0.1259 1.079 0.979 1.189 
Unknown 0.25068 0.1683 2.2184 0.1364 1.285 0.924 1.787 
West 0.02114 0.05969 0.1255 0.7231 1.021 0.909 1.148 
Year of first TNFi 
(ref=2008) 
       
2009 0.15694 0.06517 5.7997 0.016 1.17 1.03 1.329 
2010 0.20142 0.06405 9.8883 0.0017 1.223 1.079 1.387 
2011 0.28464 0.06606 18.5674 <.0001 1.329 1.168 1.513 
2012 0.40657 0.06925 34.4733 <.0001 1.502 1.311 1.72 
2013 0.48143 0.06664 52.1912 <.0001 1.618 1.42 1.844 
2014 0.51429 0.0782 43.2494 <.0001 1.672 1.435 1.949 
2015 0.87433 0.11635 56.4669 <.0001 2.397 1.908 3.011 
Plan type (ref = 
Preferred Provider 
Organization) 
       
Consumer Directed 
Health Plan 
-0.006 0.08697 0.0048 0.945 0.994 0.838 1.179 
Comprehensive -0.0637 0.07454 0.7302 0.3928 0.938 0.811 1.086 
Exclusive Provider 
Organization 
0.10703 0.2063 0.2692 0.6039 1.113 0.743 1.668 
High Deductible 
Health Plan 
-0.16465 0.12163 1.8324 0.1758 0.848 0.668 1.077 
Health maintenance 
Organization 
0.05106 0.05848 0.7623 0.3826 1.052 0.938 1.18 
Point of Service 0.0542 0.06808 0.6337 0.426 1.056 0.924 1.206 
Point of Service - 
Capitated 
0.01684 0.30349 0.0031 0.9557 1.017 0.561 1.843 
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Fourth line 
 
Kaplan Meier 
 
  TNFi non-TNFi 
Percent 
Point 95% Confidence Interval Point 95% Confidence Interval 
Estimate Transform [Lower Upper) Estimate Transform [Lower Upper) 
75 1235 LOGLOG 1087 1452 1053 LOGLOG 885 1263 
50 402 LOGLOG 350 493 374 LOGLOG 328 414 
25 144 LOGLOG 121 172 142 LOGLOG 118 160 
 
Summary of the Number of Censored and Uncensored Values 
Stratum group Total Failed Censored 
Percent 
Censored 
1 TNFi 799 468 331 41.43 
2 non-TNFi 1175 677 498 42.38 
Total  1974 1145 829 42 
 
 
Test of Equality over Strata 
Test Chi-Square DF 
Pr > 
Chi-Square 
Log-Rank 2.4185 1 0.1199 
Wilcoxon 0.4462 1 0.5042 
-2Log(LR) 5.2429 1 0.022 
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Cox Proportional Hazards Model 
 
Variable Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > ChiS
q 
Hazard 
Ratio 
95% Confidence 
Limits 
Drug group (ref = 
TNFi cyclers) 
       
non-TNFi swappers 0.07171 0.0621 1.3337 0.2482 1.074 0.951 1.213 
Age -0.03163 0.01679 3.5491 0.0596 . . . 
Age2 0.0002918 0.000164 3.1646 0.0753 . . . 
Comorbidity score 
(ref=0) 
       
1 0.01807 0.08669 0.0434 0.8349 1.018 0.859 1.207 
2+ 0.19755 0.12917 2.3389 0.1262 1.218 0.946 1.569 
Region (ref = North 
West) 
       
Northeast 0.02787 0.10709 0.0677 0.7947 1.028 0.834 1.268 
South 0.03212 0.08013 0.1607 0.6885 1.033 0.883 1.208 
Unknown 0.28744 0.26845 1.1465 0.2843 1.333 0.788 2.256 
West -0.04347 0.09623 0.2041 0.6515 0.957 0.793 1.156 
Year of first TNFi 
(ref=2008) 
       
2009 -0.07757 0.09846 0.6208 0.4307 0.925 0.763 1.122 
2010 0.05877 0.09956 0.3484 0.555 1.061 0.873 1.289 
2011 0.12084 0.1008 1.4369 0.2306 1.128 0.926 1.375 
2012 0.03623 0.11482 0.0996 0.7523 1.037 0.828 1.299 
2013 0.11646 0.10823 1.1577 0.2819 1.124 0.909 1.389 
2014 0.50976 0.13039 15.2853 <.0001 1.665 1.289 2.15 
2015 0.38716 0.21876 3.1323 0.0768 1.473 0.959 2.261 
Plan type (ref = 
Preferred Provider 
Organization) 
       
Consumer Directed 
Health Plan 
-0.13383 0.15118 0.7837 0.376 0.875 0.65 1.176 
Comprehensive -0.01128 0.12048 0.0088 0.9254 0.989 0.781 1.252 
Exclusive Provider 
Organization 
-0.01593 0.38169 0.0017 0.9667 0.984 0.466 2.08 
High Deductible 
Health Plan 
-0.41585 0.21737 3.6598 0.0557 0.66 0.431 1.01 
Health maintenance 
Organization 
-0.07619 0.09004 0.7161 0.3974 0.927 0.777 1.105 
Point of Service -0.28589 0.11205 6.5104 0.0107 0.751 0.603 0.936 
Point of Service - 
Capitated 
-0.03679 0.50445 0.0053 0.9419 0.964 0.359 2.591 
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Fifth line 
 
Kaplan Meier 
 
  TNFi non-TNFi 
Percent 
Point 95% Confidence Interval Point 95% Confidence Interval 
Estimate Transform [Lower Upper) Estimate Transform [Lower Upper) 
75 653 LOGLOG 516 1106 885 LOGLOG 640 1313 
50 304 LOGLOG 248 370 280 LOGLOG 239 333 
25 118 LOGLOG 87 155 133 LOGLOG 109 150 
Summary of the Number of Censored and Uncensored Values 
Stratum group Total Failed Censored 
Percent 
Censored 
1 TNFi 268 158 110 41.04 
2 non-TNFi 411 241 170 41.36 
Total   679 399 280 41.24 
 
Test of Equality over Strata 
Test Chi-Square DF 
Pr > 
Chi-Square 
Log-Rank 0.0805 1 0.7767 
Wilcoxon 0.0506 1 0.822 
-2Log(LR) 0.0896 1 0.7647 
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Cox Proportional Hazards Model 
 
Variable Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > ChiS
q 
Hazard 
Ratio 
95% Confidence 
Limits 
Drug group (ref = 
TNFi cyclers) 
       
non-TNFi swappers -0.01755 0.10611 0.0274 0.8686 0.983 0.798 1.21 
Age -0.05474 0.02811 3.7915 0.0515 . . . 
Age2 0.0005922 0.0002895 4.184 0.0408 . . . 
Comorbidity score 
(ref=0) 
       
1 0.11384 0.14939 0.5807 0.446 1.121 0.836 1.502 
2+ -0.14763 0.2891 0.2608 0.6096 0.863 0.49 1.52 
Region (ref = North 
West) 
       
Northeast -0.00293 0.1814 0.0003 0.9871 0.997 0.699 1.423 
South -0.22292 0.13399 2.7677 0.0962 0.8 0.615 1.041 
Unknown 0.18664 0.59511 0.0984 0.7538 1.205 0.375 3.869 
West -0.20196 0.16547 1.4898 0.2223 0.817 0.591 1.13 
Year of first TNFi 
(ref=2008) 
       
2009 0.16775 0.15704 1.1411 0.2854 1.183 0.869 1.609 
2010 0.38048 0.16264 5.4727 0.0193 1.463 1.064 2.012 
2011 0.37198 0.16958 4.8114 0.0283 1.451 1.04 2.023 
2012 0.09308 0.21015 0.1962 0.6578 1.098 0.727 1.657 
2013 0.39826 0.19349 4.2368 0.0396 1.489 1.019 2.176 
2014 0.15235 0.27248 0.3126 0.5761 1.165 0.683 1.987 
2015 0.13242 0.51873 0.0652 0.7985 1.142 0.413 3.155 
Plan type (ref = 
Preferred Provider 
Organization) 
       
Consumer Directed 
Health Plan 
0.26111 0.25514 1.0473 0.3061 1.298 0.787 2.141 
Comprehensive -0.27408 0.23648 1.3433 0.2465 0.76 0.478 1.209 
Exclusive Provider 
Organization 
0.20048 0.59502 0.1135 0.7362 1.222 0.381 3.922 
High Deductible 
Health Plan 
0.15704 0.46077 0.1162 0.7332 1.17 0.474 2.887 
Health maintenance 
Organization 
-0.13618 0.15159 0.807 0.369 0.873 0.648 1.175 
Point of Service 0.26547 0.17688 2.2526 0.1334 1.304 0.922 1.844 
Point of Service - 
Capitated 
0.02324 1.01401 0.0005 0.9817 1.024 0.14 7.468 
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Sixth line 
 
Kaplan Meier 
 
  TNFi non-TNFi 
Percent 
Point 95% Confidence Interval Point 95% Confidence Interval 
Estimate Transform [Lower Upper) Estimate Transform [Lower Upper) 
75 1150 LOGLOG 759 . 951 LOGLOG 415 . 
50 379 LOGLOG 206 759 323 LOGLOG 183 394 
25 139 LOGLOG 113 190 117 LOGLOG 84 146 
 
 
Summary of the Number of Censored and Uncensored Values 
Stratum group Total Failed Censored 
Percent 
Censored 
1 TNFi 98 51 47 47.96 
2 non-TNFi 137 74 63 45.99 
Total  235 125 110 46.81 
 
Test of Equality over Strata 
Test Chi-Square DF 
Pr > 
Chi-Square 
Log-Rank 1.3219 1 0.2503 
Wilcoxon 1.3866 1 0.239 
-2Log(LR) 1.732 1 0.1882 
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Cox Proportional Hazards Model 
 
Variable Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
Pr > ChiS
q 
Hazard 
Ratio 
95% Confidence 
Limits 
Drug group (ref = 
TNFi cyclers) 
       
non-TNFi swappers 0.27762 0.20423 1.8479 0.174 1.32 0.885 1.97 
Age 0.19459 0.07805 6.2153 0.0127 . . . 
Age2 -0.00218 0.0008216 7.0561 0.0079 . . . 
Comorbidity score 
(ref=0) 
       
1 -0.255 0.28643 0.7926 0.3733 0.775 0.442 1.359 
2+ -0.05162 0.61793 0.007 0.9334 0.95 0.283 3.188 
Region (ref = North 
West) 
       
Northeast 0.16559 0.33415 0.2456 0.6202 1.18 0.613 2.272 
South 0.11614 0.26001 0.1995 0.6551 1.123 0.675 1.87 
Unknown -12.79163 557.67253 0.0005 0.9817 0 0 . 
West 0.28647 0.30809 0.8646 0.3525 1.332 0.728 2.436 
Year of first TNFi 
(ref=2008) 
       
2009 -0.06237 0.31643 0.0388 0.8438 0.94 0.505 1.747 
2010 0.3333 0.28193 1.3977 0.2371 1.396 0.803 2.425 
2011 0.33788 0.30731 1.2088 0.2716 1.402 0.768 2.56 
2012 -0.06289 0.40023 0.0247 0.8751 0.939 0.429 2.058 
2013 -0.02594 0.44365 0.0034 0.9534 0.974 0.408 2.325 
2014 -0.26082 0.53482 0.2378 0.6258 0.77 0.27 2.198 
2015 -13.13722 3189 0 0.9967 0 0 . 
Plan type (ref = 
Preferred Provider 
Organization) 
       
Consumer Directed 
Health Plan 
-0.38884 0.53897 0.5205 0.4706 0.678 0.236 1.949 
Comprehensive 0.4223 0.38439 1.207 0.2719 1.525 0.718 3.24 
Exclusive Provider 
Organization 
-0.50905 1.03651 0.2412 0.6233 0.601 0.079 4.584 
High Deductible 
Health Plan 
0.56996 1.04625 0.2968 0.5859 1.768 0.227 13.744 
Health maintenance 
Organization 
-1.11019 0.38191 8.4501 0.0037 0.329 0.156 0.697 
Point of Service -0.2301 0.31924 0.5195 0.471 0.794 0.425 1.485 
Point of Service - 
Capitated 
-13.82519 726.43432 0.0004 0.9848 0 0 . 
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Appendix M – Costs: TNFi vs non-TNFi 
 
  Variable N Mean Std Dev Min 25th 
Pctl 
Median 75th 
Pctl 
Max p 
TNFi Drug costs_06mon 6,626 12,709 7,321 4 7,795 11,821 16,421 150,267 0.023 
non-TNFi Drug costs_06mon 3,816 13,053 7,604 0 8,366 12,512 16,407 73,905  
TNFi Other costs_06mon 6,626 6,138 13,962 0 1,215 2,730 5,857 433,647 <0.001 
non-TNFi Other costs_06mon 3,816 8,228 16,709 0 2,080 3,941 7,814 307,414  
TNFi Drug costs _712mon 6,626 7,683 8,732 0 - 6,246 12,561 141,679 0.237 
non-TNFi Drug costs _712mon 3,816 7,886 7,960 0 - 7,233 13,113 84,903  
TNFi Other costs _712mon 6,626 5,100 13,502 0 275 1,742 4,690 408,690 <0.001 
non-TNFi Other costs _712mon 3,816 7,474 19,140 0 852 2,761 6,578 505,420  
TNFi Drug costs _1yr 6,626 20,392 14,514 4 9,222 18,906 27,729 291,946 0.058 
non-TNFi Drug costs _1yr 3,816 20,939 13,678 0 10,775 20,322 28,412 151,091  
TNFi Other costs _1yr 6,626 11,238 22,798 0 2,190 5,118 11,731 745,918 <0.001 
non-TNFi Other costs _1yr 3,816 15,702 29,226 0 3,731 7,581 16,112 723,371  
 
 
Adherent 
month  
1-6 
Group Variable N Mean 
Std 
Dev 
Min 
25th 
Pctl 
Median 
75th 
Pctl 
Max p 
No  TNFi Drug costs_06mon 3,073 8,756 5,819 3.5 4,825 7638.9 11138 73855 <0.001 
No  non-TNFi Drug costs_06mon 1,803 9,711 6,669 17 5,041 8,861 13,266 66,497  
No TNFi Other costs_06mon 3,073 6,767 17,718 - 1,014 2,484 5,846 433,647 0.002 
No non-TNFi Other costs_06mon 1,803 8,423 18,232 - 1,618 3,495 7,539 307,414  
Yes TNFi Drug costs_06mon 3,553 16,128 6,743 150 11,785 14,665 18,986 150,267 0.668 
Yes  non-TNFi Drug costs_06mon 2,013 16,046 7,130 21 11,952 14,421 18,468 73,905  
Yes TNFi Other costs_06mon 3,553 5,594 9,562 - 1,427 2,908 5,860 223,595 <0.001 
Yes non-TNFi Other costs_06mon 2,013 8,053 15,219 - 2,545 4,304 8,013 305,051  
 
 
Adherent 
month  
7-12 
Group Variable N Mean 
Std 
Dev 
Min 
25th 
Pctl 
Median 
75th 
Pctl 
Max p 
No  TNFi Drug costs _712mon 4,428   3,721   5,770  0    0 0  6,917   59,198   <0.001 
No  non-TNFi Drug costs _712mon 2,491   4,393   6,374  0 0 0  7,628   84,903    
No TNFi Other costs _712mon 4,428   4,779  13,835  0 0  1,026   3,883  408,690   <0.001 
No non-TNFi Other costs _712mon 2,491   7,176  21,225  0  127   1,901   5,748  505,420    
No TNFi line2totalpay_1yr 4,428  14,977  11,003   4   6,492   12,465  20,772  133,053   <0.001 
No non-TNFi line2totalpay_1yr 2,491  16,170  11,948  0  7,125   14,008  22,875  151,091    
No TNFi othertotalpay_1yr 4,428  11,117  24,996  0  1,753   4,369  11,006  745,918   <0.001 
No non-TNFi othertotalpay_1yr 2,491   15,844  32,771  0  2,936   6,733  15,500  723,371    
Yes TNFi Drug costs_712mon 2,198   15,665   8,214   175  10,958   13,586  18,796  141,679   <0.001 
Yes  non-TNFi Drug costs_712mon 1,325   14,455   6,324   28  10,642   13,293  17,001   70,150    
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Adherent 
month  
7-12 
Group Variable N Mean 
Std 
Dev 
Min 
25th 
Pctl 
Median 
75th 
Pctl 
Max p 
Yes TNFi Other costs_712mon 2,198   5,746  12,784  0  1,430   2,973   5,930  404,588   <0.001 
Yes non-TNFi Other costs_712mon 1,325   8,035  14,418  0  2,152   4,076   7,659  208,996    
Yes TNFi Drug costs _1yr 2,198   31,301  14,600   325  22,851   27,836  36,820  291,946   0.0035 
Yes non-TNFi Drug costs _1yr 1,325   29,906  12,138  3,950  22,584   27,646  34,749  121,280    
Yes TNFi Other costs _1yr 2,198   11,482  17,554   56   3,353   6,551  12,852  408,179   <0.001 
Yes non-TNFi Other costs _1yr 1,325   15,435  21,008   139   5,096   8,966  16,825  222,226    
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Appendix N – Drug specific costs  
 
LINE2_drg Variable N Mean StdDev Min 
25th 
Pctl 
Median 
75th 
Pctl 
Max 
ABATACEPT 
Drug costs_06mon 2,073 13,244 7,228 0 8,837 12,520 16,418 73,905 
Other costs_06mon 2,073 7,852 14,057 0 2,270 4,120 7,912 215,271 
Drug costs _712mon 2,073 7,756 7,676 0 - 7,273 12,468 70,150 
Other costs _712mon 2,073 7,479 19,668 0 1,032 2,914 6,878 505,420 
Drug costs _1yr 2,073 21,000 13,276 0 11,519 19,984 27,811 121,280 
Other costs _1yr 2,073 15,331 26,803 0 4,036 7,867 16,355 509,699 
ADALIMUMAB 
Drug costs_06mon 2,732 12,873 7,277 305 7,700 12,015 16,792 62,378 
Other costs_06mon 2,732 5,553 11,848 0 1,053 2,340 5,120 249,259 
Drug costs _712mon 2,732 7,900 9,214 0 0 5,577 13,042 70,365 
Other costs _712mon 2,732 4,543 12,332 0 124 1,484 4,051 404,588 
Drug costs _1yr 2,732 20,773 14,892 305 8,799 18,785 29,048 126,436 
Other costs _1yr 2,732 10,096 18,601 0 1,905 4,438 10,195 408,179 
ANAKINRA 
Drug costs_06mon 16 8,158 6,299 49 3,078 7,051 11,147 22,610 
Other costs_06mon 16 12,807 29,704 1,428 2,815 5,059 7,969 123,519 
Drug costs _712mon 16 4,885 7,171 0 0 0 9,514 20,336 
Other costs _712mon 16 14,674 34,135 0 151 2,657 16,250 138,311 
Drug costs _1yr 16 13,043 13,113 49 3,078 7,051 20,424 40,671 
Other costs _1yr 16 27,482 63,416 1,428 5,471 7,058 19,451 261,830 
CERTOLIZUMAB 
Drug costs_06mon 738 12,870 6,494 150 8,435 12,145 16,448 60,000 
Other costs_06mon 738 6,804 16,263 0 1,397 2,869 6,168 242,057 
Drug costs _712mon 738 6,638 7,098 0 0 5,439 11,380 48,000 
Other costs _712mon 738 6,758 20,356 0 274 2,054 5,733 408,690 
Drug costs _1yr 738 19,507 11,912 325 9,742 18,652 26,015 108,000 
Other costs _1yr 738 13,562 32,656 0 2,387 5,892 13,022 650,747 
ETANERCEPT 
Drug costs_06mon 1,612 12,000 6,207 10 7,283 11,748 15,883 33,001 
Other costs_06mon 1,612 5,708 13,664 0 1,113 2,403 5,303 250,678 
Drug costs _712mon 1,612 7,244 7,517 0 0 6,109 12,429 44,964 
Other costs _712mon 1,612 4,545 11,143 0 228 1,542 4,100 254,085 
Drug costs _1yr 1,612 19,243 12,361 10 8,453 18,679 26,730 66,912 
Other costs _1yr 1,612 10,253 19,687 0 2,038 4,552 10,276 275,990 
GOLIMUMAB 
Drug costs_06mon 855 12,591 8,235 4 7,787 11,501 15,764 150,267 
Other costs_06mon 855 6,386 18,514 0 1,115 2,669 5,677 433,647 
Drug costs _712mon 855 7,548 8,677 0 0 7,262 12,320 141,679 
Other costs _712mon 855 5,079 14,965 0 318 1,636 4,340 312,271 
Drug costs _1yr 855 20,139 15,696 4 9,372 19,690 26,856 291,946 
Other costs _1yr 855 11,464 30,541 - 2,072 4,818 11,754 745,918 
INFLIXIMAB 
Drug costs_06mon 689 13,693 9,168 408 8,212 11,744 17,300 76,374 
Other costs_06mon 689 8,447 12,892 0 2,994 4,814 8,877 201,792 
Drug costs _712mon 689 9,140 10,652 0 0 7,085 12,908 130,058 
Other costs _712mon 689 6,855 11,456 0 1,612 3,751 7,515 127,718 
Drug costs _1yr 689 22,833 17,949 408 11,579 19,089 28,772 206,432 
Other costs _1yr 689 15,303 19,839 0 5,243 9,105 17,910 216,501 
RITUXIMAB Drug costs_06mon 539 16,469 8,713 21 11,584 13,577 21,368 61,015 
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LINE2_drg Variable N Mean StdDev Min 
25th 
Pctl 
Median 
75th 
Pctl 
Max 
Other costs_06mon 539 10,457 23,640 0 2,318 4,137 8,719 305,051 
Drug costs _712mon 539 8,437 8,952 0 0 7,699 13,559 41,518 
Other costs _712mon 539 7,776 16,187 0 1,116 2,851 7,413 166,417 
Drug costs _1yr 539 24,906 14,119 182 13,574 24,244 30,880 94,912 
Other costs _1yr 539 18,233 33,190 0 3,917 7,654 19,446 421,973 
TOCILIZUMAB 
Drug costs_06mon 640 11,984 7,466 269 6,975 11,395 16,224 66,497 
Other costs_06mon 640 8,903 20,471 31 2,202 3,931 7,511 307,414 
Drug costs _712mon 640 8,365 8,280 0 0 7,736 13,756 84,903 
Other costs _712mon 640 8,487 22,444 0 1,107 3,156 6,943 415,957 
Drug costs _1yr 640 20,348 14,272 269 9,099 19,188 28,331 151,091 
Other costs _1yr 640 17,390 37,411 31 4,082 7,925 15,460 723,371 
TOFACITINIB 
Drug costs_06mon 548 10,363 6,603 0 4,791 11,160 15,149 29,088 
Other costs_06mon 548 6,536 11,219 0 1,200 2,796 6,939 131,879 
Drug costs _712mon 548 7,368 7,564 0 0 6,862 14,184 32,408 
Other costs _712mon 548 5,764 14,349 0 0 1,503 4,775 144,527 
Drug costs _1yr 548 17,731 13,053 0 5,559 17,803 28,767 56,161 
Other costs _1yr 548 12,300 19,537 0 2,234 5,534 13,041 159,796 
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Adherent 
0-6mon 
LINE2_drg Obs Variable Mean Std 
Dev 
Min 25th 
Pctl 
Media
n 
75th 
Pctl 
Max 
0 ABATACEPT 820 Drug costs_06mon 9,776 6,198 0 5,373 8,436 13,216 37,486 
Other costs_06mon 8,246 17,187 0 1,534 3,541 7,771 215,271 
ADALIMUMAB 1,180 Drug costs_06mon 7,654 4,645 305 4,357 6,870 10,150 46,304 
Other costs_06mon 5,849 13,612 0 828 2,079 4,799 249,259 
ANAKINRA 10 Drug costs_06mon 4,401 3,168 49 1,614 4,175 6,230 10,331 
Other costs_06mon 16,716 37,625 1,428 2,271 5,282 7,572 123,519 
CERTOLIZUMAB 448 Drug costs_06mon 10,494 5,987 1,434 6,412 9,413 12,736 60,000 
Other costs_06mon 7,849 19,737 0 1,406 3,051 6,834 242,057 
ETANERCEPT 726 Drug costs_06mon 7,298 4,239 10 4,214 6,798 9,403 32,431 
Other costs_06mon 7,053 18,876 0 977 2,361 5,609 250,678 
GOLIMUMAB 589 Drug costs_06mon 11,842 7,647 4 6,497 10,124 15,986 73,855 
Other costs_06mon 6,698 20,625 0 1,176 2,810 5,983 433,647 
INFLIXIMAB 130 Drug costs_06mon 6,926 6,090 408 3,197 5,791 8,628 43,906 
Other costs_06mon 10,100 21,638 0 1,834 4,278 9,442 201,792 
RITUXIMAB 92 Drug costs_06mon 10,339 4,845 182 6,683 11,211 12,838 33,608 
Other costs_06mon 9,834 19,534 0 1,518 2,947 5,618 96,718 
TOCILIZUMAB 557 Drug costs_06mon 11,712 7,677 269 6,458 10,781 16,204 66,497 
Other costs_06mon 9,054 21,325 31 2,130 3,864 7,613 307,414 
TOFACITINIB 324 Drug costs_06mon 6,094 4,624 0 2,133 6,278 9,550 17,300 
Other costs_06mon 7,131 13,060 0 1,070 2,715 7,135 131,879 
1 ABATACEPT 1,253 Drug costs_06mon 15,513 6,950 1,595 11,660 14,183 17,763 73,905 
Other costs_06mon 7,593 11,558 157 2,749 4,425 8,000 143,370 
ADALIMUMAB 1,552 Drug costs_06mon 16,842 6,353 4,986 12,182 15,362 19,759 62,378 
Other costs_06mon 5,328 10,305 0 1,234 2,546 5,307 223,595 
ANAKINRA 6 Drug costs_06mon 14,421 5,067 10,60
9 
11,090 11,662 18,895 22,610 
Other costs_06mon 6,292 4,173 2,236 3,358 5,059 8,367 13,672 
CERTOLIZUMAB 290 Drug costs_06mon 16,540 5,463 150 12,791 15,235 18,515 38,650 
Other costs_06mon 5,189 8,226 79 1,370 2,605 5,467 69,846 
ETANERCEPT 886 Drug costs_06mon 15,852 4,735 4,731 12,320 14,782 18,481 33,001 
Other costs_06mon 4,607 6,732 0 1,244 2,414 5,207 79,977 
Drug costs_06mon 5,693 12,652 6 1,060 2,224 4,952 136,167 
INFLIXIMAB 559 Other costs_06mon 15,266 9,050 1,185 9,566 13,206 18,442 76,374 
Drug costs_06mon 8,063 9,793 518 3,148 5,105 8,729 108,888 
RITUXIMAB 447 Other costs_06mon 17,730 8,800 21 12,019 14,360 22,931 61,015 
Drug costs_06mon 10,586 24,417 7 2,554 4,328 9,619 305,051 
TOCILIZUMAB 83 Other costs_06mon 13,809 5,556 2,682 10,561 12,799 16,512 36,099 
Drug costs_06mon 7,888 13,456 1,393 2,750 4,037 6,772 102,024 
TOFACITINIB 224 Other costs_06mon 16,539 3,343 8,458 14,166 15,904 18,320 29,088 
Drug costs_06mon 5,675 7,774 0 1,384 2,972 6,659 60,839 
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Adherent 
612 
LINE2_drg Obs Variable Mean Std 
Dev 
Min 25th
Pctl 
Median 75th 
Pctl 
Max 
0 ABATACEPT 1,196 Drug costs _712mon 3,420 5,319 0 0 0 5,996 31,765 
Other costs _712mon 7,351 23,545 0 98 1,709 5,729 505,420 
Drug costs _1yr 15,271 10,771 0 7,181 13,347 20,500 79,668 
Other costs _1yr 15,687 31,375 0 2,936 6,789 15,905 509,699 
ADALIMUMAB 1,894 Drug costs _712mon 3,600 5,899 0 0 0 6,548 48,753 
Other costs _712mon 4,252 10,507 0 0 927 3,443 144,977 
Drug costs _1yr 14,851 11,131 305 6,226 12,232 20,354 79,904 
Other costs _1yr 9,925 18,533 0 1,580 3,787 9,651 259,078 
ANAKINRA 11 Drug costs _712mon 702 2,330 0 0 0 0 7,727 
Other costs _712mon 18,615 40,835 0 0 2,749 19,564 138,311 
Drug costs _1yr 5,722 5,313 49 1,614 5,061 7,872 18,930 
Other costs _1yr 34,244 76,220 1,428 5,019 7,197 21,213 261,830 
CERTOLIZUMAB 548 Drug costs _712mon 3,889 5,504 0 0 0 7,877 48,000 
Other costs _712mon 6,736 22,226 0 0 1,342 5,475 408,690 
Drug costs _1yr 15,806 10,303 1,434 8,316 13,912 21,768 108,000 
Other costs _1yr 13,921 36,375 0 2,069 5,158 13,346 650,747 
ETANERCEPT 1,100 Drug costs _712mon 3,360 4,838 0 0 0 6,695 24,440 
Other costs _712mon 4,532 12,598 0 0 940 3,580 254,085 
Drug costs _1yr 13,674 9,327 10 5,885 11,815 19,294 54,378 
Other costs _1yr 10,667 21,972 0 1,666 4,181 10,639 275,990 
GOLIMUMAB 655 Drug costs _712mon 5,622 7,195 0 0 1,764 10,905 59,198 
Other costs _712mon 5,052 15,748 0 17 1,402 4,217 312,271 
Drug costs _1yr 17,908 13,272 4 7,352 15,000 26,091 133,053 
Other costs _1yr 11,668 33,258 0 2,017 4,914 11,812 745,918 
INFLIXIMAB 231 Drug costs _712mon 651 1,658 0 0 0 0 10,887 
Other costs _712mon 4,863 11,189 0 0 500 5,623 80,327 
Drug costs _1yr 11,944 9,887 408 4,870 9,535 16,500 72,396 
Other costs _1yr 14,827 23,547 0 2,867 7,228 16,886 216,501 
RITUXIMAB 289 Drug costs _712mon 2,067 4,545 0 0 0 0 31,631 
Other costs _712mon 6,397 14,462 0 151 1,648 5,745 164,860 
Drug costs _1yr 17,977 10,974 182 11,56
8 
14,231 23,602 73,034 
Other costs _1yr 18,621 38,969 0 3,132 6,681 19,179 421,973 
TOCILIZUMAB 585 Drug costs _712mon 7,793 8,211 0 0 6,659 12,803 84,903 
Other costs _712mon 8,496 22,902 0 910 3,030 7,105 415,957 
Drug costs _1yr 19,646 14,273 269 8,633 18,295 27,721 151,091 
Other costs _1yr 17,355 38,111 31 3,983 8,019 15,500 723,371 
TOFACITINIB 410 Drug costs _712mon 4,117 5,497 0 0 0 8,458 18,762 
Other costs _712mon 5,024 13,222 0 0 1,013 3,832 144,527 
Drug costs _1yr 12,839 10,852 0 2,697 9,596 21,537 39,581 
Other costs _1yr 11,692 18,487 0 1,974 5,072 11,912 159,796 
1 ABATACEPT 877 Drug costs _712mon 13,669 6,331 28 9,870 12,350 16,235 70,150 
Other costs _712mon 7,654 12,598 0 2,424 4,187 7,716 208,996 
Drug costs _1yr 28,812 12,358 3,950 21,32
6 
26,277 33,534 121,280 
Other costs _1yr 14,844 18,866 172 5,433 9,357 16,831 222,226 
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Adherent 
612 
LINE2_drg Obs Variable Mean Std 
Dev 
Min 25th
Pctl 
Median 75th 
Pctl 
Max 
ADALIMUMAB 838 Drug costs _712mon 17,620 7,867 8,374 12,04
4 
15,200 21,348 70,365 
Other costs _712mon 5,202 15,681 0 1,168 2,483 5,240 404,588 
Drug costs _1yr 34,159 13,588 12,13
2 
24,70
5 
30,691 40,058 126,436 
Other costs _1yr 10,484 18,760 150 2,814 5,588 11,485 408,179 
ANAKINRA 5 Drug costs _712mon 14,087 5,032 8,200 10,82
9 
13,011 18,061 20,336 
Other costs _712mon 6,005 8,014 381 1,554 2,565 5,612 19,913 
Drug costs _1yr 29,152 10,121 18,80
8 
21,91
9 
25,131 39,230 40,671 
Other costs _1yr 12,605 12,438 2,617 5,923 6,919 13,979 33,585 
CERTOLIZUMAB 190 Drug costs _712mon 14,564 4,873 175 10,99
9 
12,718 18,146 31,904 
Other costs _712mon 6,824 13,643 129 1,622 3,453 6,432 126,329 
Drug costs _1yr 30,183 9,583 325 23,46
7 
27,231 35,941 57,270 
Other costs _1yr 12,526 18,100 361 3,667 7,149 12,442 148,972 
ETANERCEPT 512 Drug costs _712mon 15,588 5,057 4,731 11,76
7 
14,323 18,382 44,964 
Other costs _712mon 4,571 7,080 0 1,218 2,413 4,648 80,543 
Drug costs _1yr 31,210 9,185 9,462 24,25
9 
28,424 36,428 66,912 
Other costs _1yr 9,364 13,509 56 2,734 5,314 9,962 141,743 
GOLIMUMAB 200 Drug costs _712mon 13,853 10,040 7,962 10,54
9 
11,888 15,342 141,679 
Other costs _712mon 5,168 12,082 125 962 2,214 5,022 144,809 
Drug costs _1yr 27,442 20,207 13,65
6 
21,30
9 
23,586 29,643 291,946 
Other costs _1yr 10,798 19,161 347 2,277 4,651 11,618 180,808 
INFLIXIMAB 458 Drug costs _712mon 13,422 10,708 890 7,085 10,650 17,000 130,058 
Other costs _712mon 7,860 11,469 390 2,684 4,481 7,996 127,718 
Drug costs _1yr 28,325 18,591 2,187 17,06
2 
23,873 35,393 206,432 
Other costs _1yr 15,543 17,701 2,133 6,356 9,994 18,368 204,138 
RITUXIMAB 250 Drug costs _712mon 15,800 6,910 2,354 12,21
7 
13,559 16,180 41,518 
Other costs _712mon 9,370 17,874 132 2,042 3,977 8,596 166,417 
Drug costs _1yr 32,915 13,088 4,765 25,02
9 
28,813 37,431 94,912 
Other costs _1yr 17,785 24,964 139 4,913 9,100 19,672 180,230 
TOCILIZUMAB 55 Drug costs _712mon 14,447 6,403 5,838 10,78
5 
13,880 16,800 39,137 
Other costs _712mon 8,401 16,977 1,004 2,095 3,871 6,299 113,743 
Drug costs _1yr 27,818 12,037 11,73
0 
21,59
5 
25,427 32,353 75,235 
Other costs _1yr 17,765 29,217 2,618 5,539 7,849 14,881 182,699 
TOFACITINIB 138 Drug costs _712mon 17,027 3,554 7,032 14,73
8 
16,175 18,875 32,408 
Other costs _712mon 7,961 17,135 0 1,246 3,306 6,473 134,892 
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Adherent 
612 
LINE2_drg Obs Variable Mean Std 
Dev 
Min 25th
Pctl 
Median 75th 
Pctl 
Max 
Drug costs _1yr 32,266 6,656 13,61
0 
27,87
5 
30,882 36,758 56,161 
Other costs _1yr 14,107 22,347 194 3,146 6,888 14,328 142,901 
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Mean drug costs in descending order 
 
Drug costs for the first 6 months 
adherent06 LINE2_drg Mean 
0 GOLIMUMAB 11841.8 
TOCILIZUMAB 11711.8 
CERTOLIZUMAB 10494.2 
RITUXIMAB 10339 
ABATACEPT 9775.6 
ADALIMUMAB 7653.6 
ETANERCEPT 7297.9 
INFLIXIMAB 6925.5 
TOFACITINIB 6094 
ANAKINRA 4400.6 
1 RITUXIMAB 17730.1 
ADALIMUMAB 16841.6 
CERTOLIZUMAB 16539.6 
TOFACITINIB 16538.5 
ETANERCEPT 15852.2 
ABATACEPT 15513.1 
INFLIXIMAB 15266.4 
ANAKINRA 14421 
GOLIMUMAB 14249.9 
TOCILIZUMAB 13808.7 
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Drug costs for the second 6 months 
 
adherent612 LINE2_drg Mean 
0 TOCILIZUMAB 7792.6 
GOLIMUMAB 5622.1 
TOFACITINIB 4116.7 
CERTOLIZUMAB 3889.4 
ADALIMUMAB 3599.7 
ABATACEPT 3419.8 
ETANERCEPT 3360.1 
RITUXIMAB 2067.4 
ANAKINRA 702.4 
INFLIXIMAB 651.1 
1 ADALIMUMAB 17619.7 
TOFACITINIB 17027 
RITUXIMAB 15800.3 
ETANERCEPT 15587.6 
CERTOLIZUMAB 14563.8 
TOCILIZUMAB 14447.4 
ANAKINRA 14087 
GOLIMUMAB 13853.2 
ABATACEPT 13669.3 
INFLIXIMAB 13421.6 
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Annual drug costs 
 
adherent612 LINE2_drg Mean 
0 TOCILIZUMAB 19646 
RITUXIMAB 17977.3 
GOLIMUMAB 17908.4 
CERTOLIZUMAB 15805.8 
ABATACEPT 15271 
ADALIMUMAB 14850.7 
ETANERCEPT 13673.7 
TOFACITINIB 12838.9 
INFLIXIMAB 11943.8 
ANAKINRA 5721.5 
1 ADALIMUMAB 34159.1 
RITUXIMAB 32914.7 
TOFACITINIB 32265.7 
ETANERCEPT 31209.6 
CERTOLIZUMAB 30183.3 
ANAKINRA 29151.6 
ABATACEPT 28811.6 
INFLIXIMAB 28324.7 
TOCILIZUMAB 27817.5 
GOLIMUMAB 27442.1 
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Appendix O – Drug specific costs per Deyo score 
In descending cost order 
 
DEYO
=0 
adherent LINE2_drg Variable Mean  LINE2_drg Variable Mean 
 
0 
INFLIXIMAB Other costs _06mon 8,169 
 
ANAKINRA othertotalpay_612mon 11,998 
 
TOCILIZUMAB Other costs _06mon 6,926 TOCILIZUMAB othertotalpay_612mon 7,469 
ABATACEPT Other costs _06mon 6,659 CERTOLIZUMAB othertotalpay_612mon 5,574 
CERTOLIZUMAB Other costs _06mon 6,337 ABATACEPT othertotalpay_612mon 5,458 
ETANERCEPT Other costs _06mon 5,899 RITUXIMAB othertotalpay_612mon 4,594 
TOFACITINIB Other costs _06mon 5,777 ETANERCEPT othertotalpay_612mon 4,137 
ANAKINRA Other costs _06mon 5,724 TOFACITINIB othertotalpay_612mon 4,003 
RITUXIMAB Other costs _06mon 5,517 ADALIMUMAB othertotalpay_612mon 3,750 
ADALIMUMAB Other costs _06mon 5,134 GOLIMUMAB othertotalpay_612mon 3,584 
GOLIMUMAB Other costs _06mon 4,595 INFLIXIMAB othertotalpay_612mon 3,310 
adherent LINE2_drg Variable Mean 
 
LINE2_drg Variable Mean 
 
1 
RITUXIMAB Other costs _06mon 8,770 
 
TOCILIZUMAB othertotalpay_612mon 8,240 
 
INFLIXIMAB Other costs _06mon 7,230 RITUXIMAB othertotalpay_612mon 7,302 
ABATACEPT Other costs _06mon 6,424 INFLIXIMAB othertotalpay_612mon 7,167 
GOLIMUMAB Other costs _06mon 5,414 TOFACITINIB othertotalpay_612mon 6,737 
TOCILIZUMAB Other costs _06mon 5,066 ABATACEPT othertotalpay_612mon 6,380 
ADALIMUMAB Other costs _06mon 4,832 CERTOLIZUMAB othertotalpay_612mon 5,385 
TOFACITINIB Other costs _06mon 4,589 ADALIMUMAB othertotalpay_612mon 4,814 
CERTOLIZUMAB Other costs _06mon 4,397 GOLIMUMAB othertotalpay_612mon 4,238 
ETANERCEPT Other costs _06mon 4,020 ETANERCEPT othertotalpay_612mon 4,044 
ANAKINRA Other costs _06mon 2,797 ANAKINRA othertotalpay_612mon 1,473 
        
DEYO
=1 
adherent LINE2_drg Variable Mean LINE2_drg Variable Mean 
0 
ANAKINRA Other costs _06mon 27,556 ANAKINRA othertotalpay_612mon 26128.7 
INFLIXIMAB Other costs _06mon 19,181 INFLIXIMAB othertotalpay_612mon 10381.4 
RITUXIMAB Other costs _06mon 17,876 TOCILIZUMAB othertotalpay_612mon 10242.2 
TOCILIZUMAB Other costs _06mon 14,308 ABATACEPT othertotalpay_612mon 10080.5 
ETANERCEPT Other costs _06mon 11,958 RITUXIMAB othertotalpay_612mon 7645.9 
ABATACEPT Other costs _06mon 11,730 CERTOLIZUMAB othertotalpay_612mon 7630.8 
CERTOLIZUMAB Other costs _06mon 10,523 GOLIMUMAB othertotalpay_612mon 6465.3 
GOLIMUMAB Other costs _06mon 10,135 TOFACITINIB othertotalpay_612mon 6118.6 
TOFACITINIB Other costs _06mon 8,405 ADALIMUMAB othertotalpay_612mon 6047.4 
ADALIMUMAB Other costs _06mon 7,578 ETANERCEPT othertotalpay_612mon 5547.6 
adherent LINE2_drg Variable Mean LINE2_drg Variable Mean 
1 
ADALIMUMAB Other costs _06mon 18,172 RITUXIMAB othertotalpay_612mon 14,812 
TOFACITINIB Other costs _06mon 17,072 CERTOLIZUMAB othertotalpay_612mon 13,440 
ABATACEPT Other costs _06mon 16,099 ANAKINRA othertotalpay_612mon 10,733 
RITUXIMAB Other costs _06mon 15,803 ABATACEPT othertotalpay_612mon 9,389 
ETANERCEPT Other costs _06mon 15,606 INFLIXIMAB othertotalpay_612mon 9,040 
ANAKINRA Other costs _06mon 15,311 TOFACITINIB othertotalpay_612mon 9,036 
INFLIXIMAB Other costs _06mon 15,190 TOCILIZUMAB othertotalpay_612mon 7,058 
CERTOLIZUMAB Other costs _06mon 14,889 ADALIMUMAB othertotalpay_612mon 6,879 
GOLIMUMAB Other costs _06mon 13,798 ETANERCEPT othertotalpay_612mon 6,147 
TOCILIZUMAB Other costs _06mon 11,876 GOLIMUMAB othertotalpay_612mon 5,742 
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DEYO≥2 
adherent LINE2_drg Variable Mean  LINE2_drg Variable Mean 
 
0 
GOLIMUMAB Other costs _06mon 27,315 
 
GOLIMUMAB othertotalpay_612mon 22052.5 
 
CERTOLIZUMAB Other costs _06mon 20,630 CERTOLIZUMAB othertotalpay_612mon 21147.4 
TOFACITINIB Other costs _06mon 19,830 ABATACEPT othertotalpay_612mon 18485.9 
TOCILIZUMAB Other costs _06mon 18,193 TOCILIZUMAB othertotalpay_612mon 14923.8 
RITUXIMAB Other costs _06mon 18,044 TOFACITINIB othertotalpay_612mon 14754.1 
ABATACEPT Other costs _06mon 15,620 INFLIXIMAB othertotalpay_612mon 12147.6 
ADALIMUMAB Other costs _06mon 13,739 RITUXIMAB othertotalpay_612mon 12111 
ETANERCEPT Other costs _06mon 11,804 ETANERCEPT othertotalpay_612mon 8207.7 
ANAKINRA Other costs _06mon 6,487 ADALIMUMAB othertotalpay_612mon 7769.3 
INFLIXIMAB Other costs _06mon 4,870 ANAKINRA othertotalpay_612mon 0 
adherent LINE2_drg Variable Mean 
 
LINE2_drg Variable Mean 
 
1 
TOCILIZUMAB Other costs _06mon 25,679 
 
GOLIMUMAB othertotalpay_612mon 41,694 
 
RITUXIMAB Other costs _06mon 14,680 RITUXIMAB othertotalpay_612mon 15,925 
ABATACEPT Other costs _06mon 14,441 ABATACEPT othertotalpay_612mon 15,218 
INFLIXIMAB Other costs _06mon 12,905 TOCILIZUMAB othertotalpay_612mon 14,345 
TOFACITINIB Other costs _06mon 10,544 INFLIXIMAB othertotalpay_612mon 13,773 
GOLIMUMAB Other costs _06mon 9,859 TOFACITINIB othertotalpay_612mon 13,561 
ADALIMUMAB Other costs _06mon 9,398 ETANERCEPT othertotalpay_612mon 8,669 
ETANERCEPT Other costs _06mon 9,372 CERTOLIZUMAB othertotalpay_612mon 7,330 
CERTOLIZUMAB Other costs _06mon 8,458 ADALIMUMAB othertotalpay_612mon 6,729 
ANAKINRA Other costs _06mon 8,367 ANAKINRA othertotalpay_612mon 5,612 
 
